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ABSTRACT 
 Mixed lineage leukemias have a relatively poor prognosis and arise as a result of 
translocations between the MLL gene and one of multiple partner genes.  Downstream 
targets of MLL are aberrantly upregulated and include the developmentally important 
HOX genes and MEIS1, as well as multiple miRNAs, including the miR-17-92 cluster and 
miR-196b.  Here I utilize custom anti-miRNA oligonucleotides to examine the 
contribution of specific miRNAs to MLL leukemias both as individual miRNAs and in 
cooperation with other miRNAs.  Combinatorial treatment with antagomirs against miR-
17 and miR-19a of the miR-17-92 cluster dramatically reduces colony forming ability of 
MLL-fusion containing cell lines but not non-MLL AML controls.   
 Further, I validated PKNOX1 as a target of both miR-17 and miR-19a. MEIS1 and 
PKNOX1 are TALE domain proteins that participate in ternary complexes with HOX and 
PBX proteins. Here I examine the competitive relationship between PKNOX1 and 
MEIS1 in PBX-containing complex formation and determine the antagonistic role of 
PKNOX1 to leukemia in a murine MLL-AF9 model. Collectively, these data implicate the 
miR-17-92 cluster as part of a regulatory mechanism necessary to maintain 
MEIS1/HOXA9 -mediated transformation in MLL leukemia. This approach represents a 
paradigm where targeting multiple non-homologous miRNAs may be utilized as a novel 
therapeutic regimen.  
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CHAPTER 1 
INTRODUCTION 
 MLL leukemias develop as the result of a balanced translocation involving the 
MLL gene located at the 11q23 locus and one of over 70 fusion partners [1].  The 
resulting leukemias develop as either acute myeloid leukemia, acute lymphocytic 
leukemia, or a mixed lineage leukemia and have a poorer prognosis than many non-MLL 
leukemias [2, 3]. MLL leukemias possess a chimeric fusion protein which aberrantly 
upregulates expression of target genes, including HOXA9 and MEIS1 [4, 5]. HOXA9 and 
MEIS1 are essential for MLL leukemia [5-7].  The poorer prognosis associated with  
MLL leukemia gives reason to better understand it, and undertake studies to clarify the 
mechanisms by which it operates. 
 MiRNAs are small noncoding RNAs of approximately 22 nucleotides which 
function through repression of target mRNAs [8, 9]. Currently, over 2500 miRNAs have 
been identified in humans and are thought to contribute to the regulation of up to half of 
all transcribed genes [10]. Previous studies by our lab and others found that multiple 
miRNAs, including miR-196b, and the miRNAs of the  miR-17-92 cluster, are 
overexpressed in MLL leukemias relative to other acute myeloid leukemias [11, 12].  
These miRNAs present an attractive target for therapeutic intervention in MLL leukemias 
due to their critical roles in regulation of important target genes. Recent work has been 
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undertaken to develop modified nucleic acids for the inhibition of miRNAs [8, 13, 14].  
Antagomirs and other anti-miRNA technologies have been tested in vitro and in vivo to 
this effect [8, 13, 14]. 
 This dissertation examines the role of miRNAs disregulated in MLL leukemias 
through two aims. My first aim is to determine the necessity of miRNAs to the 
development of leukemia, both individually and in combination. I hypothesized that one 
or more miRNA upregulated in MLL leukemia are essential to leukemia function. To 
examine the contribution of miRNAs to leukemia, I have inhibited miRNA function 
using custom oligonucleotides termed ‘antagomirs.’  I examined the changes in colony 
forming ability as a surrogate for leukemogenesis in human cell lines with MLL 
translocations and in MLL-AF9 transduced murine bone marrow utilizing individual 
antagomir treatments.  Further, I have performed colony assays in human cell lines 
(MOLM-13 MV4-11, RS4;11) accompanied by analysis of cell cycle and cell growth in 
liquid culture.  
 My second aim is to determine the potential downstream targets of miRNAs 
disregulated in MLL leukemia. I have hypothesized that miRNAs contribute to MLL 
leukemia through downregulation of PKNOX1 (a.k.a. PREP1), a TALE domain protein 
closely related to the essential MLL target gene MEIS1.  I have additionally hypothesized 
that miRNA mediated disruption of the balance between PKNOX1 and MEIS1 
contributes to MLL leukemia.  To examine the  relationship between miRNA levels and 
PKNOX1, I have performed luciferase assays and have further examined the change in 
PKNOX1 protein levels upon antagomir treatment in human cell lines. To determine the 
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competitive role between PKNOX1 and MEIS1, I have further examined the role of 
PKNOX1 in MLL leukemia through both colony assays and liquid culture experiments.  
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CHAPTER 2 
LITERATURE REVIEW 
MLL leukemia background 
The Mixed Lineage Leukemia (MLL, a.k.a. ALL-1, HRX, KMT2A) gene is located 
at the chromosomal position of 11q23 and has been identified as recurrent site of 
chromosomal translocations in leukemia [15].  Leukemias arising from MLL 
translocations may result in either Acute Lymphoid Leukemia (ALL) or Acute Myeloid 
Leukemia (AML) (reviewed in [2, 3]).  These leukemias may additionally be bi-
phenotypic or mixed lineage leukemias, as defined by the presence of mixed surface 
markers (reviewed in [2, 3]). 
Both ALL and AML are relatively heterogeneous as characterized by cytogenetic 
abnormalities, and possess numerous cytogenetic abnormalities of which MLL related 
leukemias represent a significant fraction. ALLs possess cytogenetic abnormalities, 
including t(12;21) encoding TEL-AML1; t(8;14), t(2;8) and t(8;22)  encoding MYC-
related translocations; t(1;19) encoding E2A-PBX; t(9;22) translocations encoding BCR-
ABL; and 11q23 translocations encoding MLL rearrangements [16].  AMLs also display 
numerous cytogenetic abnormalities, as well as cytogenetically normal karyotypes, which 
account for half of all AMLs.  Several commonly occurring cytogenetic abnormalities 
within AML produce fusion genes involving members of the core binding factor 
heterodimeric transcription factor complex which is comprised of AML1 (RUNX1) and 
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CBFB [17].  The balanced translocation t(8;21)(q22;q22) generates a chimeric protein 
AML1-ETO (RUNX1-RUNX1T1), while abnormalities of chromosome 16, including 
inv(16) (p13;q22) and t(16;16)(p13;q22) affect the core binding factor beta subunit 
(CBFB) [17]. The balanced translocation of t(15;17)(q22;q12) is another commonly 
observed cytogenetic abnormality associated with AML, encoding a fusion proteins 
known as PML-RARα and resulting specifically in Acute Promyelocytic Leukemia 
(APL) [17].  
AMLs are classified according to the French-American-British (FAB) 
classification system, with MLL translocation leukemias predominantly resulting in M5a 
(Monoblastic, poorly differentiated) and M5b (Monoblastic, differentiated) leukemias, 
with 38.5% and 21.2%, respectively [18].   MLL leukemias further result in M4 
(Myelomonocytic) leukemias (21.2%) [18].  ALL leukemias may be classified by FAB 
classification system (L1-L3), but are more commonly classified by immunophenotype 
under the World Health Organization guidelines. Within these guidelines, MLL 
rearrangements are present in both T-cell ALLs and B-cell ALLs [19].  
MLL leukemias are responsible for 7-10% of all ALLs and 5-8% of all AMLs [2]. 
Within infant leukemias, affecting children <1 year old, MLL leukemias account for 70% 
of infant ALLs and 35-50% of infant AMLs [3]. Additionally, MLL translocations are 
often observed in therapy associated leukemia, which presents almost exclusively as 
AML, representing approximately 10% of all leukemias, often developing after treatment 
with Topoisomerase 2 inhibitors [3].  MLL rearrangements also represent approximately 
3% of de novo leukemias [18]. Prognosis for MLL rearranged leukemias is poor, with 5 
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year overall survival rates of ~10 %, and a median survival of 9 months after diagnosis 
[18]. 
Wild-type MLL 
Human MLL is an ortholog the Drosophila gene Trithorax (Trx) which acts in 
opposition the polycomb group by maintaining the expression of target genes  (reviewed 
in [20]). The MLL gene encodes a 3969 amino acid (~430 kDa) multi-domain regulator 
of transcription encoded on chromosome band 11q23 (reviewed in [20]).  Located toward 
the N-terminus of MLL, between amino acids 170-310, the AT-Hooks of MLL recognize 
cruciform DNA and facilitate the binding of the MLL complex to DNA [21]. MLL 
possesses a repression domain located between amino acids 1101-1400 [21]. The MLL 
repression domain recruits factors associated with repression of target genes, including: 
BMI-1 and HPC2 of the Polycomb group, the histone deacetylases HDAC1 and HDAC2, 
and CtBP [22].  Within the repression domain, the MLL CXXC domain is defined by 
eight cysteine residues which coordinate 2 zinc ions to mediate interaction with 
unmethylated cytosine-containing CG dinucleotides within CpG islands [23]. Previous 
studies by our lab have shown that the MLL CXXC domain protects unmethylated CpG 
islands from DNA methylation through direct binding to DNA in the promoter regions of 
target genes and subsequently maintains the target gene expression [24].  The MLL 
CXXC-DNA relationship is essential to the leukemogenic capacity of MLL fusions.  
Disruption of this relationship by mutations in the CXXC domain decreases colony 
forming ability of an MLL-AF9 construct when transduced into murine bone marrow 
progenitor cells [23]. MLL additionally possesses 4 PHD (plant homeodomain) fingers 
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that mediate protein-protein interactions, as well as an atypical bromodomain, located 
between PHD fingers 3 and 4.  Of the 4 PHD fingers, PHD finger 3 has been shown to 
bind to bind to H3K4 modified by di- and tri- methylation [25] and also the cyclophylin 
Cyp33 [26].  However, PHD finger 3 binding of methylated H3K4 and Cyp33 are 
mutually exclusive, suggesting that PHD finger 3 may function as a key regulatory 
domain of MLL [27].  MLL possesses an H3K4 histone methyltransferase SET 
(Su(var)3-9,ehanancer of zeste, trithorax) domain located at the C-terminal end [4, 28].  
H3K4 methylation is associated with transcriptional activation [29].  The MLL protein 
domain schematic is illustrated in Figure 1.  
 Upon transcription and translation, the full length MLL protein is cleaved in two 
places by TASPASE1, a threonine aspartase protease; at amino acids 2719 and 2730, to 
excise a 12 amino acid polypeptide and form a 320 kDa N-terminal fragment (MLL-N) 
and 180 kDa C-terminal fragment (MLL-C) [30, 31].  The cleaved MLL proteins 
associate together in MLL-containing complexes involved in the regulation of 
transcription [31].  Association between MLL-N and MLL-C occurs through noncovalent 
binding between the FYRN and FYRC domains (FY-Rich C-terminal) and (FY-Rich N-
terminal) of MLL-N and MLL-C, respectively [31].  
 In addition to self-association between the N- and C-terminal proteins, MLL 
recruits >29 additional complex components [28]. Menin (Multiple endocrine neoplasia 
type 1) is a DNA binding protein, originally characterized as a tumor suppressor [32]. 
Menin associates with the N-terminus of MLL-N, where an RXRFP interaction domain 
located at the amino-terminal end of MLL binds to Menin (MEN1) [33, 34]. LEDGF 
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(lens epithelium derived growth factor), in turn, associates with Menin [35].  C-Myb has 
also been shown to associate with MLL through interaction with Menin [36]. 
Collectively, these proteins interact with DNA in cooperation with the AT-Hooks and 
CXXC domain of MLL [2]. Interaction with both Menin and LEDGF are required for 
MLL regulation of target genes [33, 35] and loss of the N-terminal domain of MLL 
abrogates the leukemogenic activity of the MLL fusion protein [34].  
 MLL-C facilitates numerous protein-protein interactions with several additional 
factors to the complex, including: WDR5 [37], ASH2L [38], RBBP5 [39], and CBP [40].  
ASH2L and RBBP5 dimerize and bind to the C-terminus of MLL, stabilizing the active 
conformation of the MLL SET domain [39]. CBP is a histone acetyltransferase that 
acetylates histones, among other substrates [41]. WDR5 recognizes H3K4 without 
discriminating between unmethylated, mono-, di-, or tri- methylation and  positions the 
H3K4 residue for methylation by the MLL SET domain [37, 42].  WDR5 has additionally 
been implicated in the binding of non-coding RNA HOTTIP [43] in the regulation of the 
HOXA cluster (schematic of MLL complex illustrated in Figure 1). 
Previous studies have characterized Mll function through the development of a 
murine hypomorphic model, which is commonly referred to as an Mll knockout model.  
Mll (-/-)  mice are embryonic lethal and embryos display developmental defects including 
brachial arch dysplasia and aberrations in segmental boundaries [44, 45].  Examination of 
the expression of known target genes, including Hoxa7 and Hoxc9, in Mll (-/-) embryos, 
implicate MLL in the maintenance, but not initiation of expression of genes.  Mll (-/-) 
embryos were able to initiate expression of these target genes, but were unable to 
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maintain expression past 8.5-9 dpc [44].  Knockout studies additionally showed a 
hematopoietic phenotype, with Mll (-/-) embryos displaying a defect in yolk sac 
hematopoiesis [46]. 
MLL fusions 
 MLL fusions arise as the result of chromosome translocations which result in an 
in-frame joining of the MLL gene to a partner gene.  MLL fusions most often occur as a 
result of incorrect non-homologous end joining from double stranded DNA break repair 
[47]. Chromosomal breakage occurs within a defined 8.3 kb region of the MLL gene 
called the Breakpoint Cluster Region (BCR). Currently, 79 partner genes have been 
identified as fusion partners in MLL translocations [1]. Despite the myriad of MLL 
fusion partners, >85 % of MLL fusions occur with only 6 partners [1]. These most 
common fusion partners are AF4 (38%), AF9 (18%), ENL (13%), AF10 (8%), ELL 
(4%), AF6 (4%) [1].  The occurrence of fusion partners is distinctly different between 
MLL AMLs and MLL ALLs, with AF4 being the most common fusion partner in MLL 
ALL (60%) and AF9 being the most common fusion within MLL AML (29%)[1].  
 MLL fusion proteins are functionally distinct from wild type MLL. In MLL-
fusions proteins, the AT-Hooks and the MLL CXXC domain is retained within the fusion 
protein.  However, while wild type MLL-C recruits additional factors involved in the 
maintenance of expression of target genes, loss of the MLL-C and replacement with a 
fusion partner alters the recruitment of cofactors.  Many of the resulting fusions enable 
the recruitment of factors including DOT1L and the super elongation complex (SEC). 
DOT1L  is a histone methyltransferase that targets H3K79 for methylation as an 
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activating chromatin mark occurring along transcriptionally active genes (reviewed in 
[48]). H3K79 methylation usually corresponds to transcription of associated genes [49]. 
MLL leukemias display aberrant H3K79 methylation along known MLL-targeted genetic 
regions, including the HOXA loci [50, 51].  DOT1L has been shown to be necessary for 
transformation of murine bone marrow by MLL fusions, with Dot1l deletion resulting in 
a loss of colony forming ability and an increase in apoptosis [52]. Subsequent studies 
have shown that selective inhibition of DOT1L catalytic function effectively blocks 
H3K79 methylation and inhibits proliferation and promotes apoptosis and differentiation 
of MLL rearranged cell lines [53]. 
 Both MLL and MLL fusions recruit the RNA Polymerase 2- interacting 
Polymerase Associated Factor complex (PAFc) through interaction between MLL 
repression domain and the PAFc subunit PAF1 [54].  Interaction with the PAF complex 
is required for proper recruitment of MLL to the Hoxa9 locus and the transformation by 
MLL fusions [54].  Several common fusion partners are components the super elongating 
complex (SEC) that enables transcriptional elongation by releasing RNA Polymerase 2 
from transcriptional pausing at the transcriptional elongation control checkpoint (TECC). 
(Function of SEC extensively reviewed in [55-57]). The SEC is comprised of several 
subunits, including: AF9 (ALL1 fused gene from chromosome 9) or its homolog ENL 
(eleven nineteen leukemia),  ELL  (eleven nineteen Lys-rich leukemia) family protein, 
AFF1/4, EAF1/2, and the kinase P-TEFb (Pol 2 transcription elongation factor comprised 
of cyclin T1 or T2 and Cdk9) [57]. Of these complex components, several are MLL 
fusion partners, including: AF4, AF9, AF10, ENL, and ELL [1, 3].  Functionally, P-TEFb  
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Figure 1. MLL domains and complexes 
 
 
 
 
A) Schematic depiction of MLL protein domains for both wild-type MLL (top) and MLL 
fusion (bottom) proteins.  Adapted from Krivstov et al. [58].  B) Cartoon depiction of 
MLL interaction with proteins and chromatin for wild-type MLL (top) and MLL fusion 
(bottom).  Adapted from Krivstov et al.[58] and Slany et al. [3].  
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phosphorylates RNA Polymerase 2 at serine 2, which allows release of RNA Pol 2 from a  
pause site [55] (schematic illustrated in Figure 1). 
 Additional, but less frequent fusions have been documented which include fusion 
partners that facilitate dimerization of MLL fusion proteins, including AF1p and GAS7 
[59].  These fusion partners are cytoplasmic proteins that possess homo-oligomerizing 
coiled-coiled domains which are sufficient to allow for leukemic transformation by these 
MLL fusion proteins [59].  Examination of a pharmacologically dimerizable MLL, MLL-
FKBP, indicates that MLL amino-terminal dimers bind to the CpG islands of the Hoxa9 
locus and upregulate critical MLL target genes including Hoxa7, Hoxa9, and Mies1 [60].  
In addition to chromosomal translocations, MLL also undergoes partial tandem 
duplications (MLL PTD) accounting for 4% of MLL leukemias [1]. MLL PTDs contain 
duplication of exons 5-11, allowing for MLL to dimerize and subsequently misregulate 
target genes [58].   
MLL target genes 
Several studies have sought to define the genes targeted by MLL and MLL 
fusions by examining the global disregulation of genes in MLL fusion leukemias [61-65].  
Examination of MLL occupancy sites indicates that MLL associates with RNA 
Polymerase 2 across the entire gene for a subset of transcriptionally active target genes, 
and dissociates upon downregulation, consistent with MLL's function in transcriptional 
maintenance [61].  Armstrong et al. examined the gene expression signature of MLL 
leukemia patients compared to non-MLL ALL and AML leukemias [62].  They found 
that MLL leukemias regulated a gene set distinct from either ALL or AML that was rich 
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with highly expressed HOX genes [62]. Examination of the binding of MLL-ENL and 
comparison of MLL-ENL binding with MLL wild-type binding, indicates that MLL 
fusions bind to a subset genes regulated by wild type MLL [63].  MLL-ENL bound to 
223 genes with significant increase in mRNA expression of 12 genes, including Hoxa9 
and Meis1 [63]. A separate study performed by Li et al. examined the deregulation of 
genes in leukemias possessing MLL-ENL and MLL-ELL translocation [64]. 88 genes were 
found to be disregulated in both human and murine leukemia models, including Hox 
genes and the miR-17-92 cluster [64]. Critically, changes in gene expression were 
conserved between human and mouse [64]. Collectively, these studies corroborate earlier 
findings that MLL functions to maintain gene expression, particularly at Hox genes.  
However, they also implicate MLL in the maintenance of expression of other target genes 
including the miR-17-92 cluster.  
HOX genes 
HOX genes are the most well studied downstream targets of MLL. MLL and MLL 
fusions directly regulate posterior HOX genes, as well as the HOX partner MEIS1, 
resulting in an aberrant maintenance of the expression in MLL leukemias [4, 5]. Both 
HOXA9 and MEIS1 and direct downstream targets of MLL [4, 5].  Previous studies have 
shown that HOXA9 is essential to the development of MLL leukemias [5-7].  Hoxa9 
deficient murine bone marrow cells cannot be transformed with MLL fusions in vitro [6], 
while depletion of HOXA9 in human cell lines harboring MLL translocations blocks 
proliferation and induces apoptosis [7].  
 HOX genes encode transcription factors critical to body patterning, development, 
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and hematopoiesis [66].  Mammals possess 39 HOX genes organized in 4 paralogous 
clusters (HOXA – HOXD) at 4 different genetic loci, with HOXA, HOXB, HOXC, and 
HOXD located on 7p15, 12q21, 12q13, and 2q31, respectively (reviewed in [67]). Each 
cluster is similarly organized with the lower numbered HOX  genes located towards the 3' 
end of the cluster and higher numbered HOX genes located at the 5' end. HOX genes are 
illustrated in Figure 2.  HOX gene expression is  important for determining the spatial 
identity and segmentation in development, with HOX genes expressed collinearly from 
lower to higher number along the anterior-posterior axis, with the lower numbered HOX 
genes expressed toward the anterior and the higher numbered HOX genes expressed 
towards the  posterior (reviewed in [67, 68]).  Temporal control of HOX gene expression 
is also controlled collinearly with lower numbered HOX genes being expressed earlier in 
development than their higher numbered counterparts (reviewed in [67, 68]).  
Disregulation and mutation of HOX genes results in limb malformations and 
developmental diseases, including cancers (reviewed in [67]). Critical to understanding 
the development of AML, the NUP98-HOXA9 fusion drives AML development [69].  
Further, a study of 6817 genes in acute leukemia identified HOXA9 expression as a 
negative prognostic indicator for AML [70].  
 HOX proteins contain a 60 amino acid homeodomain consisting of 3 alpha 
helices, with DNA helix 3 contacting DNA  [67]. The homeodomain interacts with target 
DNA sequences through the DNA helix 3. HOX proteins additionally possess a short 
amino acid sequence (YPWM)  which interacts with the homeodomain of a PBX partner 
gene [71]. 
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Figure 2. HOX gene clusters 
 
 
 
 
Schematic depiction of HOX gene clusters in human.  HOX genes are organized into 4 
paralogous clusters lettered A-D. HOX gene expression occurs in a co-linear fashion with 
Anterior expression occurring from HOX genes located towards the 3' end of the HOX 
clusters and posterior expression occurring from HOX genes located towards the 5' end of 
the HOX clusters.  Adapted from Argiropoulos and Humphries [66].  
 
  
16 
 
 
 
HOX-TALE complexes 
HOX proteins function in complexes formed with TALE domain containing partner 
proteins, primarily MEIS proteins, PBX proteins, PKNOX (PREP) proteins.  The TALE 
(Three Amino acid Loop Extension) family of proteins were identified and characterized 
as having an atypical homeodomain with 3 amino acids positioned between the first and 
second helices of the homeodomain [72, 73].  This TALE possessing homeodomain is 
highly conserved and present in all family members and subfamilies of the larger TALE 
family [72, 73].  The TALE family is subdivided into the several families, including: 
PBC, MEINOX, IRO, TGIF, and MKX families [72, 73].  MEINOX and PBC family 
members are critical cofactors of HOX genes in leukemia. 
The PBC family consists of the 4 PBX homologs (PBX1, PBX2, PBX3, PBX4) in 
both mouse and human [72]. Additional functional forms of PBX are formed by splice 
variants of PBX1 (PBX1A, PBX1B) and PBX3 (PBX3A, PBX3B) (reviewed in [74]). 
Common to all members of the TALE family of proteins, the PBC family possesses and 
homeodomain with a three amino acid loop extension.  PBC family members additionally 
possess a "bipartite" PBC domain divided into PBC-A and PBC-B, N-terminal to the 
homeodomain, which function in protein-protein interactions (reviewed in [74]).  High 
conservation is observed in both the homeodomain and the PBC domains. 
The MEINOX family (originally categorized as the  MEIS family) consists of 3 
MEIS proteins (MEIS1, MEIS2, MEIS3) and 2 PKNOX proteins (PKNOX1, PKNOX2) 
in both human and mouse [72, 73]. Members of the MEINOX family possess the TALE 
domain containing homeodomain which is highly conserved between MEIS and PKNOX 
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subfamilies [72, 73].  Additionally, both MEIS and PKNOX families share high 
homology in the bipartite MEIS domain, consisting of a MEIS-A and MEIS-B and 
utilized for protein-protein interactions (reviewed in [74]).  However, there is divergence 
in the presence or absence of nuclear localization signals, as well as the C-terminal region 
[74]. 
 While HOXA9 and MEIS1 are often discussed as the critical downstream effectors 
of MLL leukemias and are used to generate AML independently of MLL involvement, 
these proteins are able to participate in a diverse combination of protein complexes. 
MEINOX proteins are capable of forming binary MEINOX-PBX complexes through 
interaction of the MEIS-A and MEIS-B domains of MEIS1/PKNOX1 with the PBC-A 
and PBC-B of PBX partners [75, 76]. MEINOX-PBX complexes form in the presence or 
absence of DNA, indicating that interaction is not DNA dependent [75]. This interaction 
does not occlude or otherwise interfere with the PBX component's homeodomain. In 
addition to interactions with MEINOX family proteins, PBX proteins are capable of 
forming stable HOX-PBX dimers with HOX protein partners (reviewed in [71]). HOX-
PBX interactions are mediated by the Tryptophan of the HOX protein's YPWM motif 
binding to the homeodomain of the PBX partner (reviewed in [71]).  Notably, HOX-PBX 
interactions do not utilized the PBC-A or PBC-B domains required in PBX-MEINOX 
interactions. 
Numerous studies document the formation of ternary complexes containing a 
HOX component, a MEINOX component, and a PBC component [77-81].  HOX-PBX-
MEIS protein complexes may contain PKNOX1 (also known as PREP1) as an alternative 
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to MEIS1 as protein-protein interactions within the ternary complexes are mediated 
through MEINOX-PBX interaction [82].  PKNOX1 and MEIS1 are highly homologous 
in the domains required for both PBX interaction and DNA binding and interact with the 
same surface on PBX1 [76].   
AbdB-like HOX proteins, encoding HOX9-13, are uniquely capable of directly 
interacting with MEIS1 [83-85].  This interaction is not conserved across the MEINOX 
family as it requires residues located within the C-terminal domain of MEIS1 that are not 
conserved in PKONX1 [84]. Thus, only MEIS1, and not PKNOX proteins, directly bind 
to with HOX partners. TALE domain complexes are illustrated in Figure 3. 
Functional roles of TALE proteins 
While numerous studies have utilized PBX1 to study the protein-protein 
interactions of the PBX family of proteins, an increasing body of evidence has implicated 
PBX3 as the critical PBX protein in MLL leukemia.  Recently, PBX3 upregulation has 
been identified as part of a 4 gene signature associated with poorer prognosis in MLL 
leukemias [86].  Though PBX3 is highly upregulated, its homologs, PBX1 and PBX2, are 
down regulated [87].  Functionally, inhibition of the PBX-HOX interaction through an 
18-mer peptide in cell lines harboring MLL-related translocations results in decreased 
proliferation and apoptosis [87].  
Meis1 was initially identified as a viral insertion site in BHX2 mice in the 
development of leukemia [88].  The gene for human MEIS1 was cloned and identified as 
a homoebox-containing gene located at chromosome 2p13-p14 [89]. Along with HOXA7 
and HOXA9, MEIS1 overexpression was implicated in the development of AML [90].   
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Figure 3. TALE domain proteins and complexes 
 
 
 
 
A) Schematic depiction of HOX protein families. HOX family members are depicted in green.  PBX 
family members are depicted in purple. MEIS1 is depicted in blue. PKNOX1 is depicted in orange.  
Homeodomains are shown in black, while TALE domains are shown with a red stripe located 
within the Homeodomain.  PBC domains are shown in dark purple, while MEIS domains are 
shown in gray. Adapted from Ladam, et al. [71] Longobardi, et al. [74] B) Cartoon depiction of 
different HOX-TALE complexes and their DNA interactions. Coloring of proteins and protein 
domains are matched to schematics in panel A.   
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Numerous studies have indicated that Meis1 is essential to the development of 
MLL leukemia. In fetal liver cells, Meis1 (-/-) cells are incapable of serial replating 
ability after transformation with MLL fusion-expressing retrovirus [91]. Moreover, the 
level of Meis1 expression correlates to the latency of leukemia development in murine 
models [91].  Knockdown of Meis1 using a lentiviral shRNA results in a decrease in 
proliferation and an increase in survival in vivo [92].   
The leukemogenic capacity of Meis1 requires several domains to generate 
leukemia when infected into murine bone marrow along with Hoxa9.  Meis1 oncogenic 
activity requires both the Pbx interacting motif and the C-terminal region [93].  Specific 
deletion of the C-terminal domain in Meis1 ablates transforming capacity of Meis1, while 
replacement with a strongly activating VP16 activation domain allows Meis1 to retain 
leukemogenic capabilities [94].  The retention of leukemogenic capability in a chimeric 
Meis1-VP16 mutant indicates that Meis1 generates leukemia through activation of target 
genes.  The oncogenic activity of Meis1 is located in the C-terminal domain which differs 
from that of Pknox1 [93-95]. Meis1 cooperates with Hoxa9 in transformation; whereas 
co-expression of Pknox1 with Hoxa9 lacks this effect [94].  However, chimeric Pknox1 
proteins which replace the Pknox1 C-terminal domain with the Meis1 C-terminus can 
restore acceleration of leukemia development [94].   
The MEIS1 C-terminal domain is responsible for numerous protein-protein 
interactions including interaction with HOX proteins in binary complexes.  Several lines 
of evidence, however, implicate ternary complexes as the critical leukemogenic 
complexes. Deletion of the Pbx-interacting domains of Meis1 abrogated its leukemogenic 
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potential when co-infected with a Hoxa9-expressing virus [93]. PBX3 is upregulated in 
MLL leukemia and disruption of the HOX-PBX interaction through a small peptide 
inhibitor promoted apoptosis and decreased expression of known HOX-MEIS targets in 
an MLL leukemia cell line [87]. Collectively, these findings suggest that HOX-MEIS 
activity requires PBX participation in a ternary complex.   
Numerous HOXA9-MEIS1 target genes have been identified.  Most prominently, 
MEIS1 regulates FMS-like tyrosine kinase 3 (FLT3) in AML [93].  FLT3 encodes a 
receptor tyrosine kinase expressed in hematopoietic stem and progenitor cells whose 
signaling pathway regulates proliferation, apoptosis, and differentiation (FLT3 function 
reviewed in [96]. Activating mutations, such as FLT3 internal tandem duplications have 
been identified as a causative genetic lesion in cytogenetically normal AML.  Within 
infant MLL leukemias FLT3 expression is often elevated and corresponds to a worse 
prognosis.  However, transduction of murine bone marrow with Meis1 and Hoxa9 
generates leukemia in both Flt3 (+/+) and Flt3 (-/-) cells, indicating that Flt3 is 
dispensable for the Meis1-Hoxa9 viral overexpression-generated leukemia [97].  
c-Myb was additionally identified as a target for upregulation by Hoxa9-Meis 
leukemogenesis after being identified in an array analyzing genetic disregulation of 
Hoxa9-Meis1 transformed murine bone marrow [98].  Inhibition of c-Myb through either 
a dominant negative mutant or siRNA ablated the leukemogenic capability of MLL-ENL, 
indicating that c-Myb function is essential for MLL transformation [98]. Subsequent 
studies showed c-Myb directly interacts with MLL complexes through binding to Menin, 
suggesting a regulatory feedback mechanism whereby Hoxa9-Meis1 activity influences 
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MLL complex composition. 
Additional documented HoxA9-Meis1 targets include: gata1 [99], Trib2 [100], 
Ccl [100], and cyclin D3 [101].  An Illumina-based ChIP-Seq examination of Hoxa9 and 
Meis1 binding sites indicated that Hoxa9 and/or Meis1 bind to 825 genomic regions, with 
approximately 200 genomic regions bound by both [102].  Hoxa9 binding is enriched at 
enhancers, and coincides with binding by additional lineage restricted transcription 
factors including PU.1, C/EBP, CREB, STAT, and RUNX1 [102].   
PKNOX1 (also known as PREP1) was identified as a homeodomain containing 
protein and the gene subsequently localized to the human chromosome 21q22.3 and 
mouse chromosome 17B/C [103, 104].  Pknox1 was initially characterized as a Pbx 
binding partner [105].  Functional characterization of Pknox1 indicated that it is a binding 
partner of Pbx1 in both the presence and absence of DNA [106, 107].  Upon binding to 
DNA, Pknox1 contributes to the specificity of complex binding through recognition of a 
TGACAG motif [107]. Pknox1 expression correlates inversely with Meis1 expression 
during mouse hematopoiesis, as indicated in publicly available datasets (Figure 4). 
Pknox1 is expressed at low levels in more immature cells and increases in expression 
during differentiation, while Meis1 expression is highest in immature cells and decreases 
during differentiation.  
Deletion of Pknox1 in a mouse is embryonic lethal early in development (day 7.5) 
(Blasi lab, unpublished, discussed in [108]).  A hypomorphic Pknox1 mutation, generated 
by an insertion into the 5’ UTR of the Pknox1 transcript results in decreases in Pknox1 
mRNA and protein levels, with Pknox1 (i/i) mutants expressing  <10% relative to wt.  
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Hypomorphic Pknox1 mutants display high rates of embryonic lethality with deaths 
occurring between 17.5 dpc and birth.  Embryos exhibited multiple developmental 
defects, including reduced angiogenesis, eye development abnormalities, and severe 
anemia [108].   Mice which survive to birth exhibit T-cell developmental defects and 
develop lymphomas [109].  Further, a decrease in Pbx1 and Meis1 levels were observed 
in a Pknox1 hypomorph, attributed to a loss of stabilizing effect that derived from 
interaction with Pknox1 [108]. The stabilization effect of Pknox1 on partner proteins may 
be governed with the nuclear import [110] .  
Further characterization of Pknox1 hypomorphic mutants in an Eµ-myc model of 
lymphomagenesis implicate Pknox1 as a tumor suppressor [109]. Loss of Pknox1 in cells 
homozygous for a hypomorphic mutation Pknox1 (i/i) or heterozygous for a knockout 
Pknox1(+/-) result in an increase in tumor volume, an acceleration of lymphoma 
development, and decreased survival [109].   
Pknox1 and Meis1 are highly homologous in their homeodomains and their Pbx 
interacting motifs, but do not share much homology in the C-terminus [94].  Chimeric 
Pknox1 proteins with the Meis1 C-terminus appended to the C-terminus of Pknox1 are 
able to generate leukemia when transfected into murine bone marrow, along with Hoxa9 
[94].  Further, chimeric Pknox1-VP16 mutants are similarly able to generate leukemia 
[94].  These studies suggest that the C-terminus of Pknox1 lacks the gene activating 
capabilities of Meis1.  Recent ChIP-seq analysis of Meis1, Pknox1, and Pbx1/2/3 
occupancies performed during murine embryo development in conjunction with analysis 
of gene expression have further suggested that Pknox1- and Meis1-containing complexes  
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Figure 4. Pknox1 and Meis1 expression during hematopoiesis 
 
 
 
A) mRNA expression patterns from compiled microarray studies in mouse hematopoiesis 
for Pknox1 (left) and Meis1 (right) as depicted by GEXC database indicating mRNA 
upregulation (red) or downregulation (blue).  B) Normalized values for Pknox1 and 
Meis1 expression levels from panel A in mouse hematopoiesis.  All stages in 
differentiation indicated with blue dots. Arrows indicate HSC (red), GMP (purple), 
Granulocyte (black), and Monocyte (green).  
 
  
25 
 
 
 
often have antagonistic roles in the regulation of common target genes [111].  Both 
Pknox1 and Meis1 are capable of interacting with Pbx proteins or in Hox-Meinox-Pbx 
ternary complexes.  ChIP-seq data characterizing the occupancies of Meis, Pbx1/2/3, and 
Pknox1 in murine embryonic development indicate the diversity of co-occupancies of 
TALE domain proteins in vitro [111].   Intriguingly, these studies have found that while 
both Meis1 and Pknox1 can participate in ternary complexes in vitro, co-occupancies of 
Meis1 and Pknox1 do not equally coincide with other complex components (e.g. Hoxc9 
and/or Pbx1/2/3).  Meis1 peaks often coincide with Hox peaks in the absence of Pbx1, 
while Pknox1 peaks coincide with Pbx1 in the absence of Meis1 [111].  Consistent with 
previous biochemical studies, this indicates that Meis1 may interact directly with Hox 
partners. However, Meinox-Pbx dimers were primarily comprised of Pknox1 bound to a 
Pbx component.   
Recently, additional studies performed by the Blasi group published 2 papers 
clarifying the competitive role of Pknox1 and Meis1 in Hox-Meinox-Pbx complexes in a 
mouse model.  In examining the colony forming ability of mouse embryonic fibroblasts 
(MEFs), they found that Meis1 transforms in a Pknox1 (i/i) background, while exogenous 
expression of Pknox1 ablates Meis1-mediated transformation [112]. Further, Pknox1 
indirectly regulates the stability of Meis1 through binding to Pbx1, as unbound Meis1 is 
degraded [112]. Examination of the Pknox1 - Meis1 relationship in bone marrow cells 
indicates that Pknox1 functions as a tumor suppressor in hematopoietic cells [113].  
Exogenous over expression of Pknox1 inhibits the capability of Hoxa9 and Meis1 to 
transform hematopoietic stem cells; Hoxa9 and Meis1 transformation is accelerated in a 
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Pknox1 (i/i) background [113].  These studies, however, do not address the competitive 
relationship of PKNOX1 and MEIS1 in an MLL leukemia model. 
miRNA Biogenesis and function 
MiRNAs are small non-coding RNAs (~22 nt) that post-transcriptionally 
downregulate the expression of mRNA targets and are among the many genes regulated 
by MLL (reviewed in [8, 9]).  miRNAs were initially identified  and characterized in C. 
elegans with the discovery of lin-4 [114].  While lin-4 has no homologs in human or 
mouse, subsequent studies identified let-7, a gene regulating the developmental timing of 
the C.elegans L4/Adult  switch by down-regulating the developmental timing switch lin-
41 [115]. Let-7 is conserved in human and mouse [116]. According to the most recent 
catalog of miRNAs,  miRBase 21, as predicted by deep sequencing,  2588 miRNAs are 
known to exist in human and 1915 are known in mouse [10].   
miRNAs are located in genomically fragile hot-spots that are often subject to 
DNA damage [117]. More than 50% of miRNAs are located in polycistronic clusters 
where a single transcript gives rise to more than one mature miRNA [117].  miRNAs 
arise from a diverse array of primary-miRNA transcripts.  Most miRNAs arise from 
capped and poly-adenylated primary-miRNA transcripts transcribed by RNA Polymerase 
2 [118].  However, several studies have shown the production of miRNAs from 
transcripts transcribed by RNA Polymerase 3 [119].  MiRNAs may arise from either 
exonic or intronic sequences of both coding and non-coding RNAs, as well as 3' UTRs 
[120, 121]. 
Mature miRNAs are generated through sequential processing events. Within the 
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primary-miRNA transcript, the miRNAs form thermodynamically stable hairpins of ~70 
nt that are cleaved within the nucleus by DROSHA, a type III RNAse, with assistance 
from the RNA binding protein DGCR8/PASHA, which guides the positioning of the 
RNAse onto the pri-miRNA [122-124].  The resulting hairpin, designated as a pre-
miRNA, is subsequently exported to the cytoplasm by Exportin-5, a RAN-GTPase 
nuclear exporting protein [125].  The pre-miRNA is loaded onto Dicer, which cleaves the 
hairpin into 2 strands of ~22 nt, leaving 2 nucleotide overhangs at the ends of each strand 
to produce a mature miRNA duplex [126].   
The mature miRNA duplex is loaded into an Argonaute containing complex, 
consisting of Dicer, TRBP, and an Argonaute component [127]. Humans possess four 
argonaute genes (AGO1/2/3/4), which are defined by common domains including a PAZ 
and PIWI domains  [128].  Together, these domains form a "bilobal" structure engaged in 
binding to both the miRNA and the target mRNA. For each mature miRNA duplex, only 
one strand is incorporated as a miRNA into the RISC complex while the opposite strand 
is rapidly degraded, with strand selection being determined by the stability of the cleaved 
5' end of each strand of the miRNA duplex [129, 130].  The Argonaute component 
additionally associates with GW182 to form the core of the RISC complex.  
The most critical nucleotides of the mature miRNA are nucleotides 2-7, which are 
termed the "seed region" of the miRNA [131].  These nucleotides must be 
complementary to the target mRNA, with some exceptions allowing for G:U wobble, in 
order for the RISC-miRNA complex to effectively downregulate the target mRNA  [132, 
133]. Within the RISC complex, the miRNA is situated within the complex so that the 
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miRNA seed region is projected outward toward the targeted mRNA [134].  The RISC 
complex then scans target mRNAs for complementarity, with miRNA targeting focused 
on the 3’ UTR of the target mRNA.  Perfectly matched miRNA:mRNA pairing results in 
a cleavage event in Argonaute 2-containing complexes whereby the target mRNA is 
cleaved opposite the  miRNA by the "slicer" activity present in Ago2 [135].  In both 
perfectly matched and  imperfectly matched pairings, the RISC complex recruits 
additional factors to the mRNA to de-cap and degrade the mRNA transcript [136].  In this 
manner, all targeted mRNAs are reduced upon recognition and binding by miRNA 
containing RISC complexes. miRNA mediated degradation of target mRNAs occurs in 
the cytoplasm within subcellular structures known as P-Bodies (aka GW bodies) which 
consist of miRISC complexes and decapping and deadenylation factors [137]. 
Recognition of the target mRNA is primarily mediated by the 'seed' region of the 
miRNA  [131], and may be predicted using computer matching algorithms that seek to 
identify complementarities between the miRNA and target mRNA (review of target 
prediction algorithms in [132, 133, 138]).  Numerous publicly available algorithms have 
been developed, including (but not limited to): TargetScan [131], MiRanda [139], Diana-
microT [140], RNA22 [141], and miRWalk [142]. While most miRNA target prediction 
algorithms require a match between the seed region and the putative target mRNA [138], 
targeting models require different spans of matching complementarity within the seed 
region and several allow for a less stringent matching with a G:U wobble in the seed 
region [132].  miRNA biogenesis is illustrated in Figure 5. 
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Figure 5. miRNA biogenesis 
 
 
 
Canonical miRNA biogenesis pathway. miRNAs are generated as a result of transcription 
by RNA Polymerase and sequential cleavage steps. Mature miRNAs are incorporated 
into a RISC complex. Adapted from Mian and Zeleznik-Le [8].  
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Further advances in the understanding of miRNA will likely change the targeting 
prediction for miRNAs, and our understanding of miRNA function. It has been accepted 
that miRNAs may target the 5'UTR of mRNA target transcripts as well as the 3'UTR for 
downregulation by the RISC complex [143].  Meanwhile several groups have explored 
alternate novel mechanisms of miRNA activity such as miRNA upregulation of target 
transcripts, whereby miRNA binding to the target mRNA may occlude a binding site 
targeted by a repressive factor and thereby protect the transcript from downregulation.  
The primary example of this form of regulation is the relationship between miR-10 and 
TOP motifs [144]. Additionally, a bioinformatic analysis of miRNA binding has 
suggested that miRNA may simultaneously bind to both the 5'UTR and 3'UTR of a target 
mRNA [145]. However, this phenomenon has yet to be functionally demonstrated, and 
may be impeded by steric hindrance. Examination of miRNA:mRNA  through RISC-
complex pulldowns, coupled with target mRNA sequencing (HITS-CLIP) has been used 
to document the interactions of miRNAs in neuronal cells. Strikingly, this study found 
many instances of miRNA:mRNA interaction in the absence of matched seed 
region[146]. Further study is required to fully examine the functional interaction of 
miRNAs with targeted transcripts.  
In addition to dysregulation of specific miRNAs, the miRNA biogenesis pathway 
has been implicated as a potential target of dysregulation in various cancer models.  
Schmittgen et al. found that downregulation of Dicer occurred in a several cancer 
models, resulting in global miRNA downregulation [147].   
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miRNA disregulation in leukemia 
 MiRNA dysregulation has been implicated in numerous forms of cancer, 
including leukemia.  Considerable effort has been applied toward discerning the 
disregulation of miRNAs within leukemias to determine how miRNA disregulation 
corresponds to lineage, cytogenetic abnormality, and clinical prognosis (reviewed in [8]). 
Further effort has been applied to discerning the signature of miRNA disregulation within 
leukemias (illustrated Table 1). 
 Acute leukemias are divided into lymphoid and myeloid lineages, with different 
gene expression patterns.  To examine the potential difference in miRNA expression 
between lineages, a study by the Chen group examined the miRNA expression between 
ALL and AML leukemias with common cytogenetic abnormalities including MLL 
related translocations in both the AML and ALL subsets, and identified 27 miRNAs 
differentially expressed between AML and ALL [148]. The 4 most discriminatory were: 
miR-128a and miR-128b upregulated in ALL and let-7 and miR-223 downregulated in 
ALL. Interestingly, MLL related leukemias clustered with their lymphoid or myeloid 
counterparts, and not together. Several AMLs and ALLs with the same MLL-ENL 
translocation clustered with their lymphoid and myeloid counterparts, suggesting that 
these miRNAs are regulated by factors other than MLL.  
 Further examination of the miRNA expression differences between ALL and 
AML, were performed using 85 leukemia patient samples with either ALL or AML and 
identified a signature of 16 miRNAs differentially expressed between ALL and AML 
[149]. This signature identified 9 miRNAs upregulated (miR-128a, miR-128b, miR-155, 
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miR-146a, miR-150, miR-17, miR-20a, miR-29a/c, and miR-29b) and 7 miRNAs 
downregulated (miR-223, miR-196b, miR-221, miR-222, miR-23a, miR-27a/b, and let-7) 
in ALL relative to AML. This study also identified miRNAs whose expression positively 
or negatively correlated with overall survival for ALL (miR-221 was associated with 
improved survival, while miR-146a, miR-181a/c were associated with poorer survival) 
and AML patients (miR-25 was associated with improved survival, while miR-26, miR-
29b, miR-146a, and miR-196b were associated with poorer survival). 
 Numerous studies have examined the expression of miRNAs in both ALL and 
AML, looking for patterns of miRNA dysregulation corresponding to molecular subtype 
and prognosis.  Studies of miRNA dysregulation in ALL have examined the differential 
expression of miRNAs within ALL, including those harboring MLL translocations.  One 
study performed by Zanette et al. examined the miRNA expression profiles of 
lymphocytic leukemias utilizing a Taqman system designed to asses miRNA levels for 
164 commonly expressed miRNAs [150].  ALL samples were pooled and compared to 
both B-CLL and CD19+ B-Cells.  Pooled ALL samples identified a  miRNA signature 
differentiating ALL from CD19+ B-Cells.  The 5 most highly upregulated miRNAs were 
miR-128b, miR-204, miR-218, miR-331, and miR-181; while the 5 most downregulated 
miRNAs were miR-135b, miR-132, miR-199, miR-139, and miR-150 [150].  In addition to 
the most highly upregulated miRNAs, the authors also detected elevated expression of 
miRNAs of the miR-17-92 cluster, as well as the miR-17 family member miR-106a [150].  
Schotte et al. examined miRNA expression in MLL and non-MLL precursor B-ALLs 
(including TEL-AML1, BCR-ABL, E2A-PBX1, hyperdiploid leukemias, and B-ALLs 
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lacking known genetic abnormalities) [151].  ALLs had a genetic signature or 19 
miRNAs differentially expressed between ALL and CD34+ cells, with 14 upregulated 
miRNAs (miR-128a, -142-3p, 142-5p, -150, -151-5p, -181a, -181b, -181c, -193, -30e-5p, 
-34b, -365, -582, -708) and 5 downregulated miRNAs (miR-100, -125b, -99a, -196b, let-
7e). MLL ALLs had a miRNA expression pattern that was distinct from non-MLL 
precursor B-ALLs with 1 miRNA upregulated (miR-196b) and 7 miRNAs downregulated 
(miR-193, -151-5p, -30e-5p, -34b, -582, -708, let-7e) (Table 1). Strikingly, miR-196b was 
expressed 560-fold higher than in B-ALLs lacking known genetic abnormalities [151]. 
 Numerous studies have examined miRNA dysregulation of AML through high 
throughput methodologies, attempting to characterize differential miRNA expression 
between different cytogenetic abnormalities [152-156] and among cytogenetically normal 
AML [155, 157-159].  Jongen-Lavrencic et al. utilized a multiplex qRT-PCR assay 
system to characterize miRNA dysregulation of AMLs with common cytogenetic 
abnormalities and molecular abnormalities [153]. Unsupervised clustering analysis 
indicated 22 clusters of similar miRNA expression, which in turn corresponded to 
cytogentic subgroups (i.e. cytogenetic abnormalities) and molecular subgroups (i.e. 
commonly observed mutations observed within cytogenetically normal AMLs).  MLL 
leukemias showed upregulation of miR-9 and miR-429 and downregulation of miR-213 
and miR-146a relative to all non-MLL AMLs.  Dixon-McIver, et al. analyzed 157 
miRNAs from 100 AML patients via a multiplex qRT-PCR platform [154].  Normal bone 
marrow vs. AML showed a signature of 17 upregulated miRNAs (miR-27a, miR-30d, 
miR-142-5p, miR-155, miR-181a/b/c, miR-195, miR-221, miR-222, miR-324-5p, miR-326, 
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miR-328, miR-331, miR-340, miR-374, and let-7) and 16 downregulated miRNAs (miR-
9*, miR-15b, miR-26a, miR-30a-3p, miR-34c, miR-103, miR-147, miR-151, miR-182, 
miR-184, miR-199a, miR-302b*, miR-302d, miR-325, miR-367, miR-372).   MLL 
leukemias clustered together with monocytic leukemias.  Garzon et al. examined the 
differential miRNA expression patterns by microarray and qPCR validation with respect 
to both cytogenetic abnormality and prognosis [155]. Examination of miRNA levels in 
AML samples revealed a signature of 26 miRNAs downregulated and none upregulated 
relative to miRNA expression in CD34+ cells from normal bone marrow donors. Further, 
elevated miR-191 or miR-199 expression were negatively correlated to event-free and 
overall survival.  Within AML samples, MLL leukemias were identified by a signature of 
8 upregulated miRNAs and 14 downregulated miRNAs relative to non-MLL patients. 
Variance within the MLL translocated samples was further present with 16 miRNAs 
upregulated in MLL-AF6 relative to MLL-AF9, indicating an increased level of 
complexity governing MLL miRNA regulation.  A high throughput bead based study by 
Jianjun Chen's group examined the differential miRNA expression between several 
common cytogentically abnormal AMLs, including Core Binding Factor translocations, 
PML-RARα translocations, and MLL translocations [152]. The miR-17-92 cluster was 
strongly upregulated in MLL leukemias relative to non-MLL AMLs.  Several miRNAs 
from within the HOX cluster, miR-196b, miR-10a, and miR-10b are upregulated in MLL 
leukemias. MiR-124a and j-miR-2 were also upregulated. Several miRNAs were down 
regulated in MLL leukemias relative to non MLL leukemias including the miR-181 
family (miR-181a/b/c/d), miR-126/miR-126*, miR-130a, miR-146a, miR-224, miR-368,  
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TABLE 1. miRNAs differentially expressed in acute leukemias 
     
Subject Compared Upregulated Downregulated Reference 
t(11q23) ALL AML 
miR-128a, - 128b,-130, -151, -
210, j-miR-1 
miR-223, -125a, -221, -222, -23a, 
-23b, -24, -27a, -27b, -199b, -26a, 
-335, -21, -22, -424, -451, let-7a, 
let-7b, let-7c, let-7e 
Mi, et 
al.[148] 
ALL AML 
miR-128a, miR-128b, miR-155, 
miR-146a, miR-150, miR-17, miR-
20a, miR-29a/c, and miR-29b 
miR-223, miR-196b, miR-221, 
miR-222, miR-23a, miR-27a/b, 
and let-7 
Wang, et al. 
[149] 
inv(16) other AMLs 
miR-424, -199b, -365, -335, -511, 
-193a 
miR-192, -296, -155, -148a, -218, 
-135b, -196b, -196a, -432, -135a, 
-10a, -10b, -127, -let-7b 
Jongen-
Lavrencic, et 
al. [153] 
t(8;21) AML other AMLs miR-126* 
miR -19a, -221, -107, -188, -338, -
342, -20b, -187, -501, -339, -210, 
-502, -182, -500, -152, -135a, -
148a, -125b, -100, -99a, -1, -133a, 
-133b, -224, -9, -10a, - 10b, -
196a, -196b, let-7b, let-7c 
Jongen-
Lavrencic, et 
al. [153] 
t(15;17) 
AML 
other AMLs 
miR-130a, -130b, -335, -148a, -
222, -146a, -181d, -193a, -450, -
213, -199, -409-5p, -181b, -496, -
181a, -424, -497, -154, -125b, -
365, -369-5p, -99a, -203, -433, -
323, -494, -100, -370, -432, -224, 
-127, -452, -299-5p, -376a, -134, -
485-5p, -382, -379, -193b 
miR-196a, -196b, -151,-10b, let-
7c 
Jongen-
Lavrencic, et 
al. [153] 
t(11q23) 
AML 
other AMLs miR-9, -429 miR-213, -146a 
Jongen-
Lavrencic, et 
al. [153] 
NPM1 
mutated AML 
other AMLs 
miR-10a, -10b, -135a, -196b, -
196a, -152, let-7b 
miR-99b, 323, -143, -146a, -497, -
320 -511, -450, -151, -494, -193b, 
-365, -203, -335, -130a, -485-5p, -
126*, -299-5p, -433, -451, -134, -
370, -379, -432, -224, -382, -376a, 
-424, -127 
Jongen-
Lavrencic, et 
al. [153] 
FLT3 
mutated AML 
other AMLs miR-511, -155, -10b, -135a 
miR-30a-3p, -203, -130a, -214, -
338, -143, -145, -182 
Jongen-
Lavrencic, et 
al. [153] 
ALL 
CD19+ 
normal 
miR-128b, -204, -218, -331, -
181b, -204, -148, -210, -218, -
296, -381, 17-3p, -17-5p, -19a, -
20, -92 
miR-135b, -132, -199, -139, -150 
Zanette, et 
al. [150] 
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ALL 
normal 
CD34+ 
miR-128a, -142-3p, 142-5p, -150, 
-151-5p, -181a, -181b, -181c, -
193, -30e-5p, -34b, -365, -582, -
708 
miR-100, -125b, -99a, -196b, let-
7e 
Schotte, et 
al. [151] 
t(11q23) ALL other ALL miR-196b 
miR-193, -151-5p, -30e-5p, -34b, -
582, -708, let-7e 
Schotte, et 
al. [151] 
AML 
normal 
CD34+ 
NA 
miR-126, -130a, -135, -93, -146, -
106b, -224, 125a, -92, -106a, -95, 
-155, -25, -96, -124a, -18, -20, -
7d, -26a, -222, -101, -338, -371, -
199b, -29b, -301 
Garzon, et 
al.[155] 
t(11q23) 
AML 
other AMLs 
miR-326, -219, -194, -301, -324, -
339, -99b, 328 
miR-34b, -15a, -29c, -372, -30a, -
29b, -30e, -196a, let-7f, -102, -
331, -229, -193 
Garzon, et 
al.[155] 
FLT3 
mutated AML 
FLT3 wt miR-155, -10a, -10b NA 
Garzon, et 
al.[155] 
NPM1 
mutated AML 
NPM1 
unmutated 
AML 
miR-10a, -10b, -100, -21, -16a, -
16b, -19b, -18a, -29c, -29a, -16-1, 
-29b, -24, -20, -17, -369, - 19a, -
106, -16-2, -195, -102, -152, -9, -
142, -378, -98, -374, -15a, 155, 
let-7a-3, let-7f, let-7c, let-7a-2, 
let-7a-1, let-7g, let-7d 
miR-22, -192, -128a, -383, -373, -
324, -127, -373, -324, -127, -373*, 
-139, -193b, -145, -498, -135a, -
299, -429, -493, -326, -204, -198, 
486 
Garzon, et 
al. [159] 
FLT3 
mutated AML 
FLT3 wt miR-155, -302a, -133a NA 
Garzon, et 
al. [159] 
t(11q23) 
AML 
Other AMLs 
miR-27a, miR-30d, miR-142-5p, 
miR-155, miR-181a/b/c, miR-195, 
miR-221, miR-222, miR-324-5p, 
miR-326, miR-328, miR-331, miR-
340, miR-374, and let-7 
miR-9*, miR-15b, miR-26a, miR-
30a-3p, miR-34c, miR-103, miR-
147, miR-151, miR-182, miR-184, 
miR-199a, miR-302b*, miR-302d, 
miR-325, miR-367, miR-372 
Dixon-
McIver, et 
al. [154] 
t(8;21), 
inv(16), 
t(16;16) 
AML 
other AMLs miR-126/126*, -130a 
miR-196b, -17-5p, -17-3p, -18a, -
19a, 19b, 20a, 92 
Li, et al. 
[152] 
t(15;17) 
AML 
other AMLs 
miR-181a, -181b, -181c, -181d, -
100, -125b, -224, -368, -382, -424 
miR-126/126*, -422b, -10a, -150, 
-124a, -17-5p, -20a, j-miR-2 
Li, et al. 
[152] 
t(11q23) 
AML 
other AMLs 
miR-10a, -10b, -124a, -196b, -17-
5p, -17-3p, -18a, -19a, -19b, -20a, 
-92, j-miR-2 
miR-126/126*, -130a, -146a, -
181a, -181b, -181c, -181d, -224, -
368, -382, -424 
Li, et al. 
[152] 
t(11q23) 
AML 
Other AMLs miR-21 
miR-26a, miR-30c, miR-30d, miR-
100, miR-125b, miR-126-3p, miR-
143, miR-146a, miR-146b-5p, 
miR-181a, miR-181b, miR-181d, 
miR-221, miR-222, and let-7 
Dashkey, et 
al. [156] 
 
miRNA dysregulation was cataloged for miRNAs dysregulated in acute 
leukemias. Adapted from Mian and Zeleznik-Le [8]. 
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miR-424.  Dashkey et al. examined 102 samples from childhood and adolescent AMLs 
by microarray across multiple cytogenetic abnormalities, including: CBF translocations, 
PML-RARα translocations, and MLL rearrangements [156]. MLL leukemias showed a 
unique signature relative to non MLL leukemias of 15 downregulated miRNAs (miR-26a, 
miR-30c, miR-30d, miR-100, miR-125b, miR-126-3p, miR-143, miR-146a, miR-146b-5p, 
miR-181a, miR-181b, miR-181d, miR-221, miR-222, and let-7) and a single upregulated 
miRNA (miR-21).  
 Collectively, these studies of miRNA signatures of AMLs with different 
cytogenetic abnormalities present very different pictures, with some overlap in results. 
These differences can be attributed to different comparison groups and different 
platforms.  However, the role of several miRNAs were verified by detailed functional 
studies verifying dysregulation of miRNAs.   
HOX associated miRNAs 
5 miRNAs are located within the HOX clusters in mammals, including miR-10a, 
miR-10b, and miR-196a-1, miR-196a-2, and miR-196b [160]. Several of these miRNAs 
have been shown to be upregulated in MLL AML relative to non-MLL AMLs [152].  
miR-196b has several homologs located at other loci within the HOX clusters.  Mir-196a-
1 and miR-196a-2 are located upstream from HOXB9 and HOXC9, respectively (Figure 
6).  Within the miR-196 family, miR-196a and miR-196b differ only at nucleotide 12 with 
miR-196a encoding an adenine and miR-196b encoding a uracil [161].  Both miR-196a-1 
and miR-196a-2 are identical in their mature miRNA sequence (Figure 6).  
MiR-196b is located within the HOXA9 locus and is evolutionarily conserved 
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throughout mammals [11]. The pri-miR-196 transcript is a non-coding transcript that is 
expressed from an alternate AB exon of HOXA9 that is directly regulated by MLL and is 
highly upregulated in MLL AMLs relative to other non-MLL AMLs [11, 152].  Previous 
work from our lab has shown that inhibition of miR-196b through 'antagomir' inhibitors 
abrogates the leukemogenic capacity of MLL-AF9 transduced bone marrow, while 
transduction of miR-196b enhances colony forming ability of murine bone marrow 
progenitor cells [11]. Studies of miR-196b in ALL have revealed that miR-196 expression 
levels correlate with HOXA9 expression and miR-196b is upregulated in ALLs where the 
HOXA cluster is often highly expressed [162]. miR-196b was implicated in the 
downregulation of HOXA9 and MEIS1 in MLL leukemia  [163].  Overexpression of miR-
196b in a murine model transformed with MLL-AF9 results in a delay in onset of AML, 
implicating miR-196b can function as a tumor suppressor.  Secondary transplantation, 
however, result in an accelerated onset of leukemia, indicating the dualistic role of miR-
196b in targeting both oncogenes and tumor suppressors [163].    
 miR-196 was initially characterized as regulator of HOXB8 despite a G:U wobble 
mismatch located within the seed region matching site of the HOXB8 MRE [161]. In 
addition to regulating HOXB8, miR-196a and miR-196b are predicted to regulate several 
additional HOX genes, including HOXC8, HOXD8, and HOXA7 (Figure 6). 
Numerous studies have implicated miR-196 in development and hematopoiesis.  
During embryonic development, miR-196 downregulates Hoxb8, which induces 
expression of Sonic hedgehog (Shh) to promote the development of nascent limb buds 
[164].  In embryonic chicken development, miR-196b regulation of Hoxb8 governs  
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Figure 6. HOX associated miRNAs 
 
 
 
 
 
A) Schematic depiction of HOX associated miRNAs in human. miRNAs are indicated by 
stem loop structures drawn onto HOX clusters.  miRNA regulatory relationships with 
HOX genes are indicated on chart. Adapted from Yekta et. al. [160]. B) miRNA sequences 
from the miR-10 and miR-196 families grouped by family and color  coded with the miR-
196 family indicated in green and the miR-10 family in orange. Seed region indicated in 
red. Underlined sequences indicate non conserved bases. 
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vertebrate segmental identity, with specific knockdown of miR-196 resulting in skeletal 
abnormalities in the last cervical vertebra [165]. 
miR-196b is dysregulated in a number of additional cancer models, as both an 
oncogene and tumor suppressor; including glioblastoma multiforme [166], cervical 
cancer [167], and chronic myeloid leukemias [168].  In glioblastoma, high miR-196b 
expression levels are correlated to lower overall survival  with increased cellular 
proliferation, implicating miR-196b as a potential oncogene [166].  However, in cervical 
cancer and chronic myeloid leukemia, miR-196b has been shown to function as a tumor 
suppressor, regulating HOXB7 in cervical cancer [167], and BCR-ABL and HOXA9 in 
CML [168]. 
 In addition to miR-196b, miR-10a also arises from within the HOX gene clusters 
and has been found to be upregulated in MLL leukemias [152].  The miR-10 family is 
comprised of two HOX cluster located miRNAs. miR-10a is located downstream of 
HOXB4, while miR-10b is located downstream of HOXD4 [169].  miR-10a and miR-10b 
differ only in nucleotide 12, with miR-10a encoding a uracil and miR-10b encoding an 
adenine [169].  miR-10 family members have been implicated in both canonical miRNA 
function through RISC-mediated mRNA downregulation as well as non-canonical 
function.  For example, miR-10b downregulates HOXD10 in breast cancer through the 
canonical miRNA:RISC mechanism, leading to a decrease in HOXD10 mRNA stability 
and an increase in tumor metastasis [170].  However,  miR-10a has been shown to bind to 
TOP motif containing mRNA transcripts, immediately downstream of the TOP motif, 
resulting in increased expression of these target mRNAs [144]. TOP (terminal 
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oligopyrimidine tract) sequences consist of a short tract of 4-15 pyrimidine residues 
located adjacent to the 5' cap within the 5'UTR of an mRNA, and have a regulatory 
function as a binding site for translational repressors [171].  The role of miR-10a in 
regulating the translation of these mRNAs is unusual in that: 1) it does not entail perfect 
seed matching between miR-10a and the target, and 2) binding of miR-10a results in an 
increase in translation rather than a decrease [144]. 
miR-17-92 cluster 
 The miR-17-92 cluster (also known as oncomir-1) consists of 6 miRNAs co-
expressed from a single transcript (miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1, and 
miR-92 located on band q31 of chromosome 13 in humans [172, 173] .  The miR-17-92 
cluster has several homologous miRNA clusters including the miR-106a cluster and the 
miR-106b cluster located on chromosome X band q26 and chromosome 7 band q22, 
respectively (Figure 7). The miR-17-92 cluster arises from an intron of a pri-miRNA 
transcript that is non-coding. However, the homologous miR-106a primary miRNA 
transcript has not been identified  [174].  The miR-106b cluster arises from an intron of 
the MCM7 mRNA transcript, which encodes a protein, mini chromosome maintenance 7, 
and includes only 3 different miRNA encoding hairpins [174]. 
Numerous studies have implicated the miR-17-92 cluster in cancers, cell cycle 
control, and development (extensively reviewed in [173, 175]).  Knockout of the miR-17-
92 cluster and its homologous clusters in mouse models produced several distinct 
phenotypes.  miR-17-92 (-/-) embryos are smaller than their wild type counterparts, and  
miR-17-92 knockout mice die shortly after birth, with lung hypoplasia [176]. In these 
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studies, bone marrow transplantation experiments implicated the miR-17-92 cluster in B 
cell development [176].  
 The miR-17-92 cluster was initially identified as a target of Myc regulation [177].  
However, recent studies have indicated that additional regulatory factors also control 
miR-17-92 expression. Examination of endogenous E2F binding indicates that E2F1, 
E2F2, and E2F3 bind to the miR-17-92 promoter and increase  transcription of the miR-
17-92 host gene [178]. Further studies, indicate that p53 suppresses miR-17-92 
expression through direct transcriptional regulation under hypoxic conditions [179]. 
Examination of the miR-17-92 cluster in MLL leukemia has identified a direct regulatory 
relationship by both wild-type MLL and MLL fusion proteins [12].  Both wild type and 
fusion MLL proteins localize to the promoter of the miR-17-92 host gene, as indicated by 
chromatin immunoprecipitation assays [12].  Cell lines with MLL translocations showed 
an increase in MLL binding to the miR-17-92 promoter, increased H3 acetylation, and 
H3K4 trimethylation as compared to those without MLL translocations [12]. Further, 
examination of miRNA expression profiles in AML with common translocations indicate 
that the miR-17-92 cluster is upregulated in MLL AMLs relative to non-MLL AMLs  
[152].  The miR-17-92 cluster and its homologous miRNA clusters, encode four families 
of miRNA categorized by homology in the seed region (miRNA sequences are reviewed 
in [172, 173]).  Homologous miRNAs are generally accepted to have overlapping 
functions and target sequences, as a result of commonalities within the seed region. For 
example,  miR-17 and -20a share the same seed sequence which is critical for target 
recognition (reviewed in [174]).  
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Figure 7. miR-17-92 cluster and related miRNAs 
 
 
A) Organization of the miRNAs within the miR-17-92 cluster (top), miR-106a-363 cluster 
(middle), and miR-106b-25 cluster (bottom). Light colored box indicates the arm (5p or 
3p) which produces the predominant mature miRNA.  miRNA families are grouped by 
color with the miR-17 family indicated in blue, miR-19 family in orange, miR-18a family 
in red, and the miR-92 family in green.  B) miRNA sequences from the miR-17-92 cluster 
and paralogous clusters.  miRNAs organized by family. Seed region indicated in red. 
Underlined sequences indicate non conserved bases.  
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The miR-17 family is comprised of miR-17 and miR-20a of the miR-17-92 cluster; 
miR-106a and miR-20b of the miR-106a-363 cluster, and miR-106b and miR-93 of the 
miR-106b-25 cluster. MiRNAs of the miR-17 family have a common seed sequence of 
AAAGUG, and share a great deal of homology throughout non-seed nucleotides as well, 
often differing at only one or two nucleotides (Figure 7). Within the miR-17-92 cluster, 
miR-17 and miR-20a differ at nucleotides 1 and 12, with miR-17 possessing cytosines in 
these positions, and miR-20a possessing uracils.  The miR-17 family, which is comprised 
of miR-17 and miR-20a, is one of the most studied miRNA families, with numerous 
defined targets, including (but not limited to): AIB1 [180], HSP27 [181], and TGFβ 
[182]. Critically, the miR-17 family has been implicated in cell cycle progression, 
through regulation of several components the G1/S checkpoint.  MiR-17 downregulates 
the negative checkpoint regulator CDKN1A (p21) [183].  Further examination of the miR-
17 homolog miR-106a, indicated that miR-106 also directly targets CDKN1A (p21) 
[184].Conversely, miR-17 also downregulates the expression of E2F1, and in doing so 
prevents the cell from dying due to double strand breaks that would otherwise occur as a 
result of unrestricted growth [177, 185].  In addition to E2F1, miR-20a regulates several 
other E2F family members, including E2F2 and E2F3 [178].  Recent work has identified 
a feedback loop whereby the miR-17-92 cluster downregulates E2Fs which regulate the 
miR-17-92 cluster. Within hematopoiesis, miR-17, 20a, and106a have been implicated as 
regulators of monocytopoiesis through downregulation of AML1, which functions to 
positively regulate the M-CSF receptor and negatively regulate the miR-17-92 and miR-
106a-363 clusters [186]. Introduction of  exogenous miRNAs from the miR-17 family 
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into cord blood CD34+ progenitor cells cultured under a monocytic differentiation 
protocol resulted in an increase in blast cells and inhibition of monocytic differentiation 
while inhibition of miRNAs from the miR-17 family results in decreased proliferation and 
increased differentiation [186].  
The miR-19 family is comprised of 2 separate 23 nucleotide miRNAs, miR-19a 
and miR-19b-1, and have a common seed sequence of GUGCAA (Figure 7).  MiR-19a 
and miR- 19b differ in only a single nucleotide at position 11; miR-19a has an uracil, 
while miR-19b has a cytosine. Located outside of the seed region, these nucleotides are 
involved in stabilization of the miRNA:mRNA interaction, but are not essential for 
targeting the miRNA to the transcript.  Numerous miR-19 targets have been identified, 
including (but not limited to): TNFα [187, 188], BCL2L11 [189], and PTEN [190]. Of 
these targets, PTEN is often cited as a critical downstream target of the miR-19 family.  
The regulatory relationship between miR-19 and PTEN was initially described using an 
Eµ-myc model of lymphoma, where overexpression of miR-19b resulted in decreased 
PTEN levels and increased cell survival [190]. 
miR-18a is additionally located within the miR-17-92 cluster, while its homolog 
miR-18b is within the miR-106a-363 cluster. MiR-18a differs from miR-18b at a single 
nucleotide with a uracil instead of a cytosine, and both share a common seed sequence of 
AAGGUG (Figure 7).  MiR-18a is one of the least well studied miRNAs of the miR-17-
92 cluster.  However, several mRNAs have been identified as miR-18a targets, including 
(but not limited to): PIAS3 [191],  CTGF [192], and SMAD4 [182]..  Intriguingly, miR-
18a was found to inhibit the global function of miRNAs through targeting of the Dicer 
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mRNA [193].  In a cardiovascular model, miR-18, along with miR-19, has been 
implicated in the regulation of angiogenesis via downregulation of the pro-angiogenic 
factors CTGF and Tsp1 [192].  MiR-18a regulates function of the TGF-β signaling 
pathway through downregulation of the downstream effector  SMAD4 [182].  
The miR-92 family is represented by miR-92a-1 within the miR-17-92 cluster; 
miR-92a-2 and miR-363 within the miR-106a-363 cluster; and miR-25 within the miR-
106b-25 cluster (Figure 7). Numerous miR-92 targets have been identified including (but 
not limited to): Integrin-5a [194], VHL [195], and PHLPP2 [196].  Critically, miR-92 has 
been implicated in regulating apoptosis through regulation of BCL2L11 (Bim) [197]. 
Several mRNAs have been validated as targets of multiple non-family miRNAs 
from the miR-17-92 cluster, suggesting that miRNAs may act cooperatively to regulate 
targets.  For example, PTEN is downregulated by miR-17, miR-19, and miR-18a through 
miRNA binding to unrelated MREs within the 3'UTR [190, 198, 199].  The pro-apoptotic 
BCL2 family member BCL2L11 (Bim) is an additional target of cooperation for miRNAs 
of the miR-17-92 cluster, regulated by both miR-19 [189] and miR-92 [197]. Despite the 
extensive work published on validating targets of the miR-17-92 cluster, few studies have 
examined the contributions of this cluster to MLL leukemia or validated the potential 
mechanism by which the miR-17-92 cluster acts in MLL leukemia. Enforced 
overexpression of miR-17-19b increases the colony forming ability of MLL-ELL 
transformed bone marrow [12]. Further, overexpression of the miR-17-92 cluster results 
in downregulation of 363 potential target genes, indicating that dysregulation of the miR-
17-92 cluster has broad implications in target mRNA regulation [12].  Within MLL 
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leukemia, miR-17 regulates CDKN1A (p21) expression [183]. Overexpression of miR-17-
19b accelerated the onset of MLL-AF10 leukemia in a murine model, which was 
phenocopied by shRNA knockdown of CDKN1A (p21).  The growing number of 
validated targets for each miRNA suggests that miRNAs are not limited to single targets, 
and that other, as yet non-validated targets, likely contribute to the disease process. 
Antisense oligonucleotide technologies 
Findings highlighting the importance of miRNAs in cancer, as well as other 
diseases, have drawn attention to the potential therapeutic value of modulating miRNA 
function, either by replacing lost/downregulated miRNAs or inhibiting 
amplified/overexpressed miRNAs.  To this end, multiple different technologies have 
emerged to modulate miRNA levels utilizing synthetically manufactured oligos (history 
of oligonucleotide therapeutics reviewed in [8, 13, 14]).   
As miRNAs function to post-transcriptionally regulate transcription, replacement 
of lost miRNA function may be achieved using anti-sense oligonucleotides (ASOs) 
complementary to sequences found in target mRNAs and function in both RISC-
dependent and RISC-independent functions.  RISC-independent mechanisms of ASO 
function target specific mRNAs with perfectly matched complementary oligonucleotides 
(oligos), and recruit the endogenously expressed RNAse H to cleave the mRNA:ASO 
duplex (reviewed in [8, 200]).  Alternatively, RISC-dependent replacements of miRNA 
function can be attained through introducing either a shRNA, siRNA, or miRNA 
analogue (reviewed in [201]). 
 Numerous chemical modifications have been developed for use in oligos (Figure 
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8). The chemical modifications utilized for anti-miRNA oligonucleotides (AMOs) were 
developed from those used for synthetic siRNAs and mRNA targeting ASOs, and utilize 
the same modifications. AMOs directed against miRNAs function through stable binding 
to miRNAs. AMO downregulation of miRNAs occurs through irreversible binding and 
sequestration of target miRNAs [202]. Thus their most valuable attributes are a high 
thermodynamic stability, compatibility with binding to RISC associated miRNAs, and 
resistance to nuclease degradation (discussed in [13, 203]).  Inhibition of miRNA 
function is dependent on chemically modified anti-sense oligonucleotides (ASOs) that are 
complementary to the target miRNAs and inhibit miRNA activity through 
thermodynamically stable Watson-Crick base pairing to target miRNAs (reviewed in 
[13]).  The simplest ASOs may employ either unmodified RNA or DNA nucleotides 
complementary to the target miRNA.  However, unmodified oligos are poor candidates 
for therapeutic use due to immune response activation, rapid oligo degradation, poor 
cellular uptake, and limited bioavailability of ASOs (reviewed in [13, 200, 203]). To 
improve bioavailability, nuclease resistance, and miRNA:AMO duplex stability; 
numerous chemical modifications have been developed for ASOs, including modification 
of the phosphodiester backbone and modification of the ribose sugars. 
Modifications of the non-bridging oxygen of the phosphate group linking the 
ribose sugars of the backbone, include methylphosphonates, phosphorothioates, and 
boranophosphonates (reviewed in [14, 201, 203]). Modification of the non-bridging 
oxygen introduces chirality to the phosphate, and each modification results in a racemic 
mixture of both stereoisoforms of the of the phosphodiester linkage [203], increasing 
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levels of nuclease incorporation result in increasing nuclease resistance. 
Phosphorothioate modifications consist of the addition of a sulfur in place of one 
of the non-bridging oxygen molecules of a phosphate within the oligo backbone.  A 
phosphorothioate modification confers resistance against RNAse degradation, at a slight 
cost of binding affinity (~0.25° C/modification)[13], and thus may require additional 
modifications to offset decrease in binding affinity.  Further, in vivo examination of 
siRNAs indicates that inclusion of phosphorothioate modifications modestly improved 
serum stability of siRNAs, and produces similar biodistribution of siRNAs among organs 
[204].  Phosphorothioate modifications are nuclease resistant, thus conferring a level of 
resistance to degradation [205], but  are compatible with RNAse H, and thus suitable for 
use in ASO designs [14, 205]. 
Numerous modifications alter the ribose sugar at the 2' position, directly binding 
either the 2' carbon or modifying the attached hydroxyl group, including: 2'- O-Methyl 
(2'-O-Me), 2'-O-methoxyethyl (2'-O-MOE), 2'-Flouro (2'-F), 2'-Deoxy-2'-fluoro-β-D-
arabino (FANA), N3'-P5' phosphoramidates (NPs), and locked nucleic acids (LNA) 
(reviewed in [13, 200, 201]).  The sugars of nucleotides exist in multiple different 
"pucker" conformations, which are described by the angles of the C2 and C3 tetrahedral 
bonds of the furanose ring [203].  The principle stable sugar conformations employ either 
a C3-endo, C2-exo conformation (a.k.a. North conformation, N-type conformation) or a 
C3-exo, C2'-endo conformation (a.k.a. South conformation, S-type conformation) [206].  
Pucker conformation, in turn,  alters the bond lengths of the sugar and phosphate bonds 
of nucleic acids, altering the thermodynamic stability of base pairing [207]. 
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2'- O-Methyl (2'-O-Me) modifications have been widely utilized in ASO 
development. As with other modifications to the 2' position of the ribose sugars, 2'-O-Me 
modifications improve the binding affinity of the oligo by forcing the ribose sugars into a 
C3-endo conformation, resulting in an increase in thermodynamic binding stability of 2-3 
°C/nucleotide [203].  Examination of chemically modified siRNAs has indicated that 
incorporation of 2'-O-Me modifications confers resistance to immune activation [208].  
2'-O-Me modified oligos were applied to AMOs targeting miRNAs incorporated in a 
RISC complex in 2004. Two independent studies examined the use of uniformly 
modified 2'-O-Me oligonucleotides to block the function of siRNAs associated with the 
RISC complex in C. elegans [209] and human cell lines [210], and found the modified 
oligonucleotides to be capable of inhibiting the function of siRNAs and miRNAs within 
RNA-protein complexes. The 2'-O-methoxyethyl (2'-O-MOE) modification is another 
commonly used 2'-alkyl ribose modification, altering ribose sugar conformation to result 
in an increase in thermodynamic binding stability of 2 °C/nucleotide [203].  
 Locked Nucleic Acids (LNAs) are a 2'-O, 4'-C-methylene-β-D-ribofuranosyl 
modified version of a ribose (consisting of a methylene bridge between the 2'-hydroxyl 
group and 4' carbon  of the ribose sugar), and were initially synthesized in 1998 [211, 
212].  As with other 2' ribose modifications, LNA modifications lock the ribose sugar 
into a C3 endo conformation and thermodynamically stabilizes binding to target 
nucleotides [213, 214].  Incorporation of locked nucleic acids additionally affects the 
pucker conformation of adjacent nucleotides [215]. LNAs increase the binding affinity of 
nucleotides in a sequence dependent manner with an increase in thermodynamic stability 
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that is partially dependent on adjacent nucleotides [216, 217], and results in a change in 
binding affinity of 1.5-6 °C/nucleotide [13].  In addition to improving the thermodynamic 
stability of binding with a target, incorporation of LNA modifications increase resistance 
to nuclease mediated degradation [218].  Further, LNAs are incompatible with RNAse H 
function but compatible with RISC activity function [219].  However, LNA 
simultaneously increase hepatic toxicity [220].  Several additional modifications are 
currently under development based on this chemistry, including amino-LNAs, thio-
LNAs, α-L-ribo-LNAs, and β-D-xylo-LNAs [213].   
 Chemical modifications appended to the ends of the oligo have been used to alter 
the distribution and serum half-life of antisense oligos.  Addition of a cholesterol to the 3' 
end of an oligonucleotide was initially described in the context of a siRNA targeting the 
ApoB mRNA transcript [221]. Cholesterol transport within the serum is mediated by 
binding to albumin, high density lipoprotein (HDL), and low density lipoprotein (LDL) 
[222, 223].  In addition to the cholesterol tag, several modified lipids (of varying lengths) 
have been employed as tags conjugated to the 3' end of siRNAs, including: myristoyl, 
lithocolic-oleyl, docosanyl, lauroyl, stearoyl, palmitoyl, oleoyl, and linoleoyl tags [224]. 
Modification of siRNAs by different lipophilic conjugates altered the biodistribution of 
siRNAs in vivo [224].  Uptake method in vivo relies on the human homolog to the C 
elegans transmembrane receptor Sid1 as well as the SR-B1 receptor [224].  
Oligonucleotide chemical modifications are modular and may be applied across 
the oligo or only at specific residues, resulting in 'mixmers," consisting of combinations 
of multiple different chemical modifications and variation in the length of antisense 
52 
 
 
 
oligonucleotides suited to different functions.  Numerous chimeric mixtures of 
oligonucleotide modifications have been employed for specifically targeting miRNAs, 
including: 2'-O-MOE/PS [225], 2'-O-MOE/LNA/PS [226], 2'-O-Me/LNA/PS [227], 
LNA/2'-O-Me [228], 2'-O-MOE/2'-F [229]. While numerous studies have utilized AMOs 
of the same length as the target miRNA, additional studies have utilized AMOs shorter 
than the target, focusing on developing the minimally required oligos so as to minimize 
toxicity and non-specific binding while maintaining target affinity. For example, an 8-
mer oligonucleotide, comprised of LNAs with a complete phosphorothioate backbone, 
targeting the seed region of miR-33, provided efficient knockdown of both miR-33a and 
miR-33b in vivo in mouse and primate [230, 231].  
Among the different ASO patterns of modifications, ‘antagomirs’ were 
empirically developed as a specific pattern of multiple modifications consisting of:  2'-O-
Me modifications across all ribose sugars of the oligo, phosphorothioate bonds at the first 
two and the last four phosphodiester linkages, and a cholesterol tag at the 3' end of the 
oligo [232, 233].  These ASOs were initially characterized as a potential therapeutic 
intervention to inhibit miRNAs in vivo [232, 233].  Krutzfeldt, et al. tested several 
potential antagomir designs with different modification patterns.  They observed a 
decrease in knockdown efficiency for oligos containing phosphorothioate modifications 
of all phosphodiester bonds, relative to oligos with phosphorothioate modifications at the 
first 2 and last 4 phosphodiester bonds [232], and thus limited use to these specific 
residues to block RNAse function while minimizing negative effects.  
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Figure 8. Antisense oligonucleotide modifications and patterns 
 
 
 
Canonical miRNA biogenesis pathway. A) Selected modifications for anti-sense 
oligonucleotides. Adapted from DeLeavey, et al. [203]. B) Depiction of an unaltered 
oligo nucleotide (top) and a modified oligonucleotide with ‘antagomir’ modifications 
(bottom).  Phosphorothioate modifications depicted with red circles, 2’-O-Me 
modifications depicted in green, and cholesterol in yellow.  
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Further, in examining the specificity of antagomirs and the potential effects of 
single or multiple mismatches between the antagomir and the targeted miRNA, 
Krutzfeldt, et. al. observed that a single mismatch at key residues abrogated miRNA 
knockdown [232]. Examination of the subcellular location of fluorescently labeled 
antagomirs indicated that antagomir modified oligonucleotides localized within punctate 
structures located in the cytoplasm, but did not co-localize alongside the P-body marker 
GW182 [232].  Examination of target miRNAs upon antagomir treatment indicate 
consistent knockdown of target miRNAs throughout examined tissues [233].   
 Several groups have utilized the antagomir pattern of modifications to inhibit 
miRNA function in vitro and in vivo.  Previous work from our group, performed in 
collaboration with the Grimes lab, utilized an anti-miR-196b antagomir in vitro colony 
assay, to test the necessity of miR-196b to the clonogenic capacity of MLL-AF9 
transduced bone marrow progenitor cells [11]. Studies by the Grimes lab have utilized 
antagomir oligonucleotides against miR-21 and miR-196b to examine the contribution of 
miRNAs in AML in vivo [234, 235].  
In my dissertation research, I examine targeting miRNAs upregulated in MLL 
leukemia both individually and in combinations as a potential therapeutic approach.  I 
find that combinatorial antagomirs function as a potent anti-leukemia treatment in vitro.  I 
further examine the regulatory role of miRNAs in modulating the expression of PKNOX1 
and its availability for inclusion in HOX-PBX complexes. This establishes one potential 
mechanism by which miRNA inhibition disrupts the leukemogenic potential of MLL 
fusion proteins in leukemia.  
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CHAPTER 3 
MATERIALS AND METHODS 
Cell lines and culture conditions 
Human leukemia cell lines were obtained from DSMZ and cultured according to 
manufacturer’s instructions. MOLM-13 was derived from the peripheral blood of  a 
patient undergoing a relapse of M5 AML leukemia and harbors t(9;11) translocation 
resulting in an MLL-AF9 fusion [236].  The THP1 cell line also harbors an t(9;11) 
translocation, and is derived from a patient with a monocytic AML [237]. In addition to 
cell lines with MLL-AF9 gene fusions, I also examined several cell lines with t(4;11) 
translocations resulting in MLL-AF4 gene fusions.  RS4;11 is an MLL-AF4 expressing 
cell line derived from the bone marrow of a patient with a biphenotypic leukemia, 
expressing characteristics of both B-cells and monocytes [238].  The MV4-11 cell line 
also possesses an MLL-AF4 gene fusion, and was derived from the bone marrow of a 
patient with a childhood leukemia [239].  I additionally utilized U937 and HL60 as  non-
MLL cell line controls. U937 cells were derived from a patient with histiocytic 
lymphoma [240], while HL60 cells were derived from a patient with Acute myeloid 
leukemia and harbors a c-Myc amplification [241]. Experiments performed in adherent 
cell lines utilized HEK293T cells, originally derived from human embryonic kidney and 
transformed with the SV40 T antigen [242].  
MOLM-13 (MLL-AF9), and RS4;11 (MLL-AF4) were maintained at 
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concentrations between 1X10
5
 cells/mL and 1X10
6
 cells/mL in RPMI with 10% Fetal 
Bovine Serum and 1% Penicillin/Streptomycin (Pen/Strep).  MV4-11 (MLL-AF9) and 
K562 (BCR-ABL) was maintained at concentrations between 1X10
5
 cells/mL and 1X10
6
 
cells/mL in IMDM with 10% FBS and 1% Pen/Strep.  Adherent cell lines were cultured 
HEK293T, Rat1A, NIH-3T3 cells were cultured in DMEM with 10% FBS and 1% 
Pen/Strep. MLL-AF9 transformed bone marrow was cultured in liquid culture at 
concentrations between 3X10
5
 cells/mL and 1X10
6
 cells/mLin RPMI with 10% fetal 
bovine serum and 1% Pen/Strep.  Cells were supplemented with IL-3 (10 ng/mL), IL-6 
(10 ng/mL), and SCF (100 ng/mL) cytokines. All cells were kept at 37˚ C with 5% CO2. 
HEK293T cells were transfected using CalPhos Mammalian transfection system 
(ClonTech, Mountain View, CA, Cat #631312) per manufacturer’s instructions.   
Constructs  
MSCV-MLL-AF9 [23] MIGR1 [23], MSCV-Meis1-pgk-EGFP [94], and pKOF2-
Prep1-GFP [94] retroviral constructs were described previously.  Briefly, the MSCV-
MLL-AF9 retroviral construct contains a human MLL-AF9 fusion gene within the Murine 
Stem Cell Virus system and can be utilized to introduce and express genes of interest in 
hematopoietic stem cells.  The MSCV-Meis1-pgk-EGFP expresses a murine Meis1 within 
the MSCV retrovirus with a gene encoding a fluorescent protein, EGFP, expressed from a 
separate promoter [94].  The pKOF2-Prep1-GFP encodes the full length of Pknox1 (also 
known as Prep1) cloned into a modified MSCV vector, with GFP expressed from a 
separate promoter [94, 243]. 
Bone marrow isolation, enrichment, and infection for generation of MLL-AF9 
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transformed bone marrow was performed as previously described [244].  Additional 
infection with MIGR1 or pKOF2-Prep1-GFP was performed on MLL-AF9 bone marrow 
cell that had been cultured in methylcellulose for 4 weeks. 
pRL-TK (Promega, Madison, WI, Cat# E2241), MSCV-PIG [190], and MSCV-
PIG- miR-17-19b [190] have been described previously. The pRL-TK construct encodes  
Renilla luciferase  driven by the HSV-1 Thymodine Kinase promoter, and serves as a 
commonly used experimental control in luciferase due to: 1) the ability to readily 
distinguish between Renilla and Firefly luminescence, and 2) the constancy of expression 
of the luciferase enzyme under the TK promoter. Exogenous miRNA expression was 
attained through transfection with the MSCV-PIG- miR-17-19b  plasmid (received as a 
generous gift from Dr. Jianjun Chen, University of Cincinnati). MSCV-PIG- miR-17-19b 
was constructed by cloning a fragment of the miR-17-92 cluster containing the miRNA 
hairpins from miR-17 to miR-19b-1, within the MSCV (Mouse Stem Cell Virus) retroviral 
backbone [190].  The construct additionally contains a PIG cassette, encoding Puro- 
IRES-GFP for use in selection [190].  MSCV-PIG, which lacks any fragment o the miR-
17-92 cluster was used as a control. 
Luciferase constructs were generated by cloning the 3’ UTR from Pknox1 in the 
pmiR-Report system (ThermoFisher Scientific, Cat#AM5795).  The pmiR-Report system 
encodes a firefly luciferase gene driven by CMV promoter within the pmiR backbone. A 
multiple cloning site is located downstream of the luciferase to allow cloning of a 3'UTR.  
Mutations to the miRNA binding sites were generated using the Stratagene Multi-site 
directed mutagenesis kit (Stratagene, La Jolla, Cat# 200514).  Details of cloning 
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techniques and strategies described elsewhere in the Materials and Methods section. 
Antagomir modifications and treatment 
Antagomirs were synthesized by the Dharmacon division of Thermo (Lafayette, 
CO) following the pattern of modifications outlined previously [232, 233].  Antagomirs 
were designed as small oligonucleotides (oligos) complementary to the targeted miRNA. 
All nucleotides contained 2’-O-methyl modifications on the ribose sugar. For all oligos, 
the first 2 and last 4 phosphodiester linkages were replaced with a phosphorothioate 
linkage. The 3’ ends of all oligos possess a cholesterol group.  Fluorescent antagomirs 
possess an additional DY547 fluorescent label at the 5’ end.   
Antagomir treatments were performed according to 3 different protocols 
(specified in text).  For superficial treatment with antagomirs, cells were counted and 
resuspended in fresh culture medium at 2X treatment concentrations (100k cells/mL).  
Cells were then added to an equal volume containing antagomirs and 10X PBS in media 
at 2X the concentration of the final solution. Superficial antagomir treatment with pre-
incubation has been previously utilized by our lab and others [11, 234, 235].  For pre-
incubation, cells were incubated in 100 µL of culture media, with antagomir at 10X the 
final treatment concentration, along with 10X PBS to compensate for antagomir volume, 
on ice for 30 mins and followed by at room temperature for 5 mins.  The cell-antagomir 
mixture was then diluted tenfold with culture media (for liquid culture experiments) or 
with . Herein, I refer to this treatment as the "superficial treatment with pre-incubation" to 
distinguish it from simple superficial treatments that do not require any pre-incubations. 
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Table 2. Sequences and modifications of antagomirs 
  
antagomir antagomir sequence (5'→3') 
anti-Ce-mir-67 
mU*mC*mUmAmCmUmCmUmUmUmCmUmAmGmGmAmGm
GmUmU*mG*mU*mG*mA-Chl 
anti-Ce-mir-67-
DY547 
DY547*mU*mCmUmAmCmUmCmUmUmUmCmUmAmGmGm
AmGmGmUmU*mG*mU*mG*mA-Chl 
anti-mir-196b 
mC*mC*mCmAmAmCmAmAmCmAmGmGmAmAmAmCmUm
A*mC*mC*mU*mA-Chl 
anti-mir-10a 
mC*mA*mCmAmAmAmUmUmCmGmGmAmUmCmUmAmCm
AmG*mG*mG*mU*mA-Chl 
anti-mir-191 
mC*mA*mGmCmUmGmCmUmUmUmUmGmGmGmAmUmUm
CmC*mG*mU*mU*mG-Chl 
anti-mir-93* 
mC*mG*mGmGmAmAmGmUmGmCmUmAmGmCmUmCmAm
G*mC*mA*mG*mU-Chl 
anti-mir-17 
mC*mU*mAmCmCmUmGmCmAmCmUmGmUmAmAmGmCm
AmC*mU*mU*mU*mG-Chl 
anti-mir-18a 
mC*mU*mAmUmCmUmGmCmAmCmUmAmGmAmUmGmCm
AmC*mC*mU*mU*mA-Chl 
anti-mir-19a 
mU*mC*mAmGmUmUmUmUmGmCmAmUmAmGmAmUmUm
UmG*mC*mA*mC*mA-Chl 
anti-mir-19b-1 
mU*mC*mAmGmUmUmUmUmGmCmAmUmGmGmAmUmUm
UmG*mC*mA*mC*mA-Chl 
anti-mir-20a 
mC*mU*mAmCmCmUmGmCmAmCmUmAmUmAmAmGmCm
AmC*mU*mU*mU*mA-Chl 
anti-mir-92a-1 
mA*mC*mAmGmGmCmCmGmGmGmAmCmAmAmGmUmGm
C*mA*mA*mU*mA-Chl 
  
Antagomir sequences are depicted above. Stars (*) indicate phosphorothioate 
modifications to phosphodiester linkages. Lower-case m preceding nucleotide letter 
indicates 2'-O-Me  modifications to the furanose ring. 
 
For Lipofectamine 2000
TM
 treatment with antagomirs, cells were counted and 
resuspended in serum-free media.  Lipofectamine complexes were generated under sterile 
conditions according to the manufacturer's protocol maximal dosage for RNAi/RNA 
delivery (20 pmol or antagomiR).  Cells were subsequently treated for 48 hrs with 
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lipofectamine-antagomir complexes per the manufacturer's instructions.  
Preparation of retrovirus 
 Virus was generated from relevant retroviral constructs using Phoenix Eco 
packaging cells supplemented with packaging vector.  Plasmids were generated by 
maxiprep according to manufacturer’s instructions.  DNA was quantified with a 
Nanodrop 2000™  and transfected into Phoenix Eco cells by Calcium Phosphate 
transfection (ClonTech, Mountain View, CA, Cat# 631312) according to manufacturer’s 
protocol. Briefly, five 10 cm dishes were plated at 3x10
6
 cells/ plate.  Twenty four hours 
later, media was changed. Transfection mix was prepared by adding DNA to H20 to 
CaPO4.  DNA was added in the following amounts: 22.5 µg of ecotropic viral plasmid 
(MSCV-MLL-AF9, MIGR1, or pKOF2-Prep1-GFP )/plate and 2.5 µg packaging vector 
(pCL-Eco)/plate.  The mixture was briefly vortexed to mix and added dropwise to 2X 
HBS while gently vortexing the HBS. Complexes were left to form for 20 minutes in the 
sterile hood, after which the DNA complex solution was added dropwise to PhoenixEco 
cells across the plates.  Cells were incubated at 32˚C for 2 days.  Supernatant was 
collected each day and fresh media was added.  Supernatant was stored at 4 degrees until 
viral concentration.  
 To improve infection efficiency, MSCV-MLL-AF9 virus was concentrated using 
Centricon Plus-70 Centrifugal Filters (Millipore, Billerica, MA, Cat# UFC710008).  
Briefly, concentration columns were primed by centrifugation of sterile H2O at 3000 rpm.  
70 mL of viral supernatant was added to the filter unit and centrifuged at 1645 rpm for 3 
hours.  To elute viral particles, filter units were inverted and spun at 1645 rpm for an 
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additional 10 minutes. Eluant was collected and total volume was adjusted to 7 mL using 
RPMI.  Virus was aliquoted to 750 µl/tube and snap frozen on dry ice.  Aliquots of virus 
were stored at -80˚ C for later use.  
 Efficacy of MLL-AF9 virus generation was tested by infection in Rat1A cells.  
Infectivity of viral aliquots was confirmed through infection titer of Rat1A cells.  8.5x10
4
 
Rat1A cells were plated in 6-well plates and cultured overnight at 37C in DMEM + 10% 
FBS + 1% P/S. The following day, cells were infected with virus diluted at multiple 
concentrations between 1:10
3
 to 1:10
6
 in DMEM+10% FBS + 16 µg/mL Polybrene. 
Media was aspirated from cells and virus dilutions were added to plates for 4 hours at 
37°C. After 4 hours of treatment, 1 mL of additional media was added to each well and 
plates were reincubated for an additional 20 hrs.  Cells were cultured in fresh media for 
48 hrs and then continuously cultured in the presence of G418 for 12days.  Colony 
formation was visualized by removing media and briefly staining plates with methylene 
blue.  Colonies were counted and multiplied by dilution factor to determine the cfu/mL 
virus.  
 pKOF2-Prep1-GFP and MIGR1 do not have a G418 resistance cassette and are 
thus unable to be subjected to viral titrations by this methodology.  To measure quality 
viral particle generation, I infected Rat1A cells with 1:10 and 1:100 dilutions of virus and 
tested for GFP positivity using FACS analysis on a LSR-FORTESSA (BD BioSciences, 
Franklin Lakes, NJ). 
Isolation and purification of bone marrow stem/progenitor cells 
Analysis of MLL-AF9 in a murine model was performed using murine bone 
62 
 
 
 
marrow stem and progenitor cells transformed with MLL-AF9-expressing retrovirus. 
Murine bone marrow was collected and transformed consistent with previous 
experiments performed by our lab. Briefly, C57BL/6 mice were euthanized with gaseous 
CO2 and immediately dissected under sterile conditions to remove legs.  Tibia and Femur 
bones from both hind legs were isolated and epiphyses were removed.  Bone marrow was 
collected in 2% FBS supplemented media by flushing diaphyses with 1 mL media 
through a 25G needle.  Cell aggregates were dispersed and a single cell suspension was 
generated by additional passing through a 1 mL syringe and 25G needle.  Collected cells 
were washed in chilled PBS supplemented with 2% FBS.  To obtain a population of 
white blood cells, red blood cells were lysed by incubating in red blood cell lysis buffer 
(155 mM NH4Cl, 11.9 mM NaHCO3, 100 nM EDTA) for 5 mins on ice.   
Bone marrow was enriched for c-Kit+ (CD117) stem and progenitor cells using 
EasySep Positive selection kit (Stemcell Technologies, Vancouver, BC, Cat# 18056) 
according to the manufacturer’s protocol. EasySep purification utilizes antibodies 
directed against surface markers used to characterize sub-populations of cells.   
Briefly, bone marrow was suspended in PBS+2%FBS at a concentration of (1x10
7
 
cells/mL). 70 µL of CD117-PE labeling reagent was added and incubated in the hood for 
15 mins.  70 µL of PE selection cocktail was added and solution was incubated for an 
additional 10 mins.  50 µL of magnetic nanoparticles were added and mixture was 
incubated for 10 mins. Cells were purified by washing 3 times in PBS+5%FBS.  To wash 
cells, tubes containing magnetically labeled cells were placed into magnet for 5 mins.  
After 5 mins, tubes were gently inverted to decant supernatant. Tubes were then removed 
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from magnet and an additional 500 µL of PBS was added to each tube.  After c-kit 
positive selection, cells were counted and were activated overnight in RPMI+10%FBS 
supplemented with cytokines.   
Infection of bone marrow cells 
 Retroviral infection was performed to introduce a human MLL-AF9 fusion to 
murine c-kit+ progenitor cells for AML transformation.  After c-kit+ selection, cells were 
activated overnight in a 96 well plate in RPMI+10%FBS supplemented with cytokines 
(10 ng/mL each of IL-6, IL-3, and 100 ng/mL SCF).   
 Spinoculations were prepared in 1 mL volumes as follows: one 750 µL aliquot of 
virus, 7.5 µL HEPES, 1 µL polybrene (4 µg/ul), 30 µL cells (at 1x10
6 
cells/mL). For viral 
infection, cells were centrifuged at 3000 rpm for 4 hrs at 33° C on 2 successive days. 
Between spinoculations, each sample was rested overnight in 100 µL of RPMI + 10% 
FBS supplemented with cytokines (10 ng/mL each of IL-6, IL-3, and 100 ng/mL SCF) in 
96 well plates. Cells were put into methylcellulose colony assays immediately after the 
second day of infection.   
Murine methylcellulose colony assay 
Murine cells were plated in H3234 Methocult supplemented with IL-3 (10 
ng/mL), IL-6 (10 ng/mL), and SCF (100 ng/mL) cytokines.  Murine cells were plated at 
concentrations between 10k cells/plate and 500 cells/plate, depending on growth the 
previous week and on anticipated colony number.  
Cells were put into methylcellulose colony assays immediately after the second 
day of infection.  For antagomir treatments, appropriate cell volumes were added to a 5 
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mL FACS tube containing a antagomirs, 10X PBS to compensate for antagomir volume, 
and RPMI+10% FBS totaling 100 µL.  Cells were incubated on ice for 30 mins and at 
room temperature for 5 mins as specified by the Grimes lab protocol.  After incubation, 
cells were immediately transferred to a 1.5 mL microcentrifuge tube containing 
antagomirs (2.3 µL for 100 nM treatment and 4.6 µL for 200 nM treatments), cytokines 
(IL-3, IL-6, and SCF totaling 9.9 µL), G418 (82.5 µL for the first week) and media to 
600 µL.  This mixture was added to thawed methylcellulose aliquots (2.7 µL each), and 
mixed via vortexing.  1.1 mL of the resulting mixture was added to culture dishes using a 
3 mL syringe with a blunt end needle. 
 The initial round of plating for colony assay additionally included G418 at 10 
ng/mL to select for successfully infected cells. All platings were set up in duplicate. 
Colonies were counted at day 7 on a Leica DMIL inverted microscope and photographed 
using a Cannon PowerShot SD1000, at 7.1 MP.  Cells were collected under sterile 
conditions by washing each plate with 2 mL PBS 3 times and collecting into a 50 mL 
Falcon tube containing 30 mL of PBS.  Cells were centrifuged for 10 minutes at 1500 
rpm in a floor centrifuge.  PBS was aspirated, and cells were resuspended in 0 .5 – 5 mL 
of fresh PBS. Cells were counted by hemocytometer and total cell number was calculated 
for each colony assay.  For weeks 1-3, cells were re-treated with antagomir according to 
the protocol described above.  At week 4, all remaining cells were collected for RNA.  
Slides were prepared for inspection of cellular morphology.  2.5x10
4
 cells were 
centrifuged onto positively charged slides at 1000 rpm for 4 minutes on a Thermo 
Cytospin 4 (Thermo Scientific, Cat# 3120110).  Slides were air dried and stained with 
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Hema 3 Wright Giemsa stain (Fisher Scientific, Waltham, MA, Cat#  23-122-929, 23-
122-937, 23-122-952) for 15 seconds with each stain.  Slides were visualized on an Evos 
imagecore microscope (Life Technologies, Carlsbad, CA). 
Cloning and screening strategy 
 Luciferase reporter constructs were generated by cloning the 3’UTR of PKNOX1 
into the pmiR-Report system (obtained from Dr. Jianjun Chen, University of Cincinnati).  
Wild-type reporter construct was cloned from human genomic DNA as described below. 
 PKNOX1 3’UTR was amplified using forward and reverse primers (Integrated 
DNA Technologies, Skokie, IL) indicated in Table 3.  The 3’UTR for PKNOX1 is 
transcribed from within a single exon of PKNOX1.  Thus, PCR amplification could be 
performed on genomic DNA without potential inclusion of intronic sequence. PCR was 
performed utilizing a high-fidelity recombinant polymerase, Phusion Taq (NEB, Ipswich, 
MA, Cat# M0530) according to manufacturer’s guidelines.  Amplification reactions were 
set up as follows: 1 µL (100 ng) human genomic DNA template, 2.5 µL (0.25 µM) 
Forward Primer, 2.5 µL (0.25 µM) Reverse primer, 5 µL 10X PCR Buffer, 1 µL dNTPs, 
0.5 µL Taq, and 32.5 µL water to volume. Amplification reactions were performed in a 
ThermoHybaid PCRExpress PCR block.  Cycling parameters were set as follows: 5 mins 
at 95˚ C, and 35 cycles at 95˚C for 30 sec, 65˚C for 30 sec, and 68˚C for 5 mins, and 
68˚C for 5 mins. 
 The amplification product was electrophoresed on 1 % agarose gels and the 
appropriately sized band (3.5 kb) was excised and purified by Qiaex II gel extraction kit 
(Qiagen, Hilden, Germany, Cat# 20021).  The resulting PCR amplicon was sequentially 
66 
 
 
 
digested with MluI and SpeI in parallel with the pmiR-Report vector. Ligations were set 
up at a 1:3 vector:insert ratio using the NEB ligation kit (NEB, Ipswich, MA, Cat# 
M0202).  Ligation was set up as follows: 1 µL vector ( 25 ng), 12.1 µL insert (75 ng), 1 
µL T4 DNA Ligase, 2 µL ligation buffer, water to 20 ul.  Ligations were incubated 
overnight at 16˚C. 
 Ligation mix was transformed into chemically competent DH5a E. coli. Briefly, 
chemically competent bacterial cells were thawed on ice for 10 mins and added to a pre-
chilled 14 mL round bottom polypropylene tube with 1 µL of ligation mix.  Mixture was 
sequentially incubated on ice for 30 mins, at 42˚C for 45 seconds, and ice for 5 mins. 900 
µL of pre-warmed SOC media was added and cultures were incubated with rotation (225 
rpm) at 37˚C for 1 hour.  Bacterial cells were plated on Ampicillin-LB plates.  Potential 
positive transformants were picked and grown in 2 mL LB-AMP.  1.5 mL was used for a 
column free miniprep.  Plasmid was digested with cloning enzymes (MluI and SpeI) to 
test for the presence of insert.  If insert is present, it will be apparent on a gel after 
digestion. 
 
Table 3. Primers for cloning luciferase constructs 
   Amplicon Primer sequence (5'→3') 
PKNOX1 
Forward: GGACTAGTCCTGGTCTTGGAGAACAGTGACT 
Reverse: CGACGCGTCGCTTTGATAAATCAATTGCTTCAC 
   Primers for cloning the 3'UTR of PKNOX1 
 
67 
 
 
 
Site directed mutagenesis and screening strategy 
 Specific mutations were generated to remove the individual miRNA binding sites 
from the PKNOX1 3’UTR.  To make multiple mutations simultaneously, I used the 
Stratagene Multi-Site Directed mutagenesis kit (Stratagene, La Jolla, CA, Cat #200514).  
Multiple primers directed against the same strand of DNA may be added to the reaction 
simultaneously.  As the extended strand meets the next downstream primer, a ligase 
present in the enzyme mix seals the nick in the DNA, allowing for multiple primer-
mediated mutations to be incorporated simultaneously.  The resulting single stranded 
product is suitable for transformation.  The PKNOX1 3’UTR possesses 6 putative binding 
sites for miRNAs from the miR-17-92 cluster.  Because of proximity of the sites to be 
mutated and the decreased efficiency of introducing too many mutations simultaneously, 
site directed mutagenesis was pursued in two separate multi-site directed mutagenesis 
rounds.  pmiR-Report-Pknox1 3’UTR (wt) was used as a template for initial mutagenesis, 
with primers designed to mutate either MRE1, MRE5, MRE6 or MRE2, MRE3, MRE4. 
Compound mutation of the miR-17 family MREs was generated by subjecting a plasmid 
with only MRE1 to additional mutagenesis using the primer for MRE4.  Compound 
mutation of all putative MREs was achieved by subjecting a compound mutant (MRE1, 
MRE5, and MRE6) to additional mutagenesis (for MRE2, MRE3, and MRE4).  Primers 
and mutations are depicted in Table 4. 
 Mutations to ablate miRNA binding were made by changing multiple nucleotides 
within the seed match of the mRNA.  To facilitate a screening strategy of restriction 
mapping, seed match sites were converted to restriction enzyme sites recognized by 
68 
 
 
 
enzymes that would only cut once in the wild type plasmid.   
 Site directed mutagenesis reactions were set up according to the manufacturer’s 
instructions.  Both rounds of mutations utilized the same reaction mix proportions.  
Reactions were set as follows: 1 µL template (100 ng), 1 µL of primer 1 (100 ng), 1 µL 
of primer 1 (100 ng), X µL of primer 3 (100 ng), 1 µL of enzyme, 2.5 µL of 10X reaction 
mix, 1 µL dNTPs mix, 1 µL multi-enzyme mix, and ddH20 to 25 µl.  Amplification 
reactions were performed in a ThermoHybaid PCRExpress PCR block.  Cycling 
parameters were set as follows: 5 mins at 95˚ C, and 40 cycles at 95˚C for 30 sec, 55˚C 
for 30 sec, and 65˚C for 10 mins. Resulting PCR products were cleared of template 
plasmid by DpnI digestion. DpnI only digests methylated DNA.  DNA methylation 
occurs in bacteria, but not in PCR amplification.  Restriction digestion of DNA with DpnI 
would eliminate only the template bacteria, but not the resulting mutants, which were 
generated via PCR. 1 µL of DpnI was added to each reaction mix and incubated for 15 
minutes at 37˚C. 1 µL of resulting mix was transformed into XL-10 Gold competent 
cells, per manufacturer's instructions (Competent cells provided with kit). 
 To screen for positive mutants, transformant colonies were picked and grown in 2 
mL LB with ampicillin. 1.5 mL was subsequently purified by column-less miniprep.  
Plasmids were digested using HindIII or MluI.  Incorporation of any mutations by site 
directed mutagenesis would result in an increasingly fragmented digestion pattern, with 
compound mutants incorporating all mutations producing a very fragmented product.   
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Table 4. Primers for mutagenesis of PKNOX1 3'UTR 
  Target Primer sequence (5'→3') 
PKNOX1 
MRE1 
(∆19ab) 
GCAGGAGCAGAACCGCACCTGACTTTTTGGAGAAGCTTCAGCA
AACATTTTACACAGTTTTATTTCTAA 
PKNOX1 
MRE2 
(∆17,20) 
TTTCTAATATGTTTTATATGTAGATATAGAAGAGTGACGCGTTG
TATTTCATAGTAAGCTTAAAGCGCGTCTTTGCC 
PKNOX1 
MRE3 
(∆18) 
CAGCATGTTTGAGGTCAGTTGGACGCGTAAAACACCTGTTCTCC
AGCCC 
PKNOX1 
MRE4 
(∆17,20) 
GCCTGTGTGAGGTAGCAGTGGGACGCGTTCATTGAGACAAACT
CCAGGG ' 
PKNOX1 
MRE5 
(∆92) 
CCCAGGCTGGAGGGCAATGGAAGCTTCTCAGCTCACTGCAACC
TC 
PKNOX1 
MRE6 
(∆92) 
CCCAGGCTGGAGGGCAATGGAAGCTTCTCAGCTCACTGCAACC
TC 
vector 
internal 
GCACCCCAGGCTTTACACTTTATGCTTCCGGCT 
  The above table depicts the primers utilized for mutagenesis.  All primers from the same 
strand. miRNA Response element in red.  Unaltered nucleotides within the seed region 
in blue.  Restriction sites in Orange  or Green.  Purine to pyrimidine changes (and vise 
versa in bold.  Nucleotide changes italicized. 
 
Putative positives were regrown and plasmids were prepared with miniprep kit to provide 
a cleaner plasmid prep suitable for sequencing.  Plasmids were then sent to ATCC for 
sequencing using both pmiR Forward and pmiR Reverse plasmids.  Internal sequence of 
the PKNOX1 3'UTR was out of range of end primers and was sequenced utilizing internal 
primers specific to the PKNOX1 3'UTR: PKNOX1 seq1 and PKNOX1 seq2 (Table 5).   
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Table 5. Primers for sequencing PKNOX1 luciferase construct 
  Target Primer sequence (5'→3') 
pmiR Forward CCCTTGAACCTCCTCGTTCGACC 
pmiR Reverse GAGACGTGCTACTTCCATTTGTC 
PKNOX1 seq1 TGAAATGGTAGCCAGTGACCCGTT 
PKNOX1 seq2 AATGGTGCAATCTCAGCTCACTGC 
  The above table indicates the primers utilized for sequencing of pmiR-Report constructs 
 
RNA isolation and cDNA synthesis 
RNA was extracted from cells treated with antagomirs for 72 hrs in liquid culture 
using Sigma TRI Reagent (Sigma Aldrich, St. Louis, Cat# T9424) according to 
manufacturer’s instructions.  Briefly, cell pellets were collected in a 1.5 mL 
microcentrifuge tube and spun down at 3000 rpm.  Cells were resuspended in .5 mL - 1 
mL of TRI reagent under a fume hood (according to cell number) Once mixture was 
homogenous, cells were frozen and stored at -80˚ C for later use.  
 RNA collection was performed under RNAse free conditions using filter tips.  All 
workspaces and pipettes were cleaned with RNAse Zap (Life Technologies, Carlsbad, 
Cat# AM9782) prior to use. RNA samples were thawed and processed according to TRI 
reagent standard protocol. Briefly, 200 µL of chloroform was added per mL of TRI 
reagent used.  Mixture was inverted vigorously 15 times to mix samples. Samples were 
separated by centrifugation at 13000 rpm at 4˚C in a microcentrifuge.  The aqueous layer 
was removed and added to a microcentrifuge tube containing 560 µL Isopropanol/mL 
TRI reagent used. After a 15 minute incubation, RNA was precipitated by centrifugation.  
Pellet was washed once in 70% ethanol and air dried. Pellets were resuspended in 
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nuclease free H20 and dissolved at 65˚C for 1 hour.  Resulting RNA mix was 
subsequently handled on ice in an RNAse free environment. 
cDNA synthesis was performed using 10 ng of total RNA using Applied 
Biosystems miRNA Reverse Transcription kit (Life Technologies, Carlsbad Cat# 
4366596) according to manufacturer’s protocol.  RNA was quantified and quality was 
assessed using a Nanodrop 2000.  RNA was normalized to a concentration of 100 ng/µL 
and subsequently diluted to a working concentration.  10 ng of RNA was used per reverse 
transcription (RT) reaction. For each sample, separate RT reactions were performed for 
each RNA or control to be quantified.  To control for potential discrepancies in RNA 
level/quality between tubes, a master mix was made for each sample with all components 
except the RT primers.  The appropriate master mix was then added to the RT tube with 
the appropriate RT primer.  Reverse transcription reactions were performed in a Thermo 
Hybaid PCR Express Cycler using the following cycling parameters: 16° C for 30 mins, 
42° C for 30 mins, 85° C for 5 mins, 4° C hold.  
Quantitative real-time polymerase chain reaction 
 To determine relative miRNA levels, quantitative real-time PCR was performed 
on an Applied Biosystems 7300 cycler using Applied Biosystems Taqman assays for hsa-
miR-17-5p, hsa-miR-19a, hsa-miR-196b, or RNU6.  
 Quantitative real-time PCR was performed in technical triplicates. Master mixes 
were prepared for each reaction in excess of 3 fold the amount required for complete 
reaction. TaqMan small RNA assay kits were utilized for hsa-miR-17, hsa-miR-19a, hsa-
miR-196b, and RNU6. Each reaction consisted of 1 µL TaqMan Small RNA Assay 
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(20X), 10 µL TaqMan Universal PCR Master Mix II, 7.67 µL RNAse free H20, and 1.33 
µL of cDNA product.  PCR reactions were prepared in the dark. Plates were spun down 
for 2 mins at 1000 rpm to collect sample at bottom of plate. 
 Cycling parameters for qPCR were defined by the kit manufacturer.  Briefly, 
cycling condition were as follows:  50˚C for 2 minutes, 95˚C for 10 mins, and 40 cycles 
of 95˚C for 15 seconds, 60˚C for 1 minute.  “No template” controls were run to verify 
that contamination was not present. Data was analyzed using the Delta Delta Ct (2
-∆∆Ct
) 
method with RNU6 serving as a control [245].  
Human methylcellulose colony assays 
Methylcellulose colony assays for human cell lines were performed using H4100 
Methocult methylcellulose (Stemcell, Vancouver, Cat# 04100) supplemented with a final 
serum concentration of 10% FBS. Methylcellulose colony assays were performed in 12-
well plates.  
To ensure consistent results, human cell lines were maintained at >90% viability 
for at least 3 days prior to use in any methylcellulose assay.  Immediately prior to 
treatment, cells were counted and resuspended at a concentration of 1X10
5
 cells/mL.  
Because each cell line has a different clonogenic potential, each cell line was plated in 
methylcellulose at different concentrations (numbers given for treatment in 12-well 
plate): MOLM-13 (100 cells/well), MV4-11 (1000 cells/well), RS4;11 (250 cells/well), 
HL-60 (250 cells/well), U937 (250 cells/well). Antagomir treatment concentrations were 
empirically determined for the MLL fusion-containing cell lines and were set to 1-2 µM).  
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Non-MLL cell lines were treated at 2 µM to be equivalent to highest treatment 
concentrations. 
Appropriate cell numbers were then added to a 1.5 mL microcentrifuge tube 
containing antagomirs (1.65 µL for 1 µM treatment, and 3.3 µL for 2 µM treatment)., 
10X PBS to compensate for antagomiR volumes, and media +10% FBS to a final volume 
of 550 µL . The resulting solution was then gently pipetted into a FACS tube containing 
(1.1 mL) methylcellulose and mixed by briefly by vortexing.  550 µL of the final 
cell/antagomir/methylcellulose mixture was added to each well in a 12-well plate in 
duplicates. Individual colonies were counted on Leica DMIL inverted microscope and 
photographed using a Cannon PowerShot SD1000, at 7.1 MP after 7-8 days in culture for 
MV4-11, MOLM-13, RS4;11 and K562. THP1 colonies were cultured for 14-15 days.  
Combinatorial treatments were counted on a Leica DMIL inverted microscope and 
photographed using a Nikon camera. 
To collect cells, 1 mL of PBS was added to each well to diluted methylcellulose.  
Methylcellulose was gently rinsed from the plate and subsequently washed 2 times with 
PBS. Each duplicate experiment was resuspended in a total of 12 mL PBS. Cells were 
spun down and resuspended in PBS (.1-2mL) for counting, collecting for slides, 
collecting for FACS, etc.  Colonies were viewed under a Nikon microscope and imaged 
with Olympus DP21 imaging system at 100X.  
Cell proliferation Assay 
To asses cell proliferation I used the Cell-Titer-Glo assay (Promega, Madison, 
Cat# G7570).  This assay measures cell number indirectly by measuring the ATP content 
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in a luminescent assay.  Because ATP content remains constant across live cells, 
quantification of ATP may be used to indirectly quantify the total number of live cells. 
Cells were counted and resuspended at 100k cells/mL in culture medium under sterile 
culture conditions.  Cells were added to a mixture of antagomirs, 10X PBS, and culture 
media to yield a final concentration of 50k cells/mL, 1-2 µM antagomirs (specified in 
figure legends), and 10X PBS to compensate for antagomir volumes. Cells were plated in 
96-well plates in triplicate with 100 µL of cell/antagomiR mixture per well in 3 
independent experiments.  Cell viability was assessed after 4 days of antagomir treatment 
using Promega Cell-Titer-Glo kit (Promega, Madison, Cat# G7570) according to 
manufacturer’s instructions.  Briefly, cells in 96 well plates were gently resuspended by 
pipetting up and down. 15 µL of cells were subsequently added to 85 µL of media in a 
white opaque plate, 100 µL of Cell Titer Glo reagent was thawed at room temperature in 
the dark and subsequently added to the cell –media mixture.   
Luminescence was measured on a Glomax 96 microplate luminometer using the 
default program setting. Integration time was set at 0.5 seconds/well for all samples. 
Averages of 3 triplicates were averaged for each sample tested. Remaining cells were 
collected for cell cycle analysis.  
Murine MLL-AF9 transformed bone marrow cells were examined for cell viability 
in culture after infection with either MIGR1, MSCV-Meis1-pgk-EGFP, or MSCV-pKOF2-
Prep1-GFP. Similarly to human cell lines, viability was assessed using Cell-Titer-Glo 
assay (Promega, Madison, G7570).  GFP+ cells were plated at 50k cells/mL in 100 µL in 
96 well plates.  At given time points, 15 µL of cells were removed from media and 
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subsequently added to 85 µL of media in a white opaque plate, 100 µL of Cell Titer Glo 
reagent was thawed at room temperature in the dark and added to cell–media mixture. 
Luminescence was measured on Glomax 96 microplate luminometer using the protocol 
utilized for human cell lines. 
Cell cycle analysis  
 To determine cell cycle distribution, cells were fixed and stained with propidium 
iodide (PI) and analyzed via FACS.  Propidium iodide (PI) is a fluorescent DNA 
intercalating agent that readily enters fixed cells and can subsequently be used to quantify 
the amount of DNA in a particular cell. Because DNA is synthesized during replication, 
the quantity of DNA can be used to indicate whether a cell is actively cycling. 
 To determine cell cycle distribution upon antagomir treatment, all three replicates 
from each sample of the previous cell viability were collected and pooled in a 5 mL 
FACS tube.  Cells were washed once with 3 mLs of PBS+5%FBS and fixed in ice-cold 
70% Ethanol.  Cell suspension was stored at -20˚C overnight for fixation.  Cells were 
then washed in PBS + 5% FBS and resuspended in 250 µL PBS solution containing 
RNAse A (10 µg/mL) to eliminate free RNA that would potentially confound results.  
250 µL PBS with propidium iodide (100 µg/mL) was then added to the mixture to yield a 
final concentration of 5 µg/mL RNAse A and 50 µg/mL propidium iodide.  Cells were 
incubated on ice for 1 hour prior to FACS analysis. Samples were analyzed on a FACS-
CANTO II and data was processed analyzed using Flowjo Software Package (Version 
9.03). Cell cycle distribution was determined using the Watson Pragmatic function within 
FlowJo.  Total live cell number was counted and percentages were calculated with MS 
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Excel.  
Luciferase reporter assays 
 Luciferase reporter assays were performed in HEK293T cells using the pmiR-
Report system. pmiR-Report constructs possess a luciferase gene driven by a CMV 
promoter.  A multiple cloning site downstream of the luciferase cassette allows cloning of 
a valid 3-UTR into the plasmid. Co-transfection with wither miRNA expressing 
plasmids, synthetic miRNAs, or miRNA inhibitors, provide a platform with which to test 
miRNA:mRNA relationships.  HEK293T cells were plated at 6.0x10
5
 cells/well in 24 
well plates.  After 24 hours, cells were co-transfected with a reporter construct containing 
either the 120 ng of pmiR-Report reporter construct (wild-type or mutant 3’UTR for 
PKNOX1, 10 ng of a control Renilla luciferase construct, and 600 ng of either MSCV-PIG 
or MSCV-PIG-miR-17-19b.  Cells were cultured for 48 hrs and collected for luciferase 
analysis with the Promega Dual-Luciferase Reporter Assay System (Promega, Madison, 
#E1910) according to manufacturer’s instructions. Due to the relatively loose attachment 
of HEK293T cells to a plate, chilled washing PBS was added directly to the well.  Plates 
were swirled and PBS was used to rinse cells loose from plate.  Cells were collected into 
1.5 mL microcentrifuge tubes and centrifuged at 3000 rpm to pellet cells.  PBS was 
removed by aspiration and cells were resuspended in 1X Passive Lysis buffer and kept at 
-20° C for future analysis.  For experimental analysis, lysate was diluted 1:20 fold to 
bring luciferase concentration into the linear range of the luminometer immediately prior 
to luminometer measurements. 
Luciferase activity was measured on a Femto manual luminometer using default 
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machine settings.  10 µL of each sample was added to the bottom of a 1.5 mL 
microcentrifuge tube. 50 µL of LARII buffer was added to each tube and gently pipette 
up and down to mix solution. Sample was immediately read in the machine to obtain 
level of Firefly luciferase activity.  50 µL of freshly prepared Stop and Glo reagent was 
added to each tube and briefly vortexed.  Samples were immediately read to obtain 
Renilla Luciferase activity level.  To ensure fidelity of experimental reads, dilution levels 
of samples was kept low enough to ensure that sample reading were below 10 million and 
remained steady during the course of the integration time. Experiments were performed 
in triplicate and measured in duplicates. 
Protein isolation and western blotting 
To collect proteins, cells were collected into a 1.5 mL microcentrifuge tube and 
washed once in chilled PBS.  Cell pellets were snap frozen on dry ice and stored at -80˚C 
for future use. Cell pellets were handled in a manner determined by cell line. Pellets from 
human leukemia cell lines were thawed on ice in 1X SDS loading buffer.  Cells from 
HEK293T cells were resuspended in IPH buffer (50 mM Tris-HCl, 150 mM NaCl, 5mM 
EDTA, .5% NP-40)  supplemented with 1:100 freshly added Protease inhibitor cocktail 
(Sigma Aldrich, St. Louis, Cat# P8340). Cells were resuspended in IPH at a 
concentration of 1x10
7
 cells/mL.  If cells were not used for a co-IP experiment, they were 
sonicated for 4 pulses at 20% power. 
 Cell pellets were thawed on ice in IPH buffer.  Appropriate quantities were 
mixed with 5X SDS loading buffer (250 mM Tris pH6.8, 500 mM DTT, 10% SDS, 0.5% 
Bromophenol Blue, 50% Glycerol).  Lysate solution was boiled for 5 minutes and 
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subsequently centrifuged at 13000 rpm for 5 mins at 4° C to clear lysate of any cellular 
debris.    
Lysates were separated by Sodium Dodecyl Sulfate –Poly Acrylamide Gel 
Electrophooresis (SDS-PAGE).  Gels were cast using the BioRad Mini-PROTEAN 
system.  Gels were comprised of a 10% resolving gel (40% Acrylamide 2.5 mL, 1.5M 
Tris pH8.8 = 2.5 mL, 10% SDS = 100 ul, 10% APS = 50 ul, TEMED = 10 ul), and a 4% 
stacking gel (40% Bis-Acrylamide .5 mL, 1M Tris pH=6.8 = .625 mL, 10%SDS 50ul, 
10% Ammonium Persulfate = 25 ul, TEMED = 5 ul, ddH2O 3.8 mL, TOTAL 5mL).  
Samples were loaded into the gel and run in parallel with 5 µL of Kaleidescope 
ladder (BioRad, Hercules, Ca, Cat# 1610324).  Gels were run in 1X Tris-Running buffer 
(15.1g Tris pH8.8, 94g Glycine, 5g SDS, H20 1L) at 50V for 15mins to condense protein 
into stacking gel, and 150V until dye front reached the bottom of the gel. Protein was 
transferred to Nitrocellulose membranes (BioRad, Hercules, Ca, Cat# 170-4158, 170-
4159) using Trans BlotTurbo transfer system (BioRad, Hercules, Ca, Cat# 170-4155).  
BioRad, Hercules, Ca 1.5 mm gel program was used (2.5A, 25V, 10 mins). Transfer was 
verified by staining membrane briefly in .5% (w/v) Ponceau S solution (Sigma Aldrich, 
St. Louis, Cat # P7170), and subsequently washing in PBS-T until Ponceau stain was 
fully removed. Membranes were blocked overnight at 4˚C in blocking solution (PBS, .5% 
Tween, 5% dry milk).   
Membranes were probed with anti-PKNOX1 (N15) (Santa Cruz Biotechnology, 
Santa Cruz, Cat# SC-6245) at 1:1000 in blocking buffer, anti-PBX1/2/3 (C-20) (Santa 
Cruz Biotechnology, Santa Cruz, Cat# SC-888) at 1:1000 in blocking buffer, anti-MEIS1 
79 
 
 
 
(Milipore, Billerica, MA, Cat# 05-779) ) at 1:1000 in blocking buffer, anti-HOXA9 
(Milipore, Billerica, MA, Cat#07-178) at 1:1000 in blocking buffer, or anti-Actin (Sigma 
Aldrich, St. Louis, A5441) at 1:8000 in blocking buffer. Secondary antibody probing was 
performed with TrueBlot anti-rabbit (eBioscience, San Diego, Cat# 18-8816-31) at 
1:1000 in blocking buffer, anti-mouse-HRP (GE Life Sciences, Piscataway, NJ, Cat# 
NA931VS) at 1:8000 in blocking buffer, or anti-Rabbit-HRP (GE Life Sciences, 
Piscataway, NJ, Cat# NA934VS) at 1:8000 in blocking buffer.  Western blots were 
imaged using a Fuji LAS-3000 lightbox system.  Images processed using MultiGauge 
v3.0. 
Co-immunoprecipitation assays 
Cells for co-immunoprecipitation were collected and washed once in PBS.  Cell 
pellet was resuspended in IPH buffer (50 mM Tris-HCl, 150 mM NaCl, 5mM EDTA, 
.5% NP-40) with 1:100 freshly added Protease inhibitor cocktail (Sigma Aldrich, St. 
Louis, Cat# P8340).  Co-Immunoprecipitation was performed in IPH buffer using 
Agarose A beads (Santa Cruz Biotechnology, Santa Cruz, Cat# SC-2001) incubated 
overnight at 4° C with 1.5X10
6
 cells. Equilibration and washes were performed with IPH 
buffer  with 1:1000 freshly added Protease inhibitor cocktail (Sigma Aldrich, St. Louis, 
Cat# P8340).   
20 µL of beads were used per reaction. Beads were equilibrated to IPH buffer by 
washing beads IPH buffer with 1:1000 Protease inhibitor cocktail (Sigma Aldrich, St. 
Louis, Cat# P8340) 3 times.  For each wash, beads were pooled into a 1.5 mL 
microcentrifuge tube and 500 µL of buffer was added.  Mixture was vortexed briefly and 
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spun down at 6000 rpm for 30 seconds. Supernatant was removed, careful not to disrupt 
bead pellet. For the final round of equilibration, bead/buffer mixture was aliquoted to 
separate microcentrifuge tubes to the equivalent of 20 µL of beads per tube. After final 
round of equilibration, cell lysates from 150k cells was added to each tube in a volume of 
150 ul. 5 µL of PBX1/2/3 antibody (Santa Cruz Biotechnology, Santa Cruz, Cat# SC-
888) was added to each tube and gently mixed by flicking the tube several times.  The 
lysate solution was incubated with beads and antibody at 4° C overnight on a rocker to 
allow complex-bead interactions to form. After incubation, beads were washed 3 times 
with 500 µL of IPH buffer (plus 1:1000 protease inhibitor cocktail), and resuspended in 
30 µL of 2X SDS lysis buffer and boiled for 10 mins at 95° C.  Lysate was cleared of 
Protein A beads by 10 mins of centrifugation at 13000 rpm at 4° C.  30 µL of each 
mixture was used for each well. 
Colony assays for cells infected with Pknox1 expressing retrovirus 
 For the examination of Pknox1 contribution to MLL-AF9 transformed murine 
bone marrow subject to additional infections with either MIGR1, MSCV-Meis1-pgk-
EGFP, or MSCV-pKOF2-Prep1-GFP were generated and checked for quality as 
described. After passing cells through methylcellulose for 4 weeks, cells were acclimated 
to liquid culture for 1 week and treated with additional spinoculations. I selected for 
successfully infected cells by FACS sorting for GFP positivity 48 hours after infection. 
Colony assays were performed over the course of 1 week, and were imaged. 
FACS analysis of surface markers  
Cell surface marker staining was performed on live cells to examine the 
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differentiation of cells after antagomir treatment.  After 6 days of antagomir treatments, 
cells from methylcellulose colony assays were isolated.  100k cells were suspended in a 
chilled PBS + 2%PBS. Antibody panels were mixed into a master mix and added to 
samples at a final dilution of antibodies. Cells were incubated in the dark, on ice for 20 
minutes and washed with 500 µL of PBS+2%PBS. Cells were resuspended in 250 µL 
PBS+2%FBS 
Cell surface marker staining was performed as previously described [23] using 
fluorophore conjugated antibodies against CD117-APC (eBioscience, San Diego, Cat# 
17-1171-82), CD11B-PE (eBioscience, San Diego, Cat# 12-0112-85), GR-1-PE-Cy5 
(eBioscience, San Diego, Cat# 15-5931-81).  FACS analysis was performed with initial 
gating on live cells.  Secondary gating was for GFP + cells.  Subsequent gates were 
drawn by excluding cells in a negative control.  Data was processed using FlowJo 
Software Package.  
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CHAPTER 4 
RESULTS 
Antagomir uptake occurs in a dose dependent manner 
Previous studies by our lab and others have utilized ‘antagomirs’ to examine the 
role of miRNA in MLL leukemia in a mouse model [11, 234, 235].  Characterization of 
the ‘antagomir’ pattern of modifications was initially performed in vivo, studying the 
knockdown of miR-122 in the liver [232, 233].   To characterize uptake in vitro, cells 
were treated with a fluorescently labeled antagomir, and examined by FACS analysis, 
with antagomir uptake being detectable as an increase in fluorescence (Figure 9).  As a 
negative control, cells were treated with anti-Ce-miR-67, while uptake was observed in 
treatments with anti-Ce-miR-67-DY547, an antagomir with a fluorescent label conjugated 
to the 5' end. Both anti-Ce-miR-67 and anti-Ce-miR-67-DY547 are designed to target a C. 
elegans miRNA that has no mammalian homolog.  If antagomirs are taken up by the 
cells, then fluorescence would increase, indicated by a rightward shift in the FACS plot. 
Uptake was examined in THP1 cells (described in Methods) and MLL-AF9 transduced 
murine bone marrow utilizing three different treatment regimens: 1) a superficial addition 
of antagomirs to the media at the final treatment concentration without any additional 
steps, 2) superficial addition with pre-incubation at 10X the final treatment concentration 
(as described in Materials and Methods), or 3) transfection by Lipofectamine 2000 
(Figure 9).  For THP1 cells, pre-incubation did not alter the uptake of fluorescently 
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labeled antagomir compared to superficial addition of antagomir to the media without 
pre-incubation  (Figure 9).  For both superficial antagomir treatment and superficial 
treatment with pre-incubation, anti-Ce-miR-67-DY547-treated THP1cells fluoresced at a 
narrow peak centered to the right of the negative control, indicating that antagomir uptake 
was both robust and very uniform.  Lipofectamine treatment resulted in two populations 
of cells with a very broad distribution of fluorescence indicating a lack of uniformity in 
cellular uptake of antagomirs when introduced by Lipofectamine. The majority of cells 
were positive for antagomir uptake, and the most brightly fluorescent cells were much 
brighter than those treated with either the superficial addition or superficial addition with 
pre-incubation. However, approximately 11% remained negative for fluorescence. 
Antagomir uptake for MLL-AF9-transduced bone marrow was similar to that observed 
for THP1 cells. However, antagomir uptake after treatment with the superficial addition 
with pre-incubation protocol resulted in a slightly broader peak with an increase in the 
most fluorescent cells, indicating an improved uptake for at least a small subset of cells. 
As with THP1 cells, Lipofectamine treated MLL-AF9 transformed bone marrow cells 
were distributed into two populations with a very broad distribution of antagomir uptake.  
Lipofectamine antagomir treatment resulted in a very high level of uptake compared to 
either superficial addition or superficial with pre-incubation.  However, approximately 
45% of MLL-AF9 cells remained negative.  
To determine treatment concentrations for antagomirs, I treated multiple cell lines 
with antagomir directed against either anti-Ce-miR-67 or a fluorescent labeled anti-Ce-
miR-67-DY547 at concentrations of 20 nM, 200 nM, 500 nM, 1000 nM, and 2000 nM for   
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Figure 9. Antagomir uptake upon treatment with different methodologies  
 
 
 
 
 
Antagomir treatments via different mechanisms of delivery. Antagomir uptake 
determined by FACS analysis for treatment with Grimes protocol (top), superficial 
addition (middle), and lipofectamine (bottom). Treatments were compared between a 
fluorescent labeled antagomir (anti-Ce-miR-67-DY547) and a non-fluorescent control 
(anti-Ce-miR-67).  A) THP1 cells were examined with all three treatment regimens as a 
representative of human cell lines. B) MLL-AF9 transformed bone marrow cells were 
examined with all three treatment regimens. 
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72 hrs and examined fluorescence by FACS analysis (Figure 10). As expected, treatment 
with increasing concentrations of anti-Ce-miR-67 without a fluorophore did not result in 
fluorescence for any treatment.  Treatment with anti-Ce-miR-67-DY547 resulted in a 
concomitant increase in fluorescence for MOLM-13, MV4-11, RS4;11, and MLL-AF9 
transformed bone marrow.  All treatments resulted in narrow peaks of fluorescence, 
indicating uniform uptake at all treatment concentrations. The ratio of detected 
fluorescence to treatment concentration remained linear even at the highest concentration, 
indicating that 2 µM antagomirs treatment did not saturate the capacity for cells to take 
up antagomirs. Antagomir uptake for each human leukemia cell line had roughly similar 
patterns of uptake.  MLL-AF9 transduced bone marrow took up antagomir at a lower rate 
than human leukemia cell lines. Further experiments for murine MLL-AF9 utilized the 
superficial with pre-incubation protocol, while treatment of human cell lines relied upon 
superficial addition of antagomir to the media. 
 To determine the efficacy of antagomir treatment, I examined the capability of 
antagomir treatment to reduce the levels of targeted miRNA.   Experiments examining 
uptake do not indicate subcellular localization or function of the antagomirs, necessitating 
further examination of antagomir function.  To assess antagomir function, I treated 
MOLM-13, RS4;11 and MV4-11 with antagomirs directed against miR-17-5p, 19a, or 
196b at concentrations of 1-2 µM (indicated in figure legend) and quantified target 
miRNA levels relative to a control treatment (Figure 11).  Both vehicle and anti-Ce-miR-
67 were used as controls to ensure that antagomir treatment did not result in a broad or 
non-specific effect on untargeted antagomirs. Anti-Ce-miR-67 is an antisense oligo  
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Figure 10. Antagomir uptake in human MLL leukemia cell lines 
 
 
 
 
 
Antagomir uptake was determined by FACS analysis using a fluorescently labeled 
antagomir utilizing superficial antagomir treatment (20 nM – 2000 nM). A) Antagomir 
uptake quantified relative to treatment concentration.  B) Treatments were compared 
between a fluorescent labeled antagomir (anti-Ce-miR-67-DY547) and a non-fluorescent 
control (anti-Ce-miR-67). Example plots of uptake for MOLM-13, RS4;11, and MV4-11 
at 20 nM, 200 nM, 500 nM, 1000 nM, 2000 nM.  
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designed to hybridize with a miRNA from C. elegans with no homologous miRNA found 
in mammals. In antagomir treated cells, target miRNA levels decreased in response to 
antagomir treatments.  Anti-miR-17 treatment in MOLM-13, RS4;11, and MV4-11 
resulted in a decrease to 16%, 5%, and 31%, respectively, when compared to anti-Ce-
miR-67.  When compared to vehicle, anti-miR-17 treatment resulted in decreases to 2.5%, 
7.8%, and 31% of miR-17 miRNA levels of control treated cells. For MOLM-13, a non-
specific decrease in miR-17 and miR-19a levels was observed after treatment with anti-
Ce-miR-67 (data not shown). MLL-AF9 transduced bone marrow cells were also tested 
for miRNA knockdown. Upon antagomir treatment with anti-miR-196b, relative levels of 
miR-196b decreased to 11% of levels observed in cells treated with anti-Ce-miR-67. 
Treatment concentration for all human cell line antagomir experiments was determined 
based on these standardization experiments.   
Effect of individual antagomir treatment on colony forming ability of human 
leukemia cell lines 
To examine MLL leukemia in a human model, I performed colony assays using 
human MLL leukemia cell lines (Figures 12-19). MOLM-13 was used to represent MLL-
AF9 gene fusion expressing leukemias, while MV4-11 and RS4;11 were used to 
represent MLL-AF4 gene fusion expression leukemias. Colony assays were performed 
over the course of approximately 1 week and were not subjected to serial replating.  
While murine colony assays examined the role of miRNAs in the initiation of leukemia, 
human colony assays examine the role of miRNAs in cells that have previously been 
transformed.  Similar to murine colony assays, I examined colony number, cell number,  
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Figure 11. Antagomir treatment results in a knockdown of target miRNAs.  
 
 
 
 
Antagomir mediated knockdown of target miRNAs was examined for anti-miR-17, anti-
miR-19a, and anti-miR-196b in human. A) Antagomir treatment effects were examined 
for anti-miR-17. miRNA levels compared to cells treated with anti-Ce-miR-67 (left) or 
vehicle (right). B) Antagomir treatment effects were examined for anti-miR-19a. miRNA 
levels compared to cells treated with anti-Ce-miR-67 (left) or vehicle (right).  C) 
Antagomir treatment effects were examined for anti-miR-196b. miRNA levels compared 
to cells treated with anti-Ce-miR-67 in human cell lines (left) or in MLL-AF9 transformed 
bone marrow (right). 
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colony morphology (Figures 12-19). I hypothesized that increased expression of 
individual miRNAs were essential for maintaining MLL leukemia cell proliferation and 
clonogenic capacity. MLL leukemia cell lines were treated with antagomirs directed 
against a subset of miRNAs overexpressed in MLL leukemia.  
Colony assays were examined at 7-8 days after initial plating. Colony morphology 
was dramatically different from the standard murine colonies.  While murine MLL-AF9 
transformed colonies are typically compact and consist of closer cell-cell contacts, human 
cell line colonies are widely diffuse and do not contain close cell-cell contacts.  Number 
of cells plated per colony assay varied based on cell line as each cell line possesses a 
different baseline capability to form colonies.  Colony assays were set up with a target of 
70 colonies/plate.  MOLM-13 cells were the most clonogenic with an approximate 
colony forming frequency of 1 colony per/2.04 cells (49.0%).  RS4;11 formed colonies at 
a frequency of 1 colony per/3.34  cells (29.86%), and MV4-11 formed colonies at a 
frequency of 1 colony per/13.42 cells (7.45%).   
Cells were treated with individual antagomirs using treatment methodology and 
concentrations determined in uptake and knockdown experiments (Figures 12-16).  
Antagomir treatments were directed against the individual miRNAs of the miR-17-92 
cluster (anti-miR-17-5p, anti-miR-18a, anti-miR-19a, anti-miR-20a, anti-miR-19b, and 
anti-miR-92).  Additional, treatments were directed against additional miRNAs 
upregulated in MLL leukemia miR-10a, miR-196b, miR-191 and miR-93*.  MOLM-13 
and MV4-11 were treated at 2 µM concentrations, while RS4;11 was treated at 1 µM 
concentrations.  Non-MLL cell lines were always treated at 2 µM concentrations to 
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control for both miRNA knockdown and potential non-specific toxic effects of 
antagomirs.  Antagomir treatment at 2 µM concentrations resulted in the formation of a 
precipitate for several different treatments. Antagomir precipitation occurred upon 2 µM 
treatments of anti-miR-67, anti-miR-18a, anti-miR-92, anti-miR-93*, and anti-miR-191 in 
both liquid culture and methylcellulose.  Notably, antagomir treatment with anti-miR-18a 
and anti-miR-191 resulted in a very faint precipitate formation. This precipitation appears 
to be sequence specific and has been linked to the presence of the cholesterol tag at the 
3’end of the oligo (technical support, Thermo).  The mechanism of the effects of 
precipitate formation on cell growth and colony forming ability are currently unclear. 
Moreover, while aggregation was visible at 2 µM for the indicated antagomir, it is 
possible that sub-microscopic aggregations occur for other antagomirs and at lower 
concentrations. Though the exact mechanism by which anti-Ce-miR-67 produced a toxic 
effect is unknown, it is likely that the toxicity is related to the precipitate which formed as 
a result of antagomir aggregation. Previous studies of antagomirs in vivo have indicated 
that antagomirs bind to lipoproteins as wells serum albumin, providing evidence for 
antagomir-protein interactions [224].  Thus, it is possible that the antagomir and its 
precipitates bind to the cell membrane and cellular proteins, impeding normal function.  
Several antagomir treatments showed minimal effects upon treatment. Anti-miR-
10a, anti-miR-191, and anti-miR-93* all had minimal effect on colony forming ability 
(Figures 12, 13, 16).  Treatment with anti-miR-10a or anti-miR-191 showed lesser effects 
than treatment with the control antagomir anti-Ce-miR-67 in several cell lines (Figures  
12,16).  The minor effects of these treatments (anti-miR-10a and anti-miR-191) suggests 
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that the miRNAs examined were either unnecessary to the function of MLL leukemia or 
that their functions were redundant with other miRNAs in colony forming ability.  As 
these treatments did not decrease any outcomes in cell lines under consideration, and 
either did not produce a precipitate in culture or produced a very faint precipitate, I have 
utilized anti-miR-10a and anti-miR-191 as a treatment controls in subsequent experiments 
(indicated in figure legends).  Antagomir treatment against members of the miR-17 
family showed a decrease in colony number and total cell number in human MLL 
leukemia cell lines.  Anti-miR-17 and anti-miR-20a both showed a decrease in colony 
numbers relative to both the vehicle and the control antagomir-treatment (anti-miR-10a) 
(Figure 14).  The effect was most pronounced in MOLM-13 and MV4-11.  Antagomir 
treatment in MV4-11 resulted in a complete loss of colony forming ability (Figure 14). 
Only anti-miR-20a treatment was significant in colony forming assays for RS4;11 
(Figure 14). Cell numbers decreased similarly to colony numbers, but with a greater 
decrease in percentage relative to vehicle.  The decrease of cell number relative to colony 
number is apparent in the changes in colony morphology.  For both antagomir treatments, 
colonies appeared smaller in radius and had an abnormal distribution of cells within the 
colony.   
Treatment against miR-19a or miR-19b resulted in a very limited decrease in 
colony forming ability.  Colony number decreased relative to vehicle, but was 
insignificant in comparison to control antagomir.  The only significant decrease observed 
was the decrease of anti-miR-19b in MV4-11 (Figure 15).  Cell number was decreased 
slightly for anti-miR-19b in both MOLM-13 and MV4-11 (Figure 15).  Colony  
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Figure 12. Antagomir treatment against miR-10a and miR-196b in human MLL 
leukemia cell lines 
 
Individual antagomir treatments against miR-10a and miR-196b.  A) Antagomir 
treatments were performed against individual miRNAs at a total concentration of 2 µM 
for MOLM-13 and MV4-11 and 1 µM for RS4;11.  MOLM-13 and MV4-11 were tested 
in three independent experiments. MV4-11 was tested in two independent experiments.  
Significance was tested against a control antagomir using Student’s t-test (α = .05). 
Significance against vehicle indicated in red. Significance against anti-Ce-miR-67 
indicated in green.  Significance against anti-miR-10a indicated in black.  B) Colony 
morphology from antagomir treated colony assays.  
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Figure 13. Antagomir treatment against miR-18a and miR-92 in human MLL 
leukemia cell lines  
 
 
 
Individual antagomir treatments against miR-18a and miR-92.  A) Antagomir treatments 
were performed against individual miRNAs at a total concentration of 2 µM for MOLM-
13 and MV4-11 and 1 µM for RS4;11.  MOLM-13 and MV4-11 were tested in three 
independent experiments. MV4-11 was tested in two independent experiments.  
Significance was tested against a control antagomir using Student’s t-test (α = .05). Anti-
Ce-miR-67 was used as a control for RS4;11, and anti-miR-10a was used as a control for 
MOLM-13 and MV4-11.  B) Colony morphology from antagomir treated colony assays.  
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Figure 14 . Antagomir treatment against miR-17 and miR-20a in human MLL 
leukemia cell lines  
 
 
 
Individual antagomir treatments against miR-17-5p and miR-20a.  A) Antagomir 
treatments were performed against individual miRNAs at a total concentration of 2 µM 
for MOLM-13 and MV4-11 and 1 µM for RS4;11.  MOLM-13 and MV4-11 were tested 
in three independent experiments. MV4-11 was tested in two independent experiments.  
Significance was tested against a control antagomir using Student’s t-test (α = .05). Anti-
Ce-miR-67 was used as a control for RS4;11, and anti-miR-10a was used as a control for 
MOLM-13 and MV4-11.  B) Colony morphology from antagomir treated colony assays.  
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Figure 15. Antagomir treatment against miR-19a and miR-19b in human MLL 
leukemia cell lines 
 
 
Individual antagomir treatments against miR-19a and miR-19b.  A) Antagomir treatments 
were performed against individual miRNAs at a total concentration of 2 µM for MOLM-
13 and MV4-11 and 1 µM for RS4;11.  MOLM-13 and MV4-11 were tested in three 
independent experiments. MV4-11 was tested in two independent experiments.  
Significance was tested against a control antagomir using Student’s t-test (α = .05). Anti-
Ce-miR-67 was used as a control for RS4;11, and anti-miR-10a was used as a control for 
MOLM-13 and MV4-11.  B) Colony morphology from antagomir treated colony assays.  
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Figure 16. Antagomir treatment against miR-93* and miR-191 in human MLL 
leukemia cell lines  
 
 
Individual antagomir treatments against miR-93* and miR-191.  A) Antagomir treatments 
were performed against individual miRNAs at a total concentration of 2 µM for MOLM-
13 and MV4-11 and 1 µM for RS4;11.  MOLM-13 and MV4-11 were tested in three 
independent experiments. MV4-11 was tested in two independent experiments.  
Significance was tested against a control antagomir using Student’s t-test (α = .05). Anti-
Ce-miR-67 was used as a control for RS4;11, and anti-miR-10a was used as a control for 
MOLM-13 and MV4-11.  B) Colony morphology from antagomir treated colony assays.  
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morphology did not change in response to antagomir treatment for anti-miR-19a or anti-
miR-19b (Figure 15). 
I additionally examined potential antagomir treatments against miR-18a, miR-92, 
and miR-196b (Figures 12, 13). For these antagomir treatments, no treatment effect were 
observed relative to control treatment for MOLM-13 or RS4;11.  Anti-miR-18a and anti-
miR-92 resulted in a minor decrease in colony forming ability for MV4-11.  Treatments 
against either anti-miR-18a or anti-miR-92 showed minor, but significant decreases in 
cell number (Figure 13).  Colony morphology reflected these treatment effects with 
minor decreases in colony size and sparseness. 
Combined inhibition of miR-17, 20a or miR-17, 19a reduces colony formation and 
increases differentiation of MLL leukemia cells 
Of the miRNAs overexpressed in MLL leukemia, several are classified into the 
same miRNA family based on miRNA seed sequence.   I examined the effects of 
combinatorial antagomir treatments on human cell lines to determine whether 
simultaneously targeting multiple miRNAs with the same seed sequence or targeting 
multiple miRNAs with different seed sequences would potentiate the effects on colony 
forming capacity or proliferation.  Combinatorial treatment resulted in a greater decrease 
in colony forming ability than treatment with either anti-miR-17 or anti-miR-20a alone 
(Figure 17). Simultaneous inhibition of both miR-19a and 19b resulted in decreased 
colony formation of RS4;11 and MV4-11 cell lines (Figure 17).   Intriguingly, treatment 
with anti-miR-17 and anti-miR-19a produced a dramatic effect beyond that observed for 
either antagomir individually.  Further, this combination produced an effect beyond an 
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additive effect on colony and cell numbers. Morphologically, cells appear more 
differentiated with a greater cytoplasmic:nuclear ratio and increased vacuolarity (Figure 
18).  For all cell lines, combinatorial treatment with antagomirs directed against miR-17, 
and miR-19a resulted in a change in cell morphology (Figure 18).   
miRNA contributions to MLL leukemia were further examined in combinatorial 
treatments against multiple miRNAs simultaneously.  To avoid the potential for non-
specific toxicity, combinatorial treatments were examined at a total concentration equal 
to that of individual treatments.  I hypothesized that miRNA contributions were 
cooperative and that simultaneous inhibition of multiple miRNAs would produce a 
greater effect than individual treatments.  In examining this hypothesis, I have tested 
against antagomirs directed against miRNAs of the same family and miRNAs of different 
families.  While miRNAs from the same family possess the same seed region and would 
likely regulate similar targets, miRNAs of different families do not possess the sequence 
homology to target the same binding sites within the 3’UTR.   
Combinatorial treatments against miR-17 and miR-20a resulted in a dramatic 
decrease in colony forming ability and cell number (Figure 17).  Effects for combinatorial  
treatment were more dramatic than for either single treatment suggesting that inhibition 
of miRNAs from the same family provides a superior model of therapeutic intervention. 
Treatment with anti-miR-17 or anti-miR-20a produced the greatest decrease in colony 
forming ability in MOLM13, RS4;11, and MV4-11 cell lines(Figure  14, 17).  Anti-miR-
20a had more pronounced activity than anti-miR-17 (Figures 14, 17)   
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Figure 17. Combinatorial antagomir treatment decreases colony forming ability and 
total cell number in colony assays.  
 
 
 
 
Combinatorial antagomir treatments result in a decrease in colony forming ability and 
total cell number. Antagomir treatments were performed against either individual 
miRNAs (anti-miR-17, anti-miR-20a, anti-miR-19a, or anti-miR-19b) or combinations of 
miRNAs (anti-miR-17, 20a; anti-miR19ab; or anti-miR-17,19a)   at a total concentration 
of 2 µM for MOLM-13, MV4-11, HL-60, and U937 and 1 µM for RS4;11.  MOLM-13, 
MV4-11, HL-60, and U937 were tested in three independent experiments. MV4-11 was 
tested in two independent experiments.  Significance was tested against a control 
antagomir using Student’s t-test (α = .05). Anti-Ce-miR-67 was used as a control for 
RS4;11, and anti-miR-10a was used as a control for MOLM-13 and MV4-11.  
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Figure 18. Combinatorial antagomir treatment results in decreased colony density 
and a change in cell morphology.  
 
 
 
 
Colony and cell morphology from combinatorial antagomir treatments in colony assays at 
1 week.  Treatment with combinations of miRNAs (anti-miR-17, 20a; anti-miR19ab; or 
anti-miR-17,19a) relative to a vehicle control were examined. MOLM-13, MV4-11, HL-
60, and U937 were treated at a total concentration of 2 µM.  RS4;11 was treated at a total 
concentration of 1 µM. Scale bars represent  200 µm. Collected cells were stained with 
Wright-Giemsa (inset).  
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Therapeutic intervention against miR-19a and miR-19b resulted in a greater defect 
in colony forming ability than intervention against either miRNA alone.  Single 
treatments did not result in significant changes for MOLM-13 or RS4;11.  However, 
combinatorial treatments resulted in a 50% decrease in colony forming ability of RS4;11.  
Treatment against miR-19a caused no significant decrease relative to treatments with a 
control antagomir (Figure 15, 17). Anti-miR-19b treatment caused a decrease relative to 
both vehicle and control antagomir treatments in MV4-11 cells (Figures  15,17). 
Colonies were smaller and contained fewer cells after treatment with either anti-
miR-17,20a, anti-miR-19a,19b, or anti-miR-17,19a (Figure 17).  Further, I observed a 
decrease in cell number that was greater than the decrease in colony number in our 
combinatorial treatments, suggesting that in addition to inhibition of colony forming 
ability, antagomir treatments either inhibited proliferation, or increased cell death and/or 
differentiation. 
Both colony number and total cell number decreased in multiple antagomir 
treatment regimens. To determine whether any decrease in cell number was independent 
of decrease in colony number, I charted the relative decrease in cell number against the 
relative decrease in colony number (Figure 19).  If a proliferative defect is present, 
independent of a colony defect, then cell number should decrease at a greater rate than 
colonies relatively to wild type control.  For MV4-11 and RS4;11, cell and colony 
number decreased proportionately.  MOLM-13 however had dramatic decreases in cell 
number without any accompanying decrease in colony number.  This suggests that 
antagomir treatments affect proliferation in addition to colony forming ability. 
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Figure 19. Cell number varies similarly to colony number in antagomir treated 
colony assays. 
 
 
 
 
Values for cell number 
relative to vehicle compared 
to colony number relative to 
vehicle for human leukemia 
cell lines after antagomir 
treatment (2 µM).  Plotted 
values indicate average of 3 
independent experiments for 
MOLM-13, MV4-11, HL-
60, and U937 and 2 
independent experiments for 
MV4-11.  
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miRNA inhibition results in a modest decrease in cell number and accumulation of 
cells at G0/G1 
To dissociate the possible proliferative effects of antagomir treatments from 
colony forming ability, antagomir treatments were performed in liquid culture (Figures 
21-23).  Decreased colony size suggests a potential deficiency in proliferation, decreases 
in cell number could potentially be attributed to a decrease in colony numbers.  Further, 
colony assays require smaller initial cell numbers and effective treatment against specific 
miRNAs results in a final cell number insufficient to examine subtle changes in cell 
cycle.  To examine the proliferation of cells upon antagomir treatment, cells were 
cultured according to standard culture conditions with antagomirs. After 4 days, cells 
were analyzed using Cell-Titer-Glo to determine the total cell number, and fixed for 
FACS analysis of cell cycle. 
As with colony assay experiments, cells were subjected to both individual and 
combinatorial treatments.  Individual antagomir treatments were performed at a 
concentration of 1 µM total concentration.  Only anti-miR-20a and anti-miR-92 resulted 
in significant decreases in cell number at 4 days (Figure 21).  These effects were 
observed in RS4;11 and Molm13.  No individual treatment resulted in significant 
decreases in MV4-11. 
Combinatorial antagomir treatments were performed at both 1 µM total 
concentration (Figure 22) and 1 µM each antagomir (Figure 23).  Treatments at higher 
concentrations included controls specific to each cell line to control for non-specific 
toxicity resulting from increased oligo concentrations.  For each cell line, I selected  
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Figure  20. Linear relationship between cell number and CTG reading 
 
 
 
 
 
 
Standard curve was a established 
for MOLM-13 (blue circles), 
RS4;11 (red square), and MV4-11 
(green triangle) cell lines using 
Promega Cell Titer Glo.  Best fit 
line and equations were 
determined using PRISM.  
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potential controls from the antagomir treatments which produced either no treatment 
effect in colony assays or very limited effects relative to vehicle (herein referred to as the 
least responding antagomir). For experiments with a total treatment concentration of 2 
µM or 3 µM, I used the least responding antagomir at 2 µM or 3 µM, respectively, as a 
control.  As an alternative, a combinatorial control treatment was performed using the 
least responding antagomir treatment in combination with the second least responding 
treatment at 1 µM each. For a 3 µM alternative control, the 3 least responsive antagomirs 
for each cell line were added at 1 µM each. Combinatorial treatments examined the 
treatment effect of antagomirs directed against miRNAs from the same family as well as 
treatments against miR-17, 19a, and 196b.  Cross family antagomir treatments were 
further divided into all 2 antagomir permutations of the miR-17, 19a, 196b combination. 
Combinatorial antagomir treatment effects were observed for anti-miR-17,20a in 
Molm13 and RS4;11 at both concentrations (Figure 22-23). Cell cycle analysis indicated 
an accumulation of cells at G0/G1.  No combinatorial antagomir treatments resulted in a 
significant decrease for MV4-11.  All combinatorial treatments resulted in a significant 
decrease in RS4;11 at 1 µM.  Due to a slight increase in toxicity, significance was less 
apparent at increased treatment concentrations RS4;11.  
To examine the effects of antagomir treatment on proliferation, I treated human 
cell lines with antagomirs in liquid culture (Figure 21-23).  Doing so allowed me to  
separate any proliferative defects from colony forming ability.  I simultaneously tested 
both individual treatments and combinatorial treatments in human MLL cell lines. In  
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Figure 21. Single antagomir treated human MLL leukemia cell lines in liquid 
culture 
 
 
 
 
 
Individual antagomir treatments in liquid culture. A) Antagomir treatments were 
performed against individual miRNAs at a total concentration of 1 µM for MOLM-13, 
MV4-11, and RS4;11 for 4 days and cell number was determined using the Cell-Titer-
Glo cell viability assay.  All cell lines were tested in three independent experiments. 
Significance was tested against a control antagomir using Student’s t-test (α = .05). Anti-
Ce-miR-67 was used as a control for RS4;11, and anti-miR-10a was used as a control for 
MOLM-13 and MV4-11.  B) Cell Cycle distribution was analyzed in parallel with cell 
viability assays on day 4.  
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Figure 22.  Combinatorial antagomir treated human MLL leukemia cell lines at 1 
µM total concentration 
 
 
Individual antagomir treatments in liquid culture. A) Antagomir treatments were 
performed against individual miRNAs at a total concentration of 1 µM for MOLM-13, 
MV4-11, and RS4;11 for 4 days and cell number was determined using the Cell-Titer-
Glo cell viability assay.  All cell lines were tested in three independent experiments. 
Significance was tested against a control antagomir using Student’s t-test (α = .05). Anti-
Ce-miR-67 was used as a control for RS4;11, and anti-miR-10a was used as a control for 
MOLM-13 and MV4-11.  B) Cell Cycle distribution was analyzed in parallel with cell 
viability assays on day 4.  
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Figure 23. Combinatorial antagomir treated human MLL leukemia cell lines at 1 
µM each antagomir.  
 
 
 
Combinatorial antagomir treatments in liquid culture. A) Antagomir treatments were 
performed against individual miRNAs at a total concentration of 1 µM for MOLM-13, 
MV4-11, and RS4;11 for 4 days and cell number was determined using the Cell-Titer-
Glo cell viability assay.  All cell lines were tested in three independent experiments. 
Significance was tested against a control antagomir using Student’s t-test (α = .05). Anti-
miR-191 was used as a control for RS4;11, and anti-miR-10a was used as a control for 
MOLM-13. Anti-miR-93* was used a control for MV4-11.  B) Cell cycle distribution was 
analyzed in parallel with cell viability assays on day 4.  
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individual treatments, I observed decreases that largely mirrored our colony assay data.  
Treatment with anti-miR-17 or anti-miR-20a resulted in a decrease in total cell number at 
4 days, while treatment with anti-miR-19a or anti-miR-19b were individually unaffected 
(Figure  22, 23).  Combinatorial treatment against miR-17,20a resulted in a decrease in 
total cell number for RS4;11, while anti-miR-17,20a and anti-miR-17,19a were both 
significant in MOLM-13 (Figure  22, 23).  I did not detect any decrease relative to control 
in MV4-11.  Antagomir-treatment produced a less dramatic effect in liquid culture than in 
colony assays.   
To further examine proliferation, I examined cell cycle by propidium iodide 
staining (Figures 21-23). Decreased cell numbers were accompanied by accumulation of 
cells at G1/G0 for those antagomir.  For example anti-miR-17,20a treatment in MOLM-
13 resulted in a modest decrease in cell number accompanied by an increase in cells at 
G0/G1 (Figure 22). Collectively, these data indicate that decrease in colony forming 
ability was accompanied by a mild proliferative defect.   
Effect of antagomir treatment on colony forming ability of MLL-AF9 transformed 
murine bone marrow 
To examine the contribution of miRNAs to MLL leukemia, I screened for 
individual antaogmiR treatment effects in MLL-AF9 transduced bone marrow (Figures 
24, 25).  Bone marrow was isolated, selected for c-Kit+ cells, spinoculated with MLL-
AF9 expressing retrovirus, and treated with antagomirs with superficial addition and pre-
incubation. 
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Figure 24. Anatagomir treatment against miR-19a and miR-196b result in a decrease 
in colony formation of MLL-AF9 transformed bone marrow 
 
 
 
 
Antagomir treatments against MLL-AF9 bone marrow cells that were serially treated with 
antagomir at 100 nM (n=3).  A) Colony formation, B) Cell growth in colony forming 
assays, C) Example colonies observed in colony assays. 
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 Previous studies by our lab, performed in collaboration with the Grimes lab, have 
shown that miR-196b is essential to the transformation process in MLL-AF9 transformed 
bone marrow [11].  Treatment with anti-miR-196b resulted in a decrease in colony 
forming ability consistent with that observed these studies (Figure 24).  Colony formation 
declined at 3 and 4 weeks of serial plating.  Week 4 colonies assays indicated a complete 
collapse of colony forming ability. Cell number decreased along with colony number 
over the same time frame.  Additionally, colony morphology was distinctly different 
between anti-miR-196b and control antagomir treatment. While anti-Ce-miR-67 treated 
colonies were predominantly type 1 tight colonies, anti-miR-196b treated colonies were 
primarily type 3 by weeks 3 and 4.  This change in colony morphology is indicative of 
more differentiated cell types and implies that the decrease in colony numbers is a result 
of differentiation over the course of 4 weeks.   
Anti-miR-19a treatment resulted in a decrease in colony forming ability over the 
course of 4 weeks (Figure 24).  Concurrently, cell number decreased with colony number.  
The decrease in colony number and cell number for anti-miR-19a was the most dramatic 
observed in these experiments and represented a complete loss of colony forming ability.  
In addition to the observed decrease in colony number, I observed a dramatic change in 
colony morphology.  Similar to anti-miR-196b treatment, anti-miR-19a treatment results 
in a change in colony morphology from type I colonies to type III colonies (Figure 24).     
Treatment of MLL-AF9 transduced bone marrow with anti-miR-17-5p resulted in 
no significant difference in colony forming ability or colony morphology relative to 
control treated cells.  However, total cell number was significantly decreased at 3 weeks.   
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Figure 25. Antagomir treatments in MLL-AF9 transformed bone marrow 
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Antagomir treatments performed against MLL-AF9 transformed bone marrow. Colony 
assays performed with 200 nM antagomiR treatments  All antagomir treatments arranged 
similarly. Left panel indicates colony numbers, middle panel indicated cell number, and 
right panel indicates colony morphology. A) anti-miR-18a, B) anti-miR-19b, C) anti-
miR-20a, D) anti-miR-92, E) anti-miR-93*, F) anti-miR-191, G) anti-miR-10a.  
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The reason for the recovery of cell number at week 4 is not immediately clear, but 
could be due to selection for cells that have increased expression of compensatory factors 
that make miRNA involvement dispensable to leukemia development.  Strikingly, the 
decrease in cell number did not correlate to any decrease in colony number or change in 
colony morphology, suggesting  the decrease in cell number is not due to differentiation.   
In addition to treatment against miR-196b and miR-19a, minor treatment effects 
were observed for anti-miR-10a treated cells (Figure 25).  Anti-miR-10a treatment 
showed a minor but significant decrease in colony forming ability at 4 weeks.  At weeks 
1 and 2, a small proportion of colonies displayed an abnormal morphology of abnormally 
large and disperse colonies (Figure 25).  No treatment effects were observed for 
additional colony assays performed with anti-miR-18a, anti-miR-92, anti-miR-191, anti-
miR-20a, or anti-miR-93* relative to either a control antagomir or vehicle (Figure 25). 
Similarly, neither colony morphology nor total cell number changed in response to 
treatment with these antagomirs (Figure 25).   
PKNOX1 is a valid target of the miR-17-92 cluster 
I next sought to identify potential mRNA targets, focusing on mRNA transcripts 
predicted to be targeted by multiple miRNAs upregulated in MLL leukemia.  Further, I 
focused on genes with functions potentially related to colony forming ability.  Search 
results using multiple target prediction algorithms (miRanda, TargetScan, Diana-mT) 
identified the MEINOX family gene PKNOX1 as an intriguing possibility.  Previous 
studies in mouse models have indicated that complexes including Hoxa9-Pknox1 
functions distinctly from Hoxa9-Meis1 [111-113].  
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Figure 26. The PKNOX1 3'UTR possesses multiple putative target sites for 
regulation by the miR-17-92 cluster 
 
 
 
 
 
 
 
 
 
Positioning and 
sequences of putative 
microRNA response 
elements in the 
PKNOX1 3'UTR. A) 
Schematic of putative 
MRE location with 
identification of miRNA 
family predicted to 
target that site. B) 
Alignment of miRNAs 
with PKNOX1 3'UTR 
for wild type and 
mutated constructs.  
Seed region:mRNA 
interation indicated with 
dotted lines. MRE 
indicated in blue. 
Mutations indicated in 
green  SNP observed in 
the putative MRE of 
miR-18a is indicated in 
red  
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Figure 27. PKNOX1 is a valid target of the miR-17-92 cluster. 
 
 
 
 
 
Luciferase assays were performed in HEK293T cells in 4 independent experiments.  A) 
Schematic of luciferase construct with miRNA binding to PKNOX1 3'UTR. Putative 
miRNA binding sites are indicated with gray miRNAs above 3' UTR.  Mutation of 
miRNA binding sites are indicated with red X's above 3'UTR.  B) Readouts of Luciferase 
assays. Experiments were normalized to control (wild type PKNOX13'UTR, treated with 
MSCV-PIG-miR-17-19b) in each experiment. Statistical significance was tested using 
student’s t-test against wild-type PKNOX1 3’UTR treated with MSCV-PIG-miR-17-19b.  
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PKNOX1 is predicted to be targeted by all miRNAs in the miR-17-92 cluster.  In 
total, the 3’UTR of PKNOX1 possesses 7 putative binding sites for miR-17-92 miRNAs 
(also known as miRNA Response Element or MREs) that are conserved between mouse 
and human (Figure 26).  The miR-17 family putatively targets the PKNOX1 3’UTR at 2 
distinct sites, while miR-19ab putatively targets the PKNOX1 3’ UTR at a single site.  
The Pknox1 3’UTR is putatively targeted by miR-18a at a single site and miR-92 at 2 
sites. Interestingly, I observed a single nucleotide polymorphism in the miR-18a binding 
site in the PKNOX1 3’UTR (Figure 26).  The polymorphism consists of a G to C 
mutation outside of the seed region, and should not affect mRNA recognition. 
I hypothesized that PKNOX1 was a valid target of regulation by the miR-17-92 
cluster. To examine the miRNA:mRNA relationship between the miR-17-92 cluster and 
PKNOX1, I performed a luciferase reporter assay against the PKNOX1 3’UTR (Figure 
27). I generated a construct fusing the PKNOX1 3’UTR to a luciferase reporter construct, 
as well as additional constructs with mutations in individual MREs as well as a 
compound mutant with mutations for all predicted MREs. If the relationship is valid, then 
mutations in the MREs will result in an increase in luciferase activity.  Transfection with 
MSCV-PIG-miR-17-19b resulted in decreased levels of luminescence relative to control 
for the wild type plasmid (Figure 27).  However, due to outliers, statistical significance 
was not apparent with 4 samples.  Mutation of miR-17, 20a MREs in luciferase construct 
resulted in an increase in luminescence consistent with the hypothesis that miR-17, or 
miR-20a regulate PKNOX1 at the mRNA level. Luminescence increased by 15% for the 
miR-17 mutant, which encompassed mutations in 2 miRNA response elements (Figure  
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Figure 28. Steady-state levels of PKNOX1 in human cell lines 
 
 
 
 
 
 
 
 
Steady state levels of PKNOX1were 
examined in several different human cell 
lines, including HEK293T (non-MLL 
adherent cell line), K562 (non-MLL AML 
cell line), MV4-11 (MLL-AF4), MOM-13 
(MLL-AF9), and RS4;11 (MLL-AF4). 
Extraneous lanes cropped from blot. 
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27).  Mutation of the single miR-19ab MRE resulted in an increase of approximately 15% 
(Figure 27).  Compound mutation of all miR-17-92 related MREs also resulted in a 
statistically significant increase (Figure 27).  The compound mutant had an 
approximately 25% increase in luminescence.  Though the increase is greater than that 
observed for individual miRNAs, no statistical significance was a reached when testing 
the compound mutation against either miR-17 or miR-19 mutants.   
To further examine the relationship between the miR-17-92 cluster, I examined 
the changes in Pknox1 at the protein level in HEK293T cells transfected with increasing 
concentrations of MSCV-miR-17-19b (Figure 29).  HEK293T cells express relatively high 
endogenous levels of PKNOX1 (Figure 28,29).   If PKNOX1 is a valid target of the 
miRNAs, protein level should decrease with increased concentrations of transfected 
MSCV-PIG-miR-17-19b in a dose dependent manner.  Consistent with the hypothesis, 
PKNOX1 levels decreased in response to increased concentrations of miR-17-92 
transfection (Figure 29). 
I examined the endogenous levels of PKNOX1 and PBX1/2/3 at the protein level 
between adherent cell lines and MLL fusion containing leukemia cell lines (Figure 28).  
It was important to determine the basal levels of PKNOX1 in MLL leukemia cell lines in 
order to ensure the potential validity of my model.  If PKNOX1 is highly expressed in 
MLL-AF9 leukemia cell lines, then PKNOX1 modulation by miRNA is not likely to be 
physiologically important to leukemia.  Simultaneously, PBX levels are an important 
potential limiting factor for the integrity of the model.  I hypothesized that PKNOX1 and 
PBX levels were lower in MLL fusion containing cell lines.  As expected, I observed low  
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Figure 29. PKNOX1 decreases in response to exogenous miR-17-19b expression  
 
 
 
 
 
 
HEK293T cells expressing with 
increasing concentrations of 
exogenous miR-17-19b.  Blot 
representative of 3 independent 
experiments. Numbers represent 
PKNOX1/ACTIN ratios for the 
depicted blot.  
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levels of PKNOX1 in all three cell lines (Figure 28) relative to HEK293T and K562 cells 
(representing an adherent cell line and non-MLL leukemia cell line). MOLM-13 cells 
expressed the least amount of PKNOX1 followed by MV4-11 and RS4;11.  Further, I 
observed low levels of PBX1/2/3 in all three MLL leukemia cell lines relative to 
HEK293T and K562 cell lines (Figure 28).  Use of a an anti-PBX1/2/3 antibody made it 
impossible to discern the relative levels of each PBX homolog, but allows to determine 
the overall combined levels of PBX1/2/3 containing complexes. 
While experiments testing the miRNA:mRNA relationship utilized HEK293T 
cells as a model system, these experiments do not establish that the miRNA:mRNA 
relationship is relevant in MLL leukemia cells or that the protein levels change in 
response to miRNA disregulation. To examine antagomir-mediated regulation of 
PKNOX1, I examined the change in PKNOX1 protein levels in response to combinatorial 
antagomir treatments (Figure 30). If PKNOX1 is regulated by the miR-17-92 cluster in 
MLL leukemia cell lines, inhibition of miRNAs that target the PKNOX1 mRNA will 
result in a de-repression of the mRNA transcript and subsequent increase in protein level.  
I hypothesized that PKNOX1 level would increase upon antagomir treatment relative to 
levels observed for cells treated with a control antagomir.  Cells were cultured in liquid 
culture for 3 days at 2 µM treatment concentration for MOLM-13 and 1 µM total 
concentration for RS4;11.  Consistent with my hypothesis, PKNOX1 protein levels 
increased in response to the treatment with antagomir combinations, indicating that 
antagomir treatment results in increased PKNOX1 (Figure 30).   
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Figure 30. PKNOX1 levels increase in response to combinatorial antagomir 
treatments  
 
 
 
 
Antagomir treatment results in increased PKNOX1 protein levels relative to treatment 
with a control antagomir (anti-miR-10a). Human leukemia cell lines were treated with 
antagomirs (2 μM for 72 hrs)  and analyzed for PKNOX1 levels by western blot.  
Numbers below bots indicate relative values of PKNOX1 after normalization to Actin for 
blot depicted.  
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PKNOX1 and MEIS1 compete for participation in PBX-containing complexes 
Physiologically, PKNOX1 upregulation has several potential outcomes.  PKNOX1 
and MEIS1 share high homology in their PBX interacting domains and homeodomains 
and have both been documented to form ternary complexes with PBX and HOX proteins, 
suggesting that these proteins compete for inclusion into ternary complexes. However, 
ChIP-seq analysis of co-occupancies indicate that Meis1-Hox and Pknox1-Pbx 
complexes are abundant during murine embryonic development [111]. Thus disregulation 
of MEIS1 or PKNOX1 in leukemia could alternatively drive the formation of binary 
complexes without affecting the balance of MEIS1 or PKNOX1 inclusion in ternary 
complexes. I hypothesized that increased PKNOX1 expression would result in a decrease 
in MEIS1 inclusion into these complexes. 
To test for MEINOX competition within ternary PBX-containing complexes, I 
examined the composition of PBX-containing complexes for the relative levels of 
MEIS1/2/3 and PKNOX1 upon transfection with increasing concentrations of Meis1 (0 
ug, .5 ug, 1 ug, 2 ug, 4 ug) and co-immunoprecipitation of PBX-containing complexes 
using an anti-PBX1/2/3 antibody (Figure 31).  Immunoprecipitation was performed with 
an antibody targeting PBX1/2/3 to pull down all PBX containing complexes in a non-
biased fashion.  HEK293T cells express reasonably high levels of PKNOX1 and 
PBX1/2/3 proteins and barely detectable levels of MEIS1/2/3 (Figure 31). If a 
competitive mechanism is not present, then total complex participation would not change 
in response to modulation of either MEINOX component. However, if PKNOX1 
competes for utilization of the same partner components, then exogenous expression of   
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Figure 31. PKNOX1 is a direct competitor of MEIS1 in PBX-containing complexes  
 
 
 
 
 
HEK293T cells were transfected with Meis1 expressing plasmid and subjected to co-
immunoprecipitation for PBX1/2/3. 20% input (left) was subject to western blotting for 
PKNOX1 and MEIS1.  Co-immunoprecipitation was performed using antibody against 
PBX1/2/3  
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MEIS1 should result in a decrease of PKNOX1 when immunoprecipitating PBX-
containing complexes.  Upon treatment with increasing levels of Meis1, I observed a 
decrease in PKNOX1 participation in these complexes, indicating that MEIS1 and 
PKNOX1 compete for inclusion into the same complexes (Figure 31).  Intriguingly, at 
very high concentrations of Meis1, I observed a decrease in the total levels of 
immunoprecipitated complex as indicated by blotting for PBX1/2/3 (Figure 31).   
Pknox1 overexpression decreases the colony formation, promotes differentiation, 
and results in a decrease in cell number in MLL-AF9 transformed bone marrow 
Pknox1 has previously been examined in the cooperation with Hoxa9  for 
transformation in mouse models [94]. These studies indicate that Pknox1 lacks the 
oncogenic capability of Meis1 in a Hoxa9-dependent transformation model.  Further, 
developmental studies indicate that Pknox1-containing complexes and Meis1-containing 
complexes often operate in opposition to each other [111].   Previous studies have relied 
upon co-infection of HoxA9 and Pbx1 with Meis1 or Pknox1. In these studies, Pknox1-
Meis1 complex partners are highly expressed under viral promoters and do not need to 
compete for inclusion into potentially limited complexes.  
The role of Pknox1 within an MLL-AF9 context remains to be tested.  I 
hypothesized that over-expression of Pknox1 would have an inhibitory role in an MLL-
AF9 leukemia models.  To examine this question, I infected MLL-AF9 transformed bone 
marrow with MIGR1, MSCV-Meis1-PGK-GFP, or MSCV-pKOF2-Prep1-PGK-GFP 
(Figure 32).  These viruses serve as an empty vector control (MIGR1), a Meis1-
expressing virus (MSCV-Meis1-PGK-GFP), and a Pknox1 expressing virus (MSCV- 
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Figure 32. Pknox1 overexpression reduces colony forming ability in MLL-AF9 
transformed bone marrow  
 
 
 
 
MLL-AF9 transformed bone marrow was infected with MIGR1, Meis1 expressing virus, 
or Pknox1 expressing virus.  Colony assays were performed in 4 independent 
experiments.  Statistical analysis was performed using Student’s t-test. A) Total colony 
count/10000 cells plated (left) and Colony type (right). B)  Total cell number. C) 
Representative colony pictures displayed for each treatment. Top panels in bright field 
microscopy, with lower panels utilizing fluorescent microscopy.  GFP fluorescence 
indicates successful infection with retrovirus. 
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Figure 33. Pknox1 overexpression in MLL-AF9 transformed bone marrow results in 
an increase in differentiation-associated surface markers  
 
Cells from colony assays were analyzed for surface markers was performed for 3 
independent experiments. A) Representative plots  showing  CD117, MAC-1 and GR-1 
staining. B) Mean fluorescence intensity shown from 4 independent experiments. 
Statistical significance was tested using Student's t-test.  Pknox1 infected cells showed 
statistically significant increases in mean fluorescence intensity for both Mac-1 (p<.0001) 
and GR-1 (p<.001), relative to levels in either MIGR1, or Meis1 infected cells. 
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pKOF2-Prep1-PGK-GFP).  MLL-AF9 transformed bone marrow readily forms colonies 
at a high rate.  If Pknox1 has an inhibitory role in MLL leukemia, then enforced 
overexpression of Pknox1 will result in a decrease in colony forming ability. To prevent 
unsuccessfully infected cells from confounding experimental readouts, all infections were 
sorted for GFP positivity 48 hrs post infection, prior to plating in methylcellulose (not 
shown).  Additionally, colonies were verified for GFP expression at counting.  
Intriguingly, Pknox1 infection resulted in a larger GFP negative population at 48 hrs, 
suggesting a selective pressure against Pknox1 expressing cells (data not shown).  
Infection with Pknox1 expressing virus resulted in a decrease in colony number 
relative to both control MIGR1 treated cells and Meis1 infected cells (Figure 32).  When I 
examined the composition of colonies by subtype, I observed that the decrease in colony 
number came primarily from a decrease in Type I colonies.  No significant differences 
were observed in type 2 colonies or type 3 colonies. Total cell number isolated from each 
colony assay also decreased upon Pknox1 overexpression.  Meis1 overexpression resulted 
in a modest but statistically insignificant decrease in cell number. 
 As type I colonies represent the least differentiated cells, I hypothesized that 
Pknox1 overexpression caused a loss of stemness (Figure 33). To examine this 
possibility, I isolated cells from colony assays at one week and stained with fluorophore 
conjugated antibodies against CD117, Sca-1, CD11B, and GR-1 for FACS analysis 
(Figure 33).  CD117 (a.k.a. C-kit) and Sca-1 are markers for stemness within 
hematopoiesis.  Conversely, MAC-1 and GR-1 are markers for differentiation.   
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Figure 34. Pknox1 overexpression reduces total cell number in MLL-AF9 
transformed bone marrow  
 
 
 
A) Standard curve for calculating cell number of MLL-AF9 transformed bone marrow B) 
Proliferation curve for MLL-AF9 bone marrow infected with MIGR1, Meis1, or Pknox1 
expressing virus in 3 independent experiments.   
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Figure 35. Pknox1 overexpression results in an accumulation of cells at G0/G1 in 
MLL-AF9 transformed bone marrow  
 
 
 
Cell cycle distribution was documented after 7 days in liquid culture by FACS analysis 
for 4 independent experiments.  A) Representative FACS plots with gating. B) 
distribution of live cells measured for MLL-AF9 transformed bone marrow infected with 
MIGR1, Meis1, or Pknox1.   
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Exogenous overexpression of Pknox1 resulted in both a decrease in c-kit expression and 
in increase in differentiation markers GR-1 and Mac-1 (Figure 32). 
As with human colony assays, examination of the proliferation and cell cycle in 
colony assays remains confounded by the decrease in colony forming ability and the 
limited number of cells.  To distinguish the effects of Pknox1 on proliferation from the 
decrease in total cell number in colony assays, I infected MLL-AF9 transformed bone 
marrow cells and plated cells in liquid culture.  I examined the proliferation curve of cells 
over the course of several days, measuring the cell number at days 3, 5, and 7 (Figure 
34). As with human cell lines, total cell number was calculated based on comparing Cell-
Titer-Glo assay readouts to a previously established standard curve. Enforced expression 
of Pknox1 resulted in a decrease in proliferation over the course of 7 days (Figure 34).  
Surprisingly, enforced overexpression of Meis1 also resulted in a small, though 
insignificant, decrease relative to MIGR1 infected cells (Figure 34). 
The remaining cells were analyzed by FACS for cell cycle (Figure 35). As with 
my human cell line experiments, I observed a modest accumulation of cells at G0/G1 
(Figure 35).  This observation is consistent with our model of differentiation and 
proliferative arrest observed in human cell lines.  Collectively, this data suggests that 
decrease in Pknox1 infected MLL-AF9 transformed cells is the result of either a cell cycle 
arrest at G1, senescence, or differentiation.  The lack of a significant increase in a 
<G0/G1 populations suggests that apoptosis in not likely the cause of Pknox1 mediated 
decrease in cell number.  
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CHAPTER 5 
DISCUSSION 
 This dissertation examines the contribution of miRNAs to MLL leukemia through 
knockdown of miRNAs that have increased expression in MLL AMLs relative to non-
MLL AMLs.  I have identified miRNAs critical to colony forming ability in MLL 
translocated human cell lines, through individual and combinatorial knockdown of 
miRNAs.  Additionally, I have validated PKNOX1 as a target of the miR-17 and miR-19 
families of the miR-17-92 cluster through luciferase reporter studies and examination of 
protein levels upon miRNA level manipulation.  Finally, this dissertation demonstrates 
the competitive relationship between PKNOX1 and MEIS1 in PBX complex formation 
and the inhibitory role of PKNOX1 in an MLL specific context (Figure 36).   
 I have determined the requirement of specific miRNAs in the miR-17-92 cluster to 
maintain the transformed phenotype of MLL leukemia by antagonizing miRNAs over-
expressed in this subtype of leukemia.  Treatment with antagomirs against miR-17 or 
miR-20a individually caused a decrease in MLL leukemia colony forming ability (Figure 
14).  For antagomir treatments against either miR-17 or miR-20a alone, colony forming 
ability decreased by >40% in MOLM-13, >30% in RS4;11, and >99% in MV4-11.  These 
treatment effects underscore the importance of the miR-17 family in MLL leukemia and 
suggest that inhibiting even a single family member is sufficient to disrupt the delicate 
regulatory balance they enforce.   Combinations of multiple antagomirs for treatment 
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caused a further decrease in colony forming ability (Figure 15). In particular, 
antagonizing both miR-17 and miR-20a, or both miR-17 and miR-19a resulted in a 
dramatic decreases in colony forming ability in methylcellulose colony assays (Figure 
15).  In this study, I approached combinatorial antagomir treatments by targeting either 
related miRNAs of the same miRNA family (e.g. miR-17, 20a) or targeting unrelated 
miRNAs (e.g. miR-17,19a). Antagonizing related miRNAs of the same family would 
potentially block redundant functions caused by multiple miRNA family members’ 
ability to target the same mRNA transcript. Antagonizing unrelated miRNAs would 
potentially expose areas of miRNA coordination in regulating a phenotype. Strikingly, 
antagonism of non-family miRNAs, miR-17 and miR-19a showed a more dramatic effect 
beyond that observed for targeting only the constituent individual miRNA family 
members, indicating that the miRNAs from different families function are coordinated 
(Figure 17).  This could be due to regulation of different target gene mRNAs or because 
multiple miRNAs simultaneously and more efficiently target the same critical mRNA.   
I observed that several single antagomir treatments have no effects relative to the 
control antagomir treatment (Figures 12, 16).  miR-10a is located in the HOX clusters and 
has been documented as being upregulated in MLL leukemias relative to non-MLL 
AMLs [148].  miR-191 is a negative prognostic indicator for AML, suggesting the 
possibility of a functional role in disease development [155].  However, neither inhibition 
of miR-10a nor of miR-191 resulted in a decrease in colony forming ability.  It is possible 
that these miRNAs share redundant functions with other miRNAs, and inhibition of a 
single miRNA is unable to relieve the repression of a target mRNA.  Alternatively, these 
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miRNAs may be upregulated but have no functional importance in leukemia.  
The antagomir treatment effects varied in scale between the different cell lines 
examined (Figure 12-17).  These studies utilized human cell lines with either t(4;11) or 
t(9;11) translocations, resulting in MLL-AF4 or MLL-AF9 fusions, respectively.  Despite 
their genetic similarities, the human cell lines examined in my experiments had 
somewhat different results in colony assays. MV4-11 showed the most dramatic effects 
upon antagomir treatment with massive decreases in colony forming ability and total cell 
number, while MOLM-13 and RS4;11 showed smaller, but still significant effects. For 
example, anti-miR-20a treatment results in a significant decrease in colony forming 
ability of MOLM-13 and RS4;11 with decreases of  62% and 42% relative to the control 
antagomir treatment.  However, in MV4-11, colony forming ability was completely lost 
(Figure 14).  It is possible that the differences in colony forming potential are caused by 
differences in genetic factors not related to the MLL fusion protein, including: 
cooperating mutations incurred throughout several decades of cell culture, or differences 
in gene expression for critical factors in colony formation. For example, the cell lines I 
examined showed differential basal levels of PBX1/2/3 (Figure 28).  It is also possible 
that there is variance in the basal levels of miRNAs necessary for MLL leukemia.  In this 
case, a decrease in colony forming ability may be more easily obtainable upon antagomir 
treatment, as decreasing the miRNA levels below the minimal required amount for 
colony formation may be more easily achieved.  Alternatively, another potential cause 
could be the different clonogenic potentials of the cell lines utilized.  Loss of colony 
forming ability was most severe in MV4-11, which possesses the lowest baseline 
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clonogenicity.  The decreased clonogenicity could result in a greater sensitivity to 
antagomir treatments.  It is not immediately clear what factors govern the differences in 
clonogenicity between cell lines.   
After observing decreased colony size and a decrease in cell number in 
methylcellulose, I hypothesized that loss of colony forming ability was accompanied by a 
decrease in proliferation.  I only observed a modest difference in the number of 
antagomir treated cells in liquid culture relative to control treatments that corresponded to 
the colony assays (Figure 22-23).  Nor did I observe a sizable change in cell cycle 
distribution (Figure 22-23). This could indicate that the decrease in cell number observed 
in colony assays is dependent on the colony forming ability.  However, because colony 
assays reflect the capabilities of only a small subset of cells, it is possible that the 
proliferative defect is only apparent in these cells, and any subsequent decrease on cell 
number is the result of an absence of colonies.  Alternatively, expression of target gene 
mRNAs may vary based on the difference in culture conditions between methylcellulose 
and liquid culture. However, the molecular aspects of cells in methylcellulose are of 
greater interest because methylcellulose colony forming ability has been utilized as a 
surrogate for Leukemia Stem Cell (LSC) activity in MLL and the ability to block colony 
forming ability in methylcellulose may be used to identify factors essential to MLL 
leukemia. 
In addition to examining miRNA inhibition in human cell lines, I have 
additionally utilized antagomirs for miRNA inhibition of MLL-AF9 transformed murine 
bone marrow progenitor cells in colony formation assays (Figures 24-25). Antagomir 
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treatments have previously been utilized by our lab in this type of murine system. The 
decrease in colony forming ability in anti-miR-196b treated cells was expected as it 
confirmed the role established for miR-196b by a previous member of our lab Dr. Relja 
Popovic [11]. Relja's work, in collaboration with the Grimes lab (Cincinnati Children’s 
Hospital), show that inhibition of miR-196b results in a loss of colony forming ability 
[11].  Decrease in colony number and change in colony morphology was observed and 
suggest a loss of stemness.  However, no treatment effect is observed for MLL-AF9 
transformed bone marrow treated with anti-miR-19b, despite the high homology between 
miR-19a and miR-19b (Figure 24-25).  It is possible that the non-seed region nucleotides 
involved in stabilization of the miRNA:mRNA interaction provide the critical balance in 
whether or not a functionally important target mRNA is successfully targeted.  
Numerous potential causes could explain the differences in results between the 
human and murine systems. Primarily, the human cell lines used contain a myriad of 
additional mutations accumulated over decades in culture. To address this possibility, 
further work may utilize primary patient derived samples. Additionally, there may be a 
difference in gene regulation, as each system may present different target mRNAs or may 
express common target mRNAs at different levels. Finally, the human and mouse model 
systems utilize cells at different disease stages.   
In addition to the miRNAs examined in this work, recent advancements have 
identified several miRNAs possessing critical functions in MLL leukemia.  miR-9 has 
been shown to be upregulated in MLL leukemia relative to both non-MLL AML and 
normal cells [246].  Inhibition of miR-9 through a miRNA-binding sponge results in a 
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decrease of MLL-AF9 transformation ability in vitro and in vivo, while over expression of 
miR-9 in conjunction with MLL-AF9 transformation increases the transformation ability 
of MLL-AF9 in colony forming assays and in vivo experiments [246]   Studies performed 
by our collaborator, Dr. Grimes (Cincinnati Children's Hospital), identify miR-21 and 
miR-196b as a having synergistic roles in AML development [234, 247].  Both miR-196b 
and miR-21 are negatively regulated by the transcriptional repressor GFI1, which 
functions in opposition to HOXA9 mediated transcriptional activation [247].  In HOX-
dependant transcriptional programs, including MLL-AF9 mediated transformation, 
antagomir inhibition of miR-196b, miR-21, or both, reduced colony forming ability and in 
vivo leukemogenesis through targeting leukemia initiating cells (LIC) activity [234]. 
Collectively, these studies implicate an additional miRNA, miR-21, in the development of 
MLL leukemia, and further illustrate the importance of miR-196b in MLL leukemia. 
While this study focused on several miRNAs upregulated in MLL leukemia, it does not 
address the roles of miRNAs that are downregulated or lost in MLL leukemia, which 
contribute to transformation. Several miRNAs, including miR-495, the miR-181 family 
(miR-181a/b/c/d), and miR-150 have been identified as tumor suppressors and have been 
shown to be down regulated in MLL leukemias [86, 148, 248, 249]. Several 
downregulated miRNAs function through regulation of the Hox complex components 
essential to MLL leukemogenesis. MLL leukemias show downregulation of, the miR-181 
family (miR-181a/b/c/d), relative to non-MLL AMLs [152]. Examination of miR-181 
among cytogenetically abnormal AMLs, identify loss of miR-181 as a negative 
prognostic indicator [86].  Further, a signature of 4 miR-181 targets,  HOXA7, HOXA9, 
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HOXA11, and PBX3 are upregulated, and have been functionally evaluated in vitro and in 
vivo [86].  Overexpression of miR-495 is downregulated in MLL leukemias relative to 
non-MLL AMLs.  Overexpression of miR-495 has been shown to reduce colony forming 
ability in vitro and leukemogenesis in vivo by targeting both PBX3 and MEIS1 [248].  
MiR-150 has been implicated as a tumor suppressor miRNA down regulated in most 
AMLs relative to normal controls [249]. The MLL-fusion/Myc/LIN28 axis represses 
miR-150 maturation [249].  MiR-150 regulates Myb and Flt3 resulting in a decrease in the 
Myb regulatory targets Hoxa9 and Meis1 [249]. Ectopic overexpression of miR-150 in 
MLL-AF9 transformed bone marrow reduced colony formation in vitro and in 
leukemogenesis in vivo [249, 250].  Critically, these miRNAs and their contributions to 
MLL leukemia are linked to regulation of components of the HOX-PBX-MEINOX 
complexes required for MLL leukemia.  However, my work differs from these critical 
studies, in that I examine the contribution of miRNAs in MLL leukemia through 
regulation of a MEIS1 competitor. 
 My data demonstrates that PKNOX1 is a valid downstream target of the miR-17-
92 cluster (Figure 27).  Multiple different miRNAs from this cluster simultaneously 
regulate PKNOX1 mRNA through binding to 3 separate miRNA response elements 
(Figure 27).  Four of the 6 miRNAs of the miR-17-92 cluster (miR-17, 20a, 19a, and 19b) 
regulate PKNOX1.  This redundancy of miRNAs targeting the same mRNA suggest that 
the relationship of miR-17-92 and PKNOX1 functions as an important regulatory switch 
which may respond to various cellular signals.   To determine the interactions between 
miRNAs and the PKNOX1 3' UTR, I performed a luciferase reporter experiment with a 
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luciferase construct modified to encode the PKNOX1 3'UTR downstream of the 
luciferase coding sequence. Mutation of PKNOX1 3'UTR at the miRNA response 
elements to which the miRNAs bind for either the miR-17 family or the miR-19 family 
show an increase in luciferase activity relative to a wild type PKNOX1 3' UTR (Figure 
27).  Simultaneous targeting of a single 3’UTR by multiple miRNAs has been reported to 
regulate mRNA levels in a cooperative manner utilizing AGO1, AGO3, and AGO4-
containing RISC complexes [251].  Efficient miRNA cooperativity requires relatively 
close proximity of MREs within the target 3'UTR, approximately 13-35 nts between the 
start of the seed region binding  [252].  A transcriptome-wide examination of miRNA 
binding sites (utilizing HITS-CLIP and PAR-CLIP) found an enrichment of miRNA-
binding sites located 15-26 nts apart [253].  Within the PKNOX1 mRNA, the initial miR-
17 family binding site (MRE1) and the sole miR-19 family binding site are located at 
nucleotide positions 20 and 52 of the 3'UTR, respectively.  This 32 nt difference in 
position, is close enough to suggest that miR-17 and miR-19 family miRNAs negatively 
regulate PKNOX1 through cooperative targeting of the same mRNA.  It is possible that 
combinatorial miRNA effects may additionally occur through non-cooperative targeting 
on separate mRNA transcripts where the overall ratio of miRNAs to mRNAs controls the 
final level of mRNA available for translation, through productive single miRNA 
mediated silencing of mRNA transcripts.  
I observed a polymorphism within the predicted miR-18 binding site of the 
PKNOX1 3'UTR (Figure 26).  This polymorphism, encoding a G to A mutation at 
position 2811 of the PKNOX1 3' UTR, is located outside of the sequence targeted by the 
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seed region and should not affect the core targeting of the PKNOX1 3' UTR by miR-18, 
but may affect the binding stability of the miR-18 miRNA:RISC complex to the PKNOX1 
3'UTR.  Previous studies have identified MRE single nucleotide polymorphisms as 
having functional roles in miRNA:mRNA interactions and as serving as prognostic 
indicators for cancers [254-256]. This polymorphism I observed is predicted to be 
involved in stabilization of binding with the miR-18 containing miRNA:RISC complex 
through interaction with the uracil located at position 15 of miR-18a.  In the previously 
documented mRNA transcript, the guanine base interacts with the uracil through a 
wobble base pairing.  The polymorphism, encoding an adenine in place of the guanine, 
would result in an improved binding stability between the PKNOX1 3'UTR and the miR-
18 containing RISC complex.  
The miR-17-92 cluster is one of the best studied miRNA clusters to date, with 
targets involved in processes including cell death, cell cycle, development, and a number 
of different cancers, including lymphoma, and breast cancer (reviewed in [173-175]). In 
addition to PKNOX1, miR-17 and miR-19a also target other mRNA transcripts that are 
important to MLL leukemia. PTEN has been validated as a target for both miR-17 and 
miR-19a [190, 257]  PTEN mRNA levels have been reported to inversely vary with 
miRNA overexpression for both miR-17 and miR-19b in transformed bone marrow [12].  
MiR-17 has additionally been shown to be important in regulating the G1 checkpoint by 
regulating both CDKN1A (p21) and E2F1 [177, 183]. While shRNA knockdown of 
CDKN1A (p21) in an MLL leukemia model phenocopies overexpression of the miR-17-
19b [183], it is not currently known to be targeted by miR-19a.  My data indicate only a 
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minor G0/G1 arrest, suggesting that the miR-17-92 cluster functions through other 
mechanisms (Figure 22-23).  A lack of visible G0/G1 arrest in cell cycle assays may be 
attributable to a decrease in cell cycle progression through both G1 and G2 checkpoints.  
Previous work performed by our lab has identified the G2/M checkpoint regulator WEE1 
as a bona fide target of the miR-17-92 cluster [258]. My antagomir treatment data 
indicate a more severe phenotype upon combinatorial treatment with anti-miR-17 and 
anti-miR-19a (Figure 17). As a result, I focused on a target that is regulated by both miR-
17 and miR-19a. While binding affinity to PKNOX1 transcript is predicted to be 
thermodynamically stable, it is likely that other mRNAs are targeted simultaneously 
dependent on availability of targets.   
 The nature of miRNA function suggests that a great deal of binding promiscuity is 
possible.  MiRNAs bind to target mRNAs based on Watson-Crick base pairing between 
the seed region and a target mRNA. While this study has characterized a single transcript 
that is regulated by miRNAs in MLL leukemia, PKNOX1 is not the sole target of the 
miR-17-92 cluster.  A previous study by our collaborator, Dr. Jianjun Chen, observed that 
overexpression of the miR-17-92 cluster in murine bone marrow results in 
downregulation of 363 potential target genes predicted to be regulated by the miR-17-92 
cluster by at least one miRNA target prediction algorithm, suggesting that disregulation 
of the miR-17-92 cluster has broad implications in target mRNA regulation [12].  
Currently, miRNA target prediction algorithms focus on predicting the actions of 
individual miRNAs.  MiRNA target prediction algorithms have predicted a number of 
target mRNAs that are shared between numerous miRNAs.  2 PBX family members, 
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PBX1 and PBX3, are predicted to be common targets of miR-196b and the miR-17-92 
cluster.  PBX1 is predicted to be targeted by the miR-19 family and miR-196b, while 
PBX3 is predicted to be targeted by the miR-17 family and miR-196b.  While PBX3 is a 
known oncogene with a critical role in the formation of MLL leukemia, the role of PBX1 
is less clearly defined, and may lack the ability to promote oncogenesis.  If PBX1 lacks 
the oncogenic capabilities of PBX3, miRNA regulation of the PBX1 transcript could 
potentially contribute to MLL leukemia through elimination of PBX1 competition with 
PBX3 for inclusion in HOXA9-MEIS1 complexes, similar to the effect I observed for 
miRNA regulation of PKNOX1.  
Studies to determine the role of the miR-17-92 cluster in MLL leukemia are 
complicated by presence of its 2 homologous clusters, miR-106a-363 and miR-106b-25. 
While direct regulation of the miR-17-92 cluster by MLL fusion proteins has been 
verified, the regulation of miR-106a-363 and miR-106b-25 in MLL leukemia has not yet 
been explored.   
The potential implications of upregulation of the miR-106 clusters is further 
complicated by the composition of each cluster.  The miR-17-92 cluster is composed of 2 
members of the miR-17 family, 2 members of the miR-19 family, a member of the miR-
18 family, and member of the miR-92 family (see Figure 7). However, miR106a-363 and 
miR-106b-25 clusters are composed of different proportions of constituent miRNAs 
(Figure 7).  If these miRNA clusters are simultaneously upregulated in MLL leukemia, 
then we must further consider the potential cooperative pathways between the miR-92  
and miR-18 families, as their representation among miRNA:RISC complexes would be 
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increased.  
In addition to the regulation by the miR-17-92 cluster, additional miRNAs have 
been documented as regulators of PKNOX1. A study performed by Zhuang, et al 
examined the mRNA targets of miR-223 in macrophages in adipose tissue inflammation 
[259]. They identified PKNOX1 as a valid targeted of miR-223 and determined that it 
regulates macrophage polarization, driving macrophage activation towards a classical M1 
pro-inflammatory Macrophage activation [259].  Additional studies have identified miR-
223 as a critical factor in granulopoiesis, with miR-223 deficient mice showing defects in 
differentiation [260, 261].  One study has identified miR-223 as being regulated by 
CEBPA binding and downregulated in AML [262].   However, no studies have identified 
miR-223 as being upregulated in leukemia. 
Future studies to expand on miRNA function may reveal additional mechanisms 
of action, and subsequently expand our understanding of miRNA contribution to 
diseases.  Though miRNA were originally identified through complementary binding to 
the 3' UTR of target mRNAs, there is evidence that miRNAs can also target the 5'UTRs 
to downregulate target genes [143].  Further, miRNAs such as miR-10a possess novel 
regulatory mechanisms [144]. For example, miR-10a has been shown to bind to the TOP 
motifs within 5' UTR of target genes and results in an increase in transcription [144].  
Further, recent experiments utilizing HITS-CLIP sequencing, an unbiased 
immunoprecipitation for RISC bound mRNAs, have indicated that miRNAs bind to a 
more diverse collection of mRNA targets than had previously been thought [146]. As 
future studies continue to unveil new miRNA functions, our understanding of the role 
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miRNAs in diseases will evolve to include new classes of targets.   
Western blotting indicated an additional band present in PKNOX1 western blots 
running slightly above the expected molecular weight (Figure 30).  This data suggests 
PKNOX1 may be regulated through post-transcriptional modifications (e.g. 
phosphorylation). While there have been no documented post-translational modification 
to PKNOX1 in the literature, such a mechanism could potentially add to the complexity 
of control of PKNOX1 levels. 
 I have examined the effects of exogenous overexpression of Pknox1 in MLL-AF9 
transformed murine bone marrow to determine the role of Pknox1 in MLL leukemia. 
(Figures 32, 33, 35).  PKNOX1 and MEIS1 are homologous in their PBX-interacting 
domains and homeodomains [72, 73].  However, Meis1 oncogenic activity is dependent 
on its C-terminal domain, which is not shared with Pknox1 [94]. The C-terminal domain 
of Meis1 is known to have multiple protein-protein interactions.  It is currently unclear 
whether the Pknox1 C-terminal domain has any protein-protein interactions of its own. 
Functional examination of the Pknox1 C-terminal domain is required to determine the 
mechanism of Pknox1 regulation of target genes. Previous studies found that infection 
with Pknox1-expressing virus fails to accelerate leukemia similarly to Meis1 when co-
expressed with Hoxa9 [94].  This dissertation demonstrates that altering the balance of 
PKNOX1 to MEIS1 levels affects MLL leukemia cell proliferation and colony-forming 
ability. Pknox1 overexpression in a murine MLL leukemia model decreased colony 
forming ability, primarily from a loss of less differentiated colonies. Antagomir treatment 
of human MLL leukemia cells had a similar outcome on colony forming ability, which 
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could possibly be due to increasing the PKNOX1:MEIS1 ratio within these cells. Colony 
forming capability has been used as a measure of leukemia stem cell activity in the MLL 
leukemia model system.  Thus, loss of colony forming ability in response to antagomir 
treatments suggests that MLL leukemia stem cell activity may be predominantly targeted 
by these miRNAs. Future work could determine whether specific cell contact-mediated 
pathways are particularly influenced by miR-17-92 cluster miRNAs in MLL leukemia.   
I observed a greater decrease in proliferation upon Pknox1 overexpression than 
upon antagomir treatment. This difference may be attributed to multiple factors, such as 
dosage of Pknox1, effectiveness of antagomir delivery, or inherent differences between 
mouse and human cell lines. Exogenous overexpression of Pknox1 from a viral promoter  
would result in a much higher amount of Pknox1 relative to Meis1.  While removing the 
inhibition of the miRNAs through use of antagomirs allows Pknox1 levels to increase, 
exogenous overexpression drives Pknox1 levels very high. Cell cycle analysis of Meis1 
transduced cells indicates no significant change in the cell cycle distribution relative to 
control vector-transduced cells.  The minor decrease in Meis1 transduced cells is thus not 
likely to be of similar origin as the decrease observed with Pknox1. 
 Pknox1 has additionally been characterized as a tumor suppressor in an Eµ-Myc 
lymphoma model with Pknox1 hypomorph mutants and Pknox1 heterozygotes resulting 
in increased tumor size and accelerated onset of lymphoma [109].  The Eµ-Myc 
lymphoma model is driven by the constituent activity of the c-Myc proto-oncogene 
behind an immunoglobulin promoter, designed to simulate a B-cell lymphoma [263].  
Loss of Pknox1 expression within this context leads to a shift in the B-cell population; 
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with Eµ-Myc; Pknox1(+/-) mice having more immature phenotypes, consisting of Pro- 
and Pre-B-cells, and Eµ-Myc; Pknox (+/+) mice having more mature phenotypes [264].  
It is possible that Pknox1 competition with Meis1 may regulate the development of B-
Cells, such that loss of Pknox1 may result in decreased B-Cell differentiation.  
  These findings indicate that the canonical HOXA9-MEIS1 pathway is regulated 
through the coordinated action of multiple miRNAs.  miRNAs including miR-495, miR-
181a/b, and miR-150, which would negatively regulate the expression of the HOXA9-
PBX3-MEIS1 complexes, are down regulated, relieving the  repression of HOXA9-
MEIS1 transcriptional regulation.  Opposing these effects, previous work has indicated 
that miR-196b down regulates both Hoxa9 and Meis1, resulting in an initial delay in 
leukemia onset in a murine leukemia model, but ultimately with development of a more 
aggressive leukemia [163].  miR-196b functions as both a tumor suppressor and oncogene 
through repression of HOXA and MEIS1 and FAS, respectively [163].  Because HOXA9 
and MEIS1 are essential for MLL leukemia, and miR-196b is upregulated in MLL 
leukemias, this relationship presents a unique puzzle. If HOXA9 and MEIS1 are 
downregulated, additional factors must either restore HOXA9 and MEIS1 levels or 
otherwise ameliorate the effect.  Both miR-196b and miR-17-92 are directly regulated by 
MLL, and are upregulated in MLL leukemias [12, 64, 152].  I propose that the miR-17-92 
cluster acts as a counterbalance to the tumor suppressor properties of miR-196b.  As 
miRNA regulation of HOXA9 and MEIS1 is held in a delicate balance, regulation of the 
MEIS1 competitor PKNOX1 provides a critical mechanism for regulation of HOXA9-
MEIS1 activity.  During leukemogenesis, miR-17-92 expression results in a decrease in 
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PKNOX1 expression, alleviating competition with MEIS1 for PBX-HOX complex 
inclusion. Additional work has indicated that 5' Hox transcription factors, acting in 
conjunction with a Cdx2 partner, positively regulate the expression of miR-196b in neural 
tube development [265].  As a result, a negative feedback loop would be present, limiting 
the overall expression of Meis1.   
 Meis1 overexpression in MLL-AF9 transformed bone marrow resulted in an 
intermediate phenotype with cell surface markers and Meis1 overexpression resulted in a 
decrease in cellular proliferation (Figure 33, 35). Exogenous overexpression of Meis1, in 
addition to MLL-AF9 transformation mediated overexpression of Meis1, appears to have 
its own toxicity.  Exogenous Meis1 overexpression is potentially toxic to the cells and 
may result in a decrease in exogenous Meis1 expression. The mechanism of toxicity is 
not yet apparent, but may be caused by a variety of factors, including mitotic catastrophe 
or apoptosis, among other possibilities. Overall levels of Meis1 may need to be 
maintained below a certain level.  Though Meis1 overexpression was originally utilized 
as a negative control for Pknox1 overexpression, Meis1 activity may present its own 
complications attributable to the regulation of target genes.   
 Complex regulatory circuits involving miRNAs are starting to be defined in MLL 
leukemia.  This includes those regulating the HOX-PBX-MEIS trimeric protein complex. 
Both HOXA9 and MEIS1 are directly regulated by MLL and are necessary for MLL 
leukemia development [6, 24, 91, 113].  HOXA9 and MEIS1 are negatively regulated by 
miR-196b, one of the miRNAs overexpressed in MLL leukemia, thus limiting the 
amounts of these proteins available for incorporation into HOX-PBX-MEIS complexes. 
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Although this causes an initial delay in the onset of leukemia, increased miR-196b 
expression ultimately contributes to a more aggressive leukemia [163].  HOX-PBX3 
protein-protein interaction is also essential for MLL leukemia development and inhibition 
of this interaction with a small peptide selectively kills cells dependent on HOXA and 
PBX3 overexpression [87].  MiRNAs in the miR-17-92 cluster are also overexpressed in 
MLL leukemia. I show here that miR-17-92 cluster miRNAs, including miR-17 and miR-
19a, target PKNOX1 and that antagonizing these miRNAs causes increased PKNOX1 
expression.  I also show that MEIS1 and PKNOX1 can compete for binding in HOX-
PBX-containing complexes and that manipulation of relative MEIS1/PKNOX1 levels has 
a dramatic effect on MLL leukemia. More HOX-PBX-MEIS1 complexes as compared to 
HOX-PBX-PKNOX1 complexes potentiate MLL leukemia colony forming activity.  
Together, this suggests that HOX-MEIS-PBX complexes may be a limiting factor in 
MLL leukemia which may be amenable to functional disruption via antagonizing critical 
regulatory miRNAs.   
 Recently, the Blasi group published data which support and complement my 
findings [112, 113].  They found that Prep1 (Pknox1) competes with Meis1 for binding to 
Pbx1, and Prep1 depletion enabled Meis1 to transform MEFs [112]. The authors 
transfected Prep1 hypomorphic MEFs with Meis1 and Prep1, and observed that Meis1 
transfected MEFs form colonies in soft agar colony assays.  Co-transfection with Prep1 
results in a decrease in Meis1 stability and colony capability. Further, Meis1 colony 
formation in MEFs as well as Pknox1 mediated inhibition of Meis1 requires Pbx1.  The 
authors further examined the complex formation, and identified the Ddx3 and Ddx5 as 
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critical complex components which are required for colony formation.  These findings 
support my hypothesis that PKNOX1 competes with MEIS1 for inclusion into PBX-
containing complexes. My studies utilize HEK293T cell with increasing expression of 
exogenously introduced MEIS1 to examine the competitive role between MEIS1 and 
PKNOX1, which my data supports. It is unclear whether Ddx3, and Ddx5 are 
functionally important for Meis1 activity in MLL leukemia. A subsequent study by the 
same group identified that deficiency of Pknox1 accelerated the onset of Meis1-Hoxa9-
mediated leukemogenesis in a murine model of serial transplantation [113]. Critically, the 
Blasi group examined the effects of a lack of Pknox1 as a factor involved in the 
acceleration of leukemogenesis.  I am interested in the opposite effects - in potentially 
increasing Pknox1 levels as a mechanism to block Meis1-Hoxa9 mediated transformation 
in hematopoietic cells. Further, while the Blasi group utilized exogenous overexpression 
of Meis1 and Hoxa9, my studies assessed the relationship between MEIS1 and PKNOX1 
within an MLL-AF9 context.  They hypothesized that increasing PKNOX1 levels may be 
an important area for future therapeutic development [112]. My work agrees with this 
suggestion. 
To examine the target genes regulated by Meis1 and Pknox1, the Sauvegeau lab 
examined the gene expression profiles of cells infected bone marrow progenitor cells 
with viruses expressing either: Hoxa9 + Pknox1,  Hoxa9 + Meis , or Hoxa9 + Pknox1-MC 
(a chimeric Pknox1 possessing the oncogenic Meis1 CTD appended to the C-terminus).  
Critically, cells with exogenously overexpressed Hoxa9 + Pknox1 or Hoxa9 + Meis1, 
resulted in very different gene expression profiles [94].  Hoxa9 + Meis1 infection results 
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in the upregulation of 1202 genes with a significant upregulation of genes related to 
chromosomal organization, cell cycle, DNA damage response. However, Hoxa9 + 
Pknox1 infection resulted in upregulation of 885 genes, with no significant enrichment in 
genes related to any cellular process.  Numerous target genes were of particular interest 
to the development and function of leukemia. For example, mRNA levels of the Meis1 
target Flt3 was differentially regulated between Meis1+ Hoxa9 and Pknox1+ Hoxa9 
[94]. Moreover, transformation with either Hoxa9 + Meis1or Hoxa9 +  Pknox1-MC 
results in the upregulation of Meis1, suggesting the possibility of a positive feedback 
mechanism whereby Hoxa9 and Meis1 contribute to the elevation of Meis1 levels [94].  
 My studies examine PKNOX1 as a competitor with MEIS1 for inclusion into 
HOX-PBX-MEINOX complexes.  However, changes in the binary complex composition 
may also vary in response to Pknox1 upregulation. Examination of Pknox1, Meis1, Hox 
and Pbx during murine embryonic development by Penkov and colleagues identify 
commonly occurring binary complexes that form in addition to Meinox-Pbx-Hox ternary 
complexes [111]. Pknox1 forms binary complexes with Pbx that bind throughout the 
coding sequences and have an inhibitory role in gene regulation [111].  Meis1, 
meanwhile, was observed in binary complexes with Hox associated with promoter 
regions and contributing to gene expression [111].  The interaction of Meis-Hox binary 
complexes occurs through the binding between Hox proteins and the Meis1 C-terminal 
domain [84].  PBX participation within a ternary complex is essential to HOXA9-MEIS1 
activity as disruption of the HOX-PBX interaction through a peptide, HRX9, blocks 
leukemia formation [87].  The peptide used was designed to mimic the conserved motif 
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found within HOX proteins which interacts with PBX binding partners [266].  Though 
initially utilized to block HOX-PBX dimers in melanoma [266], multiple myeloma [267], 
and ovarian cancer [266]; within MLL leukemia, this peptide implicates the ternary 
complexes as the active HOXA9-MEIS1 effectors in leukemia because disruption of the 
HOX-PBX interaction would only alter levels of HOXA9-PBX-MEIS1 ternary 
complexes and not HOXA9-MEIS1 complexes. However, if the MEIS1-HOXA9 binary 
complexes are similarly capable of upregulating target genes, this may provide an avenue 
of escape for leukemia cells treated with antagomirs.  Further, HOX protein availability 
would still be limited due to HOX incorporation into HOX-PBX-PKNOX1 complexes.  
The possibility of PKNOX1-PBX1 binary complex formation could potentially raise 
issues with this explanation.  However, the extent of binary PKNOX1-PBX complex 
formation is unclear. 
 It is additionally possible that complex formation varies between the different 
PBX components.  My Co-IP experiments utilize an anti-PBX1/2/3 antibody, and thus do 
not distinguish between any of the PBX homologs.  This was a deliberate choice in 
experimental design to avoid any bias towards any PBX homolog and to account for 
MEINOX inclusion into any PBX containing complexes.  However, additional 
experiments may be required to discern which PBX family members are bound by 
PKNOX1 in MLL leukemia.  Inclusion of different PBX components may alter binding 
specificity to DNA sequences.  Many of the initial studies to characterize the binding and 
function of PBX proteins were performed using overexpressed PBX1 – the founding 
member of the PBX family.  However, the biochemical differences between the different 
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PBX family members is an area of potential further study. 
Further studies may strengthen these finding by examining antagomir treatment 
effects in conjunction with PKNOX1 knockdown.  My studies have shown that antagomir 
treatment results in a decrease in colony formation and a change in colony and cellular 
morphology (Figure 12-18), and PKNOX1 protein levels (Figure 30).  To ensure that the 
antagomir treatment effect is attributable to changes in PKNOX1 protein levels, further 
studies may seek to rescue colony formation ability by knocking down PKNOX1 via 
siRNA or shRNA in conjunction with antagomir treatments.  If antagomir mediated 
decreases in colony forming ability is mediated by an increase in PKNOX1, then 
PKNOX1 knockdown will result in an increase in colony numbers. 
It would be of further interest to examine the effects of antagomir treatment in 
vivo.  This dissertation focuses on antagomir mediated treatment effects in vitro, utilizing 
colony forming ability as a surrogate for leukemogenesis.  Further studies utilizing in 
vivo antagomir treatments against MLL-AF9 transformed bone marrow would provide a 
more complete picture of the potential of antagomirs as a therapeutic option.  However, 
in vivo studies are potentially complicated by the delivery of antagomirs to a therapeutic 
level in leukemic cells.  Though antagomirs were originally developed for in vivo use, 
their delivery may be enhanced through the use of various nanoparticles currently under 
development, including dendrimers.  It is not clear whether in vivo therapeutic targeting 
of a limited number of miRNAs would have significant toxicity issues; however, it would 
be worthwhile to explore as an additional therapeutic approach for MLL leukemia. My 
data indicates that the antagomir treatments were particularly effective in human cell 
153 
 
 
 
lines and that exogenously added Pknox1 effectively reduced colony forming ability in a 
mouse model.  To bridge the gap between the two sets of data, future rescue experiments 
should be performed using both model systems.  
Additional studies are needed to further clarify the functional difference 
associated with PKNOX1 and MEIS1.  Publicly available datasets from the Gene 
Expression commons [268] indicate that Pknox1 RNA levels increase throughout 
hematopoiesis differentiation while Meis1 RNA levels decrease (Figure 4). This inverse 
level of expression suggests that Pknox1 may be an important factor in guiding 
differentiation.  As such, indirect upregulation of Pknox1 mediated by downregulation of 
Pknox1-regulating miRNAs could guide cells along a particular differentiation pathway.  
This is consistent with my results in the human cell antagomir treatments, where 
combinatorial antagomir treatment resulted in changes to cellular morphology that 
include increased vacuolarity and a decrease in nuclear to cytoplasmic ratio, possibly 
indicating monocytic differentiation (Figure 18).  Further, transfection of MLL-AF9 
transformed bone marrow with a Pknox1 expressing retrovirus resulted in a change in 
surface markers consistent with differentiation relative to cells infected with a MIGR1 
control virus (Figure 33).  To understand the mechanism of PKNOX1 in MLL leukemia, 
ChIP experiments could be performed in human leukemia cell lines upon antagomir 
treatment.  I would predict that  PKNOX1 would associate with HOXA9 and PBX1 at 
selected target genes. Treatment with antagomirs would result in an increase of PKNOX1 
association at target genes known to be regulated by MEIS1-HOXA9 complexes and a 
decrease of MEIS1 association, as MEIS1 would be excluded from PBX containing 
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complexes and degraded. To date, many MLL leukemia studies have operated on a sense 
of equivalency of different components of the same protein families.  Functional studies 
are needed to determine the different roles of PBX components and how these relate to 
pairing with either MEIS1 of PKNOX1.   
 My findings contribute to an increasing body of evidence illustrating the potential 
for miRNA inhibition by anti-miRNA oligo nucleotides (AMOs) as a therapeutic tool. At 
the dosages utilized in these studies, I observed some cellular toxicity upon antagomir 
treatment (Figures 12-17), including a modest decrease in colony forming ability. 
However, these modest treatment effects may be overcome by altering the dosages 
slightly, or by employing a modified delivery system that would improve efficacy at a 
lower dosage.  
Collectively, this dissertation implicates the miR-17-92 cluster as an essential 
component of MLL leukemia through the role of miR-17 and miR-19a in their repression 
of the MEIS1 competitor, PKNOX1 (Figure 36). MLL fusion proteins aberrantly maintain 
the expression of a variety of target genes including HOX genes, MEIS1, and several 
miRNAs, including miR-196b, miR-10a, and the miR-17-92 cluster.  Previous studies 
have shown HOXA9 and MEIS1 genes are essential for MLL leukemia.  HOXA9 and 
MEIS1 form ternary complexes with a PBX family member to regulate numerous 
downstream targets.  This study examined the necessity of specific miRNAs to MLL 
leukemia through the inhibition of miRNAs using highly specific anti-miRNA 
oligonucleotides. Here, I establish that miR-17 and miR-19a are essential to MLL 
leukemia and cooperate in their contribution to MLL leukemia. This effect is mediated 
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through miR-17 and miR-19a regulation of PKNOX1, which competes for inclusion into 
PBX containing complexes.  Blocking of miR-17 and miR-19a results in upregulation of 
PKNOX1 and an altered balance of HOX/PBX gene regulatory complexes, resulting in a 
skewing away from MEIS1-containing HOX/PBX complexes and a loss of leukemogenic 
ability. In summary, I conclude that expression of several miRNAs of the miR-17-92 
cluster are critical for the continued survival of MLL leukemia .  Further examination of 
the role of miRNAs and PKNOX1 would serve to both deepen our understanding of 
complex regulatory mechanisms that guide the development of leukemia, and also to aid 
in the development of targeted therapeutics which may someday provide a valuable 
clinical tool in leukemia treatment.    
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Figure 36. Model for miRNA involvement in MLL leukemia.  
 
 
 
 
Model of miRNA involvement in MLL leukemia. MLL fusion containing complexes 
maintain the expression of the components of oncogenic HOX-PBX-MEIS complexes as 
well as miRNAs including the miR-17-92 cluster.  MiRNAs regulate the complex 
composition through downregulation of the non-oncogenic component PKNOX1, which 
serves as a competitor to MEIS1 for complex inclusion and whose overexpression has an 
inhibitory effect on MLL leukemia function. 
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